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73-deoxychondropsin A (73-DOC), a natural product of the polyketide family 
sourced from the marine sponge Ircinia ramosa, has previously shown inhibition of 
vacuolar-type H+-ATPases. This enzyme is crucial for osteoclastic bone resorption and 
is important in the pathogenesis of metabolic bone diseases, which affect both 
osteoclasts and the bone-forming osteoblasts. Following extraction of 73-DOC from I. 
ramosa tissues, in vitro experiments were performed to establish the differential effects 
of 73-DOC on primary osteoclast and osteoblast differentiation and function. Dose-
response and time course analyses, as well as confocal microscopy assessments of 
cellular acidification, showed that 73-DOC inhibited mouse and human osteoclast 
resorption at concentrations 5-10-fold lower than those causing inhibition of osteoblast 
activity. The inhibition of bone resorption whilst maintaining bone formation 
demonstrates a novel application for 73-DOC and potential as a therapeutic for osteolytic 
diseases such as osteoporosis.  
 Symbiotic microorganisms have frequently been proposed as the true producers 
of sponge-sourced secondary metabolites. Whilst symbionts are typically resistant to 
culturing, metagenomic approaches allow for microbial biosynthetic genes from the 
sponge holobiome to be cloned and ultimately expressed in a heterologous host, leading 
to a sustainable supply of the compound. To clone and sequence the biosynthetic gene 
cluster responsible for 73-DOC, a metagenomic fosmid library was screened for 
conserved features of polyketide synthase biosynthesis. Metagenomic DNA was also 
directly sequenced and screened using in silico analysis tools, which led to the 
annotation of genes with putative partial involvement in 73-DOC biosynthesis. Further 
work required to identify the remaining biosynthetic components was suggested.  
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Chapter 1: Introduction 
 
1.1 Marine natural products 
 
The marine environment represents a rich source of novel bioactive compounds, 
with more than 20,000 discovered since the 1960s and 1,241 discovered in 2012 alone 
(Blunt et al., 2014, Martins et al., 2014). These compounds are known as natural 
products and are typically produced by living organisms as secondary metabolites with 
no direct involvement in primary metabolic pathways such as growth, development or 
reproduction (Dewick, 2002). Instead, secondary metabolites have a broad range of 
functions including pheromones, signalling molecules, transport chaperones as well as 
in the chemical defence of an organism (Demain and Fang, 2000). With this latter role 
in particular, many secondary metabolites have potent antibacterial, antiviral or 
cytotoxic activities that offer exciting potential in developing pharmaceutical leads for 
treating human disease. Over a 30 year period between 1981 and 2010, 1355 new active 
substances were approved for therapeutic use and 55 % of these are considered natural 
products, or derived from natural products (Newman and Cragg, 2012).  Additionally, 
60-70 % of current anticancer and anti-infective drugs in current clinical use are also 
believed to be derived from natural products (Cragg and Newman, 2013). The need for 
new drugs certainly exists due to the occurrence of various cancers and 
neurodegenerative diseases that cannot be effectively treated, as well as the growing 
problem of antibiotic resistance in many bacterial pathogens (Hill and Fenical, 2010).  
Marine natural products are typically discovered from marine invertebrates 
including sponges, coelenterates, echinoderms, tunicates, molluscs and bryozoans, but 
microorganisms plus macro- and microalgae are also major sources (Blunt et al., 2004, 
Bhatnagar and Kim, 2010). The majority of these invertebrates are sessile or slow-
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moving, and when faced with a predator or competitor, the release of stored cytotoxic 
secondary metabolites are thought to be relied upon to act as toxins or feeding deterrents 
(Proksch, 1994, Pawlik et al., 2002, Haefner, 2003). However, most marine invertebrates 
harbour microorganisms within host tissues that include bacteria, cyanobacteria, fungi 
and algae, and many of the natural products discovered from marine invertebrates show 
structural homology with known metabolites of a microbial origin. This has led to 
speculation that the true producers of many marine invertebrate-associated natural 
products are actually microbes living in symbiosis with the host animal (Kobayashi and 
Ishibashi, 1993, Hildebrand et al., 2004, Dunlap et al., 2006, Piel, 2006, Simmons et al., 
2008, Leal et al., 2012). As an example, the natural product trabectadin (1), sourced from 
the marine tunicate Ecteinascidia turbinata, shows structural similarity with 
cyanosafracin B (2), produced by the bacterium Pseudomonas fluorescens (Figure 1.1).  
Marine natural product research was stimulated in the 1950s following the 
discovery of the nucleosides, spongothymidine (3) and spongouridine (4), from the 
marine sponge Tethya crypta (Bergmann and Burke, 1955). These discoveries resulted 
in development of cytarabine (5) and vidarabine (6), which were subsequently approved 
for human use as anticancer and antiviral compounds respectively. Following the 
advancement of diving techniques including SCUBA (1970s), manned submersibles 
(1980s) and remote operated vehicles (1990s), exploration of the marine environment 
significantly expanded, leading to the rapid discovery of novel marine natural products 
and necessitating annual reviews started by Faulkner (1986). Currently, there are 7 
marine derived natural products approved for use in humans, with an additional 25 
compounds in various stages of clinical trials (Table 1.1) (Mayer, 2014). The structures 
of some of the compounds listed in Table 1.1 as well as other important marine natural 
products referenced in this section are shown in Figure 1.2.  
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Interest in the biochemistry of the marine environment stems from the enormous 
biodiversity present in the oceans and the fact that much of it is largely unexplored 
(Costello et al., 2010, Appeltans et al., 2012). There is also the suggestion that the marine 
environment is a superior source of natural products than the terrestrial environment, 
demonstrated by the discovery of totally novel chemical classes (Cragg and Newman, 
Trabectadin (1) 
Tunicate: Ecteinascidia turbinata 
Cyanosafracin B (2) 
Bacterium: Pseudomonas fluorescens 
Salicylihalamide A 
Sponge: Halicona sp. 
Apicularen A 
Bacterium: Chondromyces sp. 
Jasplakinolide 
Sponge: Jaspis sp. 
Chondromide D 
Bacterium: Chondromyces crocatus 
Figure 1.1 Examples of structural similarity between marine invertebrate-
derived natural products and those sourced from prokaryotes. Natural 
products sourced from marine invertebrates are shown on the left with their 
prokaryote analogues shown on the right. Compounds with numbers in brackets 
are referred to in the text. Adapted from Piel (2006). 
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2013), as well as a greater incidence of significant bioactivity amongst compounds from 
marine organisms (Munro et al., 1999). As marine organisms often have to cope with 
extreme environmental conditions such as high salt, low nutrients, low oxygen, as well 
as high pressures and limited sunlight in deep sea environments, adaptations for such 
conditions ultimately lead to differences between the biochemistry of terrestrial and 
marine organisms (Montaser and Luesch, 2011, Trincone, 2011). Due to the diluting 
effects of the aqueous environment within which marine natural products are released, 
marine compounds are also often found to be far more potent than similar compounds 
from the terrestrial environment (Hughes and Fenical, 2010). For example, the marine 
Table 1.1 Marine natural products approved for human use (Mayer 2015). 
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actinomycete-derived salinosporamide A (7) is one of the most potent known 
proteasome inhibitors (Fenical et al., 2009), and ziconotide (8), a synthetic derivative of 
a toxin produced by marine cone snails to treat severe and chronic pain in humans, is 
known to be 1000-fold more potent than that of morphine (Olivera, 2000).  
The case of ziconotide (8) highlights another benefit of studying natural 
products, the fact that many possess completely novel mechanisms of action. The 
analgesic effect of ziconotide is mediated via the reversible blocking of N-type calcium 
channels which does not result in the development of addiction or tolerance, as 
Figure 1.2 Examples of marine natural products. Chemical structures for marine 
natural product are shown with numbers in brackets used to refer to the compounds in 
the text. Ziconotide is a peptide and so the amino acid sequence has been provided in 
place of chemical structure. 
Salinosporamide A (7) 
Ziconotide (8) 
Eribulin mesylate (9) 
Halichondrin B (10) 
Vidarabine (6) Cytarabine (5) Spongothymidine (3) Spongouridine (4) 
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experienced by patients using opioids (Terlau and Olivera, 2004). This discovery 
subsequently validated N-type calcium channels as drugable targets and stimulated 
research into other drugs for this target (McGivern, 2006, Clark et al., 2012). A further 
example can be found with another marine natural product success story, the anticancer 
drug trabectadin (1). This compound, isolated from the colonial tunicate Ecteinascidia 
turbinata, and subsequently approved for the treatment of human sarcomas by the 
European Commission in 2007, induces apoptosis in cancer cells by binding with the 
minor groove of the DNA double helix (D'Incalci and Galmarini, 2010).  
Accelerated research into marine natural products by the pharmaceutical industry 
is currently underway due to the success of the compounds mentioned above, the 
demonstrated broad range of bioactivities and the large volume of novel compounds 
discovered on an annual basis (Hu et al., 2011, Martins et al., 2014). In the marine 
environment, there is one group of animals that has been responsible for the discovery 
of more natural products than any other source, and that is the sponges (Lane and Moore, 
2011). Contributing to 3 out of the 7 human approved marine natural compounds, 
sponges have enormous potential in the field of drug discovery, earning a reputation as 
the “drugstore of the sea” (Blunt et al., 2009, Mehbub et al., 2014).  
 
1.2 Marine sponges and their natural product potential 
 
Sponges (phylum: Porifera) are sessile filter-feeding organisms and the most 
ancient of extant metazoan animals, with fossil records estimating their appearance 
almost 630 million years ago (Maloof et al., 2010). Through the act of pumping and 
filtering large quantities of water, sponges actively remove microscopic particles such 
as bacteria, microalgae, viruses and organic/inorganic detritus from the surrounding 
environment. Once captured, the majority of these particles are phagocytosed as food 
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items, but a large number of microorganisms are known to remain in the sponge tissue 
existing as sponge-specific symbionts, including members of the Bacteria, Archaea as 
well as the Eukarya (Wilkinson et al., 1984, Taylor et al., 2007b). In some species, 
known as high-microbial-abundance sponges, microbial symbionts can account for as 
much 40 % of the total sponge volume, with bacterial population densities of 108-1010 
bacteria per gram of sponge wet weight (Vacelet and Donadey, 1977, Hentschel et al., 
2006). However, the environmental, metabolic and biosynthetic relationships that exist 
between the host and the complex symbiont assemblages are currently poorly 
understood. 
A total of 4851 novel compounds have been discovered from sponges, represented 
by a diverse range of chemical classes including terpenoids, alkaloids, peptides and 
polyketides (Taylor et al., 2007b, Mehbub et al., 2014). A large proportion have 
demonstrated antimicrobial, antifungal and cytotoxic activities that suggest defensive 
functions for these compounds (Blunt et al., 2005, Mehbub et al., 2014), also confirmed 
in some cases by ecological studies (Paul et al., 2011). The presence of bioactive natural 
products in sponges is therefore considered to be an adaptation that has been shaped by 
millions of years of evolution, contributing to the ecological success of these animals 
(Proksch et al., 2003a).  
The occurrence of invertebrate-derived natural products with structural 
similarities to known bacterial metabolites has led to speculation of a microbial origin. 
In the sponges, this is particularly evident in the pederin (11)/mycalamide (12) family, 
where the structure of mycalamide A (12), discovered from the sponge Mycale 
hentscheli (Perry et al., 1988), is almost identical to pederin (11), a toxin isolated from 
a bacterial symbiont of the beetle species Paederus fuscipes (Kellner and Dettner, 1996) 
(Figure 1.3). The structures of other sponge-sourced natural products such as psymberrin 
(13), theopederin A (14) and onnamide A (15) also share structural similarities with 
23 
 
pederin (Figure 1.3). Structural homology in compounds from unrelated organisms such 
as a sponge and beetle, suggests the compounds are produced by commensal organisms 
with a common ancestry, implicating the involvement of bacterial symbionts in 
producing some of the sponge-associated natural products (Newman and Hill, 2006, 
Piel, 2006).  
Mycalamide A (12) 
Sponge: Mycale sp. 
Pederin (11)  
Bacterium: Pseudomonas spp.  
Onnamide A (15) 
Sponge: Theonella swinhoei  
Psymberrin (13) 
Sponge: Psammocinia bulbosa  
Theopederin A (14) 
Sponge: Theonella swinhoei 
Figure 1.3 Structures of the pederin/mycalamide family. The chemical structures 
and source of each member of the pederin/mycalamide family are shown. Numbers in 
brackets are used to refer to the compounds in the text. 
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The first genetic evidence for the bacterial origin of a sponge-derived natural 
product came from the work of Piel et al. (2004), where metagenomic approaches (see 
Section 1.3.1) were used to clone the biosynthetic gene cluster involved in the 
production of onnamide A(15)/theopederin A (14) from the sponge Theonella swinhoei, 
showing that the gene sequences contained features indicative of a prokaryotic origin. 
Further recent work by Piel and colleagues, using single-cell genomic analyses, provided 
conclusive proof for the exact biogenic origin of onnamide A (15) and theopederin A 
(14), in addition to other structurally similar compounds found from the sponge T. 
swinhoei. Biosynthetic genes for these compounds were all encoded by the genomes of 
one bacterial phylotype, the candidate genus Entotheonella, which was proposed as 
belonging to a novel candidate phylum named the Tectomicrobia (Wilson et al., 2014). 
A total of 28 biosynthetic gene clusters were found from the 9 Mb genomes of two 
representatives of Entotheonella spp., including 14 that encoded unknown products. 
These discoveries show that the Tectomicrobia represent a new biosynthetically rich 
phylum and, given that the authors also detected Entotheonella in 28 sponge species 
from geographically distant regions, these results will likely have significant 
implications for future drug discovery in sponges. 
The sponge-derived compounds mentioned above have all demonstrated 
significant in vitro antitumour activity and additionally, are all classed as hybrid 
polyketide/nonribosomal peptides (Burres and Clement, 1989, Fusetani et al., 1992, 
Kobayashi et al., 1993, Cichewicz et al., 2004). Polyketides, nonribosomal peptides, and 
hybrids of the two, are a diverse class of secondary metabolites, and include many of the 
pharmacologically most promising natural products discovered from sponges 
(Hochmuth and Piel, 2009a). These compounds, described further in Section 1.4, are 
almost exclusively produced by bacteria, fungi and algae, supporting a role for microbial 
symbionts as the biogenic origin of some sponge-associated natural products. The 
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implication of a microbial origin for a particular compound is of great interest to drug 
discovery due to the potential offered in overcoming the principle impedance to natural 
product research, that of generating a sustainable supply.  
 
1.3 The supply problem and solutions 
 
Natural products show great potential for discovering and inspiring novel drug 
leads, but the issue of ensuring continuous large-scale production for a global market 
presents significant obstacles in the development of many exciting compounds. The 
requirements of a compound to progress to the advanced stages of preclinical candidates 
include determining mechanism and site of action, development of structure-activity 
relationships, evaluation of in vivo performance in animal models for toxicity and 
efficacy, as well as characterisation of pharmacokinetic parameters and pharmaceutical 
properties (Gerwick and Moore, 2012). An abundant supply of the test compound is 
therefore crucial for the advancement of a therapeutic candidate, but due to the fact that 
most marine natural products are found at low concentrations, or are from organisms 
whose abundance in the environment is site-specific or patchy, harvesting stocks of a 
compound from natural sources is often considered unsound or insufficient for 
producing the yields required (Proksch et al., 2003b, Dunlap et al., 2006).  
Examples of this problem can be seen with the promising anticancer agent, 
trabectadin (1), and the powerful cytostatic compound halichondrin B (10). In order to 
obtain approximately 1 g of trabectadin (1), close to 1 metric tonne of the tunicate E. 
turbinata had to be collected and extracted (Proksch et al., 2002), whilst 1 metric tonne 
of the sponge Lissodendoryx sp., a source of halichondrin B (10), only yielded 300 mg 
of the compound (Jackson et al., 2009). If, for example, halichondrin B (10) was 
successfully launched as a drug for the treatment of cancer, it is estimated that the annual 
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requirement of halichondrin B (10) would be between 1-5 kg, corresponding to 3,000-
16,000 metric tonnes of sponge material per year (Proksch et al., 2003b). Harvesting 
such quantities from the wild for a global market is ethically unsound and is therefore 
typically limited to preclinical investigations only (Munro et al., 1999).  
In the case of halichondrin B (10), the testing of hundreds of structurally simpler 
analogues eventually led to the discovery of eribulin mesylate (E7389) (9), and almost 
25 years after the discovery of halichondrin B (10), this synthetic analogue was finally 
approved by the FDA in 2010 for treating metastatic breast cancer in humans (Towle et 
al., 2001, Seletsky et al., 2004, Cortes et al., 2011, Huyck et al., 2011). For other natural 
products, such as trabectadin (1), chemical synthesis is found to be an economically 
unviable option (Corey et al., 1996). This exemplifies the need for alternative 
biosynthetic strategies such as that demonstrated by Cuevas et al. (2000), where  large-
scale fermentation of P. fluorescens is used to produce cyanosafracin B (2), which is 
used as starting material for the semi synthesis of the trabectadin (1).  
The possibility of a microbial origin for many marine invertebrate-derived natural 
products presents significant opportunities for solving the supply problem through the 
cloning of biosynthetic genes and expression in fermentable heterologous hosts. The 
heterologous expression of natural product biosynthetic genes represents an elegant and 
efficient solution to the supply problem as it capitalises on the pre-existing biosynthetic 
machinery of Nature, leading to a cheap, reliable and potentially limitless source of a 
compound. But there can be significant challenges to this solution such as the impeded 
expression of foreign genes by host codon preferences, incompatible gene promoter 
recognition and transcription factors, a lack of correct biosynthetic precursors, improper 
protein folding due to absent post-translational machinery and the toxicity of foreign 
gene products to the host cell (Wenzel and Muller, 2005, Ekkers et al., 2012).  
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Such challenges are not insurmountable, however, and there have already been 
previous successes. The cloning and successful heterologous expression of patellamide, 
for example, a marine natural product produced by a cyanobacterial symbiont of the 
ascidian Lissoclinum patella, has been achieved by two independent groups (Long et al., 
2005, Schmidt et al., 2005). The study by Long et al. (2005) showed that genes from a 
cyanobacterium could be successfully expressed in Escherichia coli using bacterial 
artificial chromosome shuttle vectors. This strategy allowed for whole isolated 
biosynthetic pathways to be shuttled between various hosts such as the genetically 
amenable E. coli, or the physiologically more flexible Streptomyces, which increased 
the chances of successfully overcoming transcription and translation barriers. The 
application of novel shuttle vectors that expand the range of potential hosts, as well as 
the engineering of E. coli to improve heterologous expression of foreign genes have also 
improved opportunities for transferring biosynthetic genes across taxonomically distant 
organisms (Martinez et al., 2004, Sørensen and Mortensen, 2005). More recent 
achievements with marine natural products include the expression of the cyanobacterial 
compound, barbamide, in a terrestrial Streptomyces sp. (Kim et al., 2012), the marine 
actinomycete product, enterocin, was also expressed in Streptomyces (Bonet et al., 
2014), and alterochromide, a product from a marine pseudoalteronomad, was 
successfully expressed in E. coli  (Ross et al., 2014).  
Heterologous expression of a sponge-derived natural product is thus a worthwhile 
strategy for ensuring large scale production of a therapeutic candidate and represents a 
logical example of how knowledge obtained from studying terrestrial molecular biology 
can be applied to marine organisms. In order to attempt this approach, the biosynthetic 
genes for a natural product of interest must first be identified and cloned, requiring an 
examination of complex microbial communities that can prove challenging. Of crucial 
importance to the study of sponge symbionts is that the majority are not amenable to 
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culturing. For example, in a study by Webster and Hill (2001) on the Australian sponge 
species, Rhopaloeides odorabile, only 0.1-0.23 % of the total bacterial community were 
reported as culturable. Despite improvements in culturing techniques, the majority of 
sponge symbionts are still resistant to culturing, likely due to the necessity of the host 
environment in providing growth signals which cannot be simulated by standard 
microbiological approaches (Joint et al., 2010). Considering this, the most feasible 
approach to solving the supply problem of sponge-sourced natural products lies with the 
development of modern -omic tools and methods such as metagenomics, which are often 
referred to as culture independent approaches. 
 
1.3.1 Metagenomic solutions to the supply problem 
 
The –omics, which include genomics, proteomics, metabolomics and 
transcriptomics, are tools that can overcome the limitations encountered with traditional 
cultivation studies by exploring the biosynthesis of natural products at the genetic level 
(Schofield and Sherman, 2013). These approaches have become particularly prevalent 
over the last 15 years, driven by increases in speed and decreases in the cost of DNA 
sequencing, as well as the expansion of publicly available bioinformatic databases which 
contain vast amounts of gene and protein information (Kircher and Kelso, 2010).  
Metagenomics represents another culture independent technique, a term first 
coined by Handelsman et al. (1998) in describing the collective genomes of a soil 
sample, but which is now used to refer to the study of multiple genomes acquired from 
any environmental sample or organism. Over recent years metagenomics has emerged 
as a highly promising tool for studying the genes of complex communities in both 
terrestrial and aquatic environments (Rondon et al., 2000, Tringe et al., 2005). For 
example, sequencing of a metagenome from the Sargasso Sea resulted in the discovery 
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of 1.2 million new genes and 148 novel microbial species, demonstrating the potential 
offered by metagenomics in accessing uncharacterised metabolic pathways, particularly 
amongst unculturable species (Venter et al., 2004). In terms of natural product discovery 
from a sponge metagenome, or holobiome, two potential approaches to metagenomic 
studies are illustrated in Figure 1.4. 
The first approach involves directly sequencing metagenomic DNA, an approach 
that has become possible due to the advent of next generation sequencing (NGS) 
technologies and the improved potential for sequencing large genomes and 
metagenomes (Hall, 2007). This approach has the advantage of circumventing the need 
to construct and screen clone libraries and instead uses genome mining and in silico 
bioinformatic techniques to search for biosynthetic genes from large sequence datasets. 
For example, pyrosequencing was recently employed by Kwan et al. (2012) to reveal 
the biosynthetic pathway of the patellazoles from a tunicate metagenome, and a 
combination of metagenomic and metaproteomic strategies was used by Rath et al. 
(2011) to elucidate the biosynthetic pathway of trabectadin (1) from an ascidian 
metagenome. The application of computer programs such as ClustScan (Starcevic et al., 
2008) and antiSMASH (Blin et al., 2013), which use profiles derived from hidden 
Markov models (HMM) to recognise protein domains and predict the catalytic functions 
of biosynthetic genes from DNA sequences, has greatly facilitated the direct sequencing 
approach to metagenomic studies. 
The second, indirect approach to metagenomic studies typically involves the 
generation and screening of large-insert DNA libraries in bacterial hosts using either 
function based or sequence based screening strategies. Once a DNA library has been 
constructed, one option is to look for the functional expression of encoded biosynthetic 
genes that result in detectable phenotypes of E. coli growing on plates (Rondon et al., 
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Figure 1.4 Metagenomic strategies for isolating biosynthetic genes from sponges. 
Isolating biosynthetic genes from the metagenomes of sponges can be approached 
directly through the use of NGS technologies, which allow for the capture of large 
volumes of sequence data which can then be mined for biosynthetic genes of interest. 
Alternatively, an indirect approach would involve construction of a metagenomic 
DNA library in a bacterial host, which can then be screened via the various options 
shown, ultimately sequencing clones of interest. Both direct and indirect strategies will 
end with assembling sequence data and using bioinformatic analyses to annotate and 





screen relevant to natural product discovery is the use of chemical analyses, such as high 
performance liquid chromatography (HPLC) or mass spectrometry (MS), to detect the 
biosynthetic products of clones. Such an approach was successfully utilised by Long et 
al. (2005) to isolate and express the gene cluster involved in patellamide biosynthesis. 
Alternatively, libraries can be screened based on the detection of DNA sequences which 
has the advantage of enabling natural product pathways to be identified even if they are 
not expressed in the host, or kept silenced under laboratory conditions. This approach is 
particularly suitable for well characterised biosynthetic pathways as the strategy relies 
upon targeting features of biosynthesis that are highly conserved, permitting the use of 
degenerate PCR primers designed from consensus sequences or the hybridisation of 
oligonucleotide probes based on homology. 
Much of the biotechnological research into marine natural product production has 
focused on the study of polyketides or nonribosomal peptides, which are diverse 
chemical families that contain nearly two thirds of all antitumour therapeutic candidates 
(Newman and Cragg, 2004). These clinically important compounds are particularly well 
suited to metagenomic and heterologous expression studies as all known bacterial genes 
encoding the producing enzymes are found in gene clusters, a feature that facilitates both 
the isolation and expression of complete biosynthetic pathways (Rodriguez et al., 2009). 
Additionally, the producing enzymes are cytosolic systems and do not require any 
specialised cellular substructures for activity, and despite their diverse structural 
complexity, polyketides and nonribosomal peptides are all formed from common 
organic molecules (Rodriguez et al., 2009). Further interest from a biotechnology 
standpoint is fuelled by the potential of manipulating the biosynthetic enzyme-producing 
genes in order to generate novel structural analogues of bioactive compounds. How this 
is accomplished is related to the modular architecture of both the biosynthetic genes and 
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the enzymes that assemble polyketides and nonribosomal peptides, which are explored 
in the following section. 
 
1.4 Polyketides and nonribosomal peptides 
 
Polyketides have given rise to many medically important compounds including 
the antibiotic erythromycin (16), the immunosuppressant rapamycin (17) and the 
anticancer epithilone B (18) (Figure 1.5) (Kwan and Schulz, 2011). Polyketides are 
synthesised by large, multimodular proteins called polyketide synthases (PKS) using 
simple carboxylic acid monomers. These enzymes are organised into coordinated groups 
of active sites or domains, arranged into modules with each module responsible for the 
catalysis of one cycle of polyketide chain elongation and any associated functional group 
modifications (Staunton and Weissman, 2001, Fischbach and Walsh, 2006). The broad 
range of biological activities found with polyketides is attributed to the diverse range of 
structures seen within this family, a feature related to the mechanism of biosynthesis 
which is highly similar to the process of fatty acid synthesis by fatty acid synthases 
(FAS) (Smith and Tsai, 2007).  
Nonribosomal peptides are an equally diverse family of secondary metabolites that 
include notable medically important examples such as cyclosporine A (19), bleomycin 
(20) and vancomycin (21) (Figure 1.5). The biosynthesis of nonribosomal peptides is 
remarkably similar to that of polyketides, but instead of carboxylic acid derived starter 
and extender units, the non-ribosomal peptide is assembled from amino acids by 
multimodular enzymes called nonribosomal peptide synthetases (NRPS) (Finking and 
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Figure 1.5 Examples of medically important polyketides and nonribosomal 
peptides with their applications. Chemical structures and applications are shown 
with the numbers in brackets used to refer to the compound in the text. 
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1.4.1 The biosynthesis of fatty acids, polyketides and nonribosomal 
peptides 
 
The PKS, FAS and NRPS enzymes all use modular biosynthetic logic to 
assemble products from simple monomers (Fischbach and Walsh, 2006, Meier and 
Burkart, 2009). Between FAS and PKS, there are further similarities such as the 
utilisation of common precursors, as well as similar overall chemistry, structure and 
domain architecture (Smith and Tsai, 2007). On the basis of domain architecture and 
relationships to previously characterised FAS enzymes, PKSs have been classified into 
3 different categories, type I-III (Hertweck, 2009): Type I refers to linearly arranged and 
covalently fused catalytic domains within large, multifunctional enzymes that may act 
in an iterative or non-iterative way; where a set of domains may be used repeatedly or 
only once. These are similar to the type I FAS of fungi and animals. Type II indicates a 
PKS complex composed of discrete mono-functional enzymes that act in an iterative 
fashion to produce aromatic compounds that to date, are only found in bacteria and show 
similarity with the type II FAS found in bacteria and plants. Type III PKSs produce the 
simplest polyketide products, also in an iterative way, but are typically associated with 
the chalcone and stilbene synthases which produce organic compounds almost 
exclusively found in higher plants.  
Both polyketide and fatty acid synthesis share a common pool of precursors that 
are used to assemble products, namely acetyl co-enzyme A (CoA) or malonyl-CoA, and 
both carry out chain extension through repetitive decarboxylative condensations of acyl 
starter units and then CoA derived extender units (Rawlings, 1998, Hertweck, 2009, 
Meier and Burkart, 2009). However, PKSs also typically use methylmalonyl-CoA 
extender units, as well as other acetyl starter units such as propionyl-, benzoyl-, 
malonamyl- or methoxymalonyl-CoA (Moore and Hertweck, 2002, Fischbach and 
Walsh, 2006). The extension reaction in both processes is performed by a β-ketoacyl-
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ACP synthase (KS) domain, with the building blocks and intermediate products 
covalently bound to acyl carrier proteins (ACP), and extender units selected and 
transferred to the ACP by acyltransferase (AT) domains.  The KS and ACP domains 
both have thiol groups which are used to bind to the carboxy groups of the extender units 
and intermediate products via a thioester linkage. The thiol group of the ACP is found 
on the phosphopantetheine, a prosthetic group of the ACP that acts as an arm to swing 
the growing product between domains (Keatinge-Clay, 2012). Typical chain extension 
in a type I PKS module is shown in Figure 1.6.  
In fatty acid biosynthesis, the intermediate products are fully reduced by the 
actions of a β-ketoreductase (KR) domain, a dehydratase (DH) domain and an 
enoylreductase (ER) domain, before another round of chain elongation takes place using 
the same domains. However, in type I modular polyketide synthesis, the reductive 
modifications to the β-position of the polyketide backbone are optional and so an 
intermediate following chain extension can be partly or fully reduced before the growing 
polyketide is further extended by successive modules, with the final product released 
from the final ACP by a thioesterase (TE) domain, also found in type I FAS (Figure 1.6) 
(Smith and Tsai, 2007). In any module of a type I PKS, there are therefore a set of 
domains that are always present, the KS, ACP and AT, whilst some or all of the KR, DH 
and ER domains may or may not be present. The variable combinations of reductive 
domains, in addition to the incorporation of different types of starter and extender units 
is what gives rise to the structural and functional diversity seen amongst polyketides.  
In addition to reductive domain use, a further major difference between modular 
polyketide synthesis and the iterative actions of the type I FAS concerns the AT domain. 
Whilst only one type of AT domain is found in FAS, with dual specificities for either 
the primer acetyl unit or the malonyl-CoA extender units, in the modular type I PKS the 




Figure 1.6 General biosynthetic steps during a round of polyketide 
extension in a single type I cis-AT PKS module. A typical cis-AT PKS 
module is shown, where the acyltransferase (AT) domain is integrated in 
each module. A malonyl-CoA extension unit has been loaded to the 
phosphopantetheinyl arm (Ppant) of the acyl carrier protein (ACP) via the 
AT domain. The charged ACP then docks with the ketosynthase (KS) 
domain, which catalyses the chain extension via decarboxylative 
condensation, before the ACP transfers the polyketide to a downstream 
module. The X domain is variable and can be filled by the shown 
combinations of ketoreductase (KR), dehydratase (DH), enoylreductase 
(ER) or methyltransferase (M) domains. The biosynthetic products for these 
domain sets are shown below each combination. Cis-AT PKSs can also 
introduce α-methyl-branched groups by AT-directed incorporation of 
methylmalonyl-CoA extension units. Adapted from Nguyen et al. (2008) 
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the potential for utilising different extender substrates during each elongation step. 
Whilst the AT domain responsible for loading the PKS starter substrate has relaxed 
specificity, like the FAS AT domains, the AT domains for PKS chain extension typically 
exhibit specificity for either malonyl or methylmalonyl-CoA (Khosla et al., 1999, Liou 
et al., 2003). The use of methyl-branched extender units in modular PKS systems allows 
for the generation of methyl-branched polyketides, but PKS-incorporated 
methyltransferase domains may also be utilised for this function (Figure 1.6) (Nguyen 
et al., 2008).  
The domains of the modular type I PKS enzyme can therefore be considered as 
a molecular assembly line, with biosynthesis following co-linearity principles where the 
number of condensation reactions dictate the chain length of the final product, each 
module is used only once, and the structures of intermediates directly correspond to the 
PKS module domain architecture. This enables polyketide structures to be predicted 
from PKS domain architecture and vice versa (Staunton and Weissman, 2001, Weissman 
and Leadlay, 2005, Hertweck, 2009, Cummings et al., 2014). However, these canonical 
rules for polyketide biosynthesis are only applied to a subclass of modular PKSs called 
the cis-AT PKS, where the AT domain is present in every module and connected to the 
KS domain via a subdomain also found in the mammalian FAS (Tang et al., 2006, Maier 
et al., 2008). The classic example of a cis-AT PKS is the 6-deoxyerythronolide B 
synthase, which produces an intermediate of the antibiotic erythromycin (16) and is the 
most studied type I modular PKS (Khosla et al., 2007). However, there are also non-
canonical PKSs, such as in the evolutionary distinct trans-AT systems, where the AT 
domain is not integrated into the assembly line and is instead expressed as a free-
standing enzyme. These discrete AT domains typically transfer malonyl-CoA extender 
units to multiple ACP domains within a PKS (Piel, 2010). Other examples of non-
canonical polyketide biosynthesis include broken or split modules, as well as module or 
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domain skipping or stuttering during chain extension (Katz, 2009).  
Nonribosomal peptide biosynthesis by NRPSs use a strategy that is very similar 
to that of modular PKSs, with the final compound arising out of linear, modular 
biosynthetic assemblies of amino acid extender units. As with polyketides, a remarkable 
structural and functional diversity is seen with nonribosomal peptides, due to a large 
pool of potential building blocks that include 20 proteinogenic amino acids as well as a 
large variety of nonproteinogenic amino and aryl acids (Marahiel and Essen, 2009). 
Domains of NRPSs are also arranged into modules, where the order and number of the 
modules in an NRPS system dictate the sequence and number of extender units in the 
resulting product (Cane and Walsh, 1999, Finking and Marahiel, 2004, Fischbach and 
Walsh, 2006). In a typical NRPS module there are at least three domains: An adenylation 
domain, responsible for the activation and incorporation of a particular amino acid or 
building block, a thiolation domain for the thioesterification of the activated amino acid, 
and a condensation domain to form an amide bond between the amino acid units (Cane 
et al., 1998, Du et al., 2001). Typical chain extension in an NRPS module in shown in 
Figure 1.7. Initiation of the process occurs via a module lacking a condensation domain, 
and a TE domain ultimately releases the completed polypeptide chain from the thiolation 
domain of the previous module (Finking and Marahiel, 2004). Like the KR, DH and ER 
domains of PKSs, NRPSs may also contain tailoring domains such as cyclisation 
domains or epimerization domains which catalyse the heterocyclisation of serine, 
threronine or cysteine residues, or epimerise amino acids into the D-configuration, 
respectively (Cane and Walsh, 1999, Finking and Marahiel, 2004). 
PKS and NRPS modules also occur in hybrid assembly lines that contain both 
types of modules (Du et al., 2001). These complexes may be referred to as hybrid 
PKS/NRPSs or NRPS/PKSs depending on the order of modules in the system. For the 
former, a ketide chain formed by an upstream PKS module is accepted by the C-domain 
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of a downstream NRPS module which subsequently mediates a C-N bond formation, 
elongating the polyketide chain with an amino acid. With NRPS/PKS hybrids, the KS 
domain accepts an upstream peptide chain rather than a ketide chain and catalyses the 
formation of a C-C bond, elongating the peptide chain with a short carboxylic acid 
(Figure 1.7 C) (Du et al., 2001). Characterised examples of such systems include 
rapamycin (17) (Aparicio et al., 1996) and bleomycin (20) (Shen et al., 1999).  
The biosynthesis of type I polyketides and nonribosomal peptides are modular at 
many levels. At the genetic level the biosynthetic genes are typically located in clusters, 
encoding the PKS/NRPS, any tailoring enzymes that may be involved in cyclisation or 
dimerisation of the final product, as well as regulatory and resistance genes (Cummings 
et al., 2014). Once transcribed and translated, the enzymes themselves also show 
modularity. Considering this, there is therefore potential to alter the end product and 
generate structural analogues through addition, removal and substitution of domains or 
Figure 1.7 Bond formation in nonribosomal peptides. In the NRPS system, a 
dedicated adenylation domain (A) activates an amino acid extension unit as an 
aminoacyl adenylate which is then transferred to the thiolation domain (T). The 
condensation domain (C) then catalyses nucleophilic attack of the amino nitrogen 
of the downstream aminoacyl group on the electrophilic carbonyl carbon of the 
upstream acyl group. Adapted from Du et al. (2001). 
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modules, either at the genetic or protein level using combinatorial biosynthesis 
(Menzella et al., 2005, Weissman and Leadlay, 2005). Consequently there is great 
interest from a pharmaceutical perspective in examining the PKS/NRPS systems of 
natural products with a view to generate novel products of therapeutic value, or even 
rationally engineering a predefined product if domains or modules can be successfully 
stitched together (Kennedy, 2008, Walsh and Fischbach, 2010, Williams, 2013, 
Cummings et al., 2014). Biosynthetic characterisation of a sponge-derived natural 
product is thus worthwhile for not only solving the supply problem of potential 
pharmaceutical leads, but also for the exciting potential in generating new leads. One 
example of a sponge natural product with a predicted, but uncharacterised type I 
PKS/NRPS mode of biosynthesis is found with the chondropsins, a group of macrolide 
lactams with demonstrated potent antiproliferative activity and the potential for 
pharmaceutical exploitation. 
     
1.5 The Chondropsins 
 
Chondropsin A (23) and B (25) were originally described by Cantrell et al. 
(2000), whilst chondropsin D (26) was subsequently reported by Rashid et al. (2001a), 
but all were found in a Chondropsis sp. sponge. A further two members of the 
chondropsin family, chondropsin C (24) and 73-deoxychondropsin A (73-DOC) (22), 
were also discovered from sponges, but from a Philippine Ircinia sp. and the Australian 
species, Ircinia ramosa, respectively (Rashid et al., 2001b) (Figure 1.8). All the 
chondropsins were observed to have structural patterns of oxygenation, alkylation and 
dehydration that indicate a polyketide biosynthetic origin but the absolute 
stereochemistry of the compounds has not yet been resolved. Additionally, the structures 
all contain amide linkages with side chains that suggest the incorporation of amino acid 
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units. The route of chondropsin biosynthesis is therefore predicted to occur via a type I 
hybrid PKS/NRPS. The fact that chondropsins have been found across two orders of 
metazoans, coupled with a predicted polyketide biosynthetic origin, suggests these 
compounds are produced by a microbial sponge-specific symbiont (Cantrell et al., 2000, 
Figure 1.8 Chemical structures of the chondropsins. Numbers in brackets are 
used to refer to the compounds in the text  
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Rashid et al., 2001b, Dunlap et al., 2007). However, whilst previous studies with I. 
ramosa have confirmed the presence of monophyletic cyanobacteria (Dunlap et al., 
2007) as well as many other microbial species (Webster et al., 2010), the biosynthetic 
origin of 73-DOC (22) and the other chondropsins has not yet been investigated.  
 The biological activities of many natural products were established following 
screening by the US National Cancer Institute (NCI) using a panel of 60 human 
antitumour cell lines, where antiproliferative activity in response to test extracts was 
assessed using cellular viability assays (Shoemaker, 2006). Since 1989, over 75,000 
crude samples from the natural environment have been screened by the NCI in this way, 
typically followed up by bioassay-guided isolation of novel bioactive compounds 
(Shoemaker, 2006). Following the discovery of chondropsin A (23), this compound was 
tested in the NCI 60-cell antitumour screen, and showed potent (low nanomolar) 
differential growth inhibition with a profile distinct from other conventional antitumour 
agents at that time (Cantrell et al., 2000). Chondropsins C (24), D (25) and 73-DOC (22) 
were also found to be cytotoxic towards melanoma and leukaemia cell lines and the 
chondropsin family were indicated as a class of compounds worthy of exploitation due 
to their potential as anticancer therapeutics by the NCI Developmental Therapeutics 
Program (NCI registry numbers (https://dtp.cancer.gov/): 719165, 719166, 720964, 
722377, 720963 for chondropsin A-D and 73-DOC, respectively) (Rashid et al., 2001a, 
Rashid et al., 2001b). 
A subsequent study by Bowman et al. (2003) used the NCI data to compare the 
profile of cellular response generated in the 60-cell screen from chondropsin A (23) to 
the profiles generated by other test compounds using the COMPARE pattern recognition 
algorithm (Boyd and Paull, 1995). The theory behind this analysis was that compounds 
that highly correlate through their activity in the NCI screen would be expected to share 
a molecular target or mechanism of action, even if different in structure. The authors 
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found that the profile for chondropsin A (23) exhibited a high correlation with profiles 
generated by the plecomacrolide compounds bafilomycin A1 (27) and concanamycin A 
(28), which are known to be potent inhibitors of vacuolar H+-ATPases (V-ATPases) 
(Figure 1.9) (Bowman et al., 1988, Huss et al., 2002). The V-ATPases are further 
discussed in Section 1.6.   
Bowman et al. (2003) subsequently investigated the inhibitory effects of the 
chondropsins on fungal V-ATPases from the vacuolar membranes of Neurospora crassa 
and mammalian V-ATPases from chromaffin granule membranes of Bos taurus. Using 
a biochemical assay for specific V-ATPase activity, which involved quantifying the 
liberation of inorganic phosphate and inhibitors of other membrane-bound ATPases (F-
type, P-type) to discriminate ATPase activity, the authors presented compelling 
Bafilomycin A1 (27) 
Concanamycin A (28) 
Figure 1.9 Structures of plecomacrolides bafilomycin A1 and 
concanamycin A. Numbers in brackets are used to refer to the 
compounds in the text.  
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evidence that the chondropsins were excellent V-ATPase inhibitors with a preference 
for inhibiting the fungal type over the mammalian type (Bowman and Bowman, 1988, 
Bowman et al., 2003). However, whilst the authors also stated that chondropsin B (25) 
and 73-DOC (22) were inactive against other membrane ATPases including the 
mitochondrial F-ATPase, the plasma membrane H+-ATPase from N. crassa and the 
Na+/K+ ATPase from canine kidney cells, the data for these experiments were not shown. 
Interestingly, these reported effects contrast with the activity of bafilomycin (27) and 
concanamycin (28) which are known to inhibit other membrane ATPases, potentially 
causing off-target effects when used in vivo which would limit their use as therapeutics 
(Bowman et al., 1988, Droese et al., 1993, Keeling et al., 1998).  
The fact that 73-DOC (22) showed selective V-ATPase inhibition, with a 
magnitude of differential activity greater than the other chondropsins, as well as a 
possible lack of inhibitory activity towards other ATPases, implies that this particular 
member of the chondropsin family could represent a novel V-ATPase inhibitor that does 
not induce in vivo systemic toxicity. As V-ATPase subunit structure is known to show 
both ubiquitous and cell-specific compositions (see Section 1.6.1), the inhibitory activity 
of 73-DOC (22) has effectively only been examined using two specific types of V-
ATPases. As such, questions remain regarding what effects this compound has on other 
mammalian V-ATPases, or other targets, and whether it can be used as a selective 




The V-ATPases are a ubiquitous class of proton pumps in eukaryotic cells that 
function to regulate intracellular pH and generate electrochemical gradients across 
membranes (Nishi and Forgac, 2002). Due to involvement in a diverse set of 
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physiological processes, as well as a wide range of diseases including tumour metastasis, 
sensorineural deafness, distal renal tubule acidosis and osteopetrosis (see Section 1.7), 
V-ATPases have been highlighted as attractive targets for therapeutics (Bowman and 
Bowman, 2005, Hinton et al., 2009, Huss and Wieczorek, 2009). Typically V-ATPases 
are found associated with components of the endomembrane system such as the Golgi 
apparatus, endosomes, lysosomes and secretory vesicles (Bowman and Bowman, 2005). 
However, some V-ATPases are involved in more specialised roles where they may be 
targeted to the plasma membrane to carry out extracellular acidification. This is known 
to occur in the renal intercalated cells of the kidney for the task of urine acidification 
(Brown et al., 2009), in epididymal clear cells where luminal acidification is critical for 
sperm maturation (Shum et al., 2009), and in osteoclast bone cells where the V-ATPase 
is crucial in generating an acidic local environment that leads to bone resorption (Frattini 
et al., 2000) (see Section 1.7.1.2). V-ATPases are also found on the plasma membranes 
of tumour cells where they are thought to generate an acidic extracellular environment 
which aids metastasis (Sennoune et al., 2004). 
However, V-ATPases also have physiological roles that extend beyond their 
ability to regulate pH and are now recognised as protein complexes critically involved 
in cellular signalling cascades. Studies have related V-ATPase activity to Wnt (Cruciat 
et al., 2010), Notch (Vaccari et al., 2010), Insulin-like growth factor (IGF-I) 
(O'Callaghan et al., 2010) and EGFR/ErbB signalling (Xu et al., 2012), thereby 
implicating the V-ATPase in all the physiological and pathophysiological processes 
associated with those pathways such as embryonic tissue development, proliferation, 





1.6.1 Structure and mechanism 
 
The V-ATPase is composed of two large complexes containing at least 14 
subunits organised into two domains, the 650 kDa V1 domain and the 260 kDa V0 domain 
(Figure 1.10). Together, these domains form a complex that functions as a molecular 
motor, where the energy generated from ATP hydrolysis on the cytoplasmic-facing V1 
domain is used to drive protons through an ion channel embedded within the membrane- 
bound V0 domain. The V-ATPases operate by a rotary mechanism, demonstrated when 
a gold bead was attached to subunits of the V1 complex and rotation coupled to ATP 
hydrolysis was observed (Imamura et al., 2003). The structure and function of the V-
ATPase is similar to that of the F-ATP synthase found in the inner mitochondrial 
membranes of eukaryotes, but V-ATPases function in reverse, using ATP to translocate 
protons rather than using proton electrochemical gradients to generate ATP (Forgac, 
2007).   
The V1 domain contains 8 different subunits (A-H), some of which are present 
in multiple copies. There are 3 copies of A and B, which are arranged in alternating 
positions of a 400 kDa hexamer with the catalytic sites of ATP hydrolysis located at the 
interface of these subunits (Nishi and Forgac, 2002). The rest of the V1 subunits form 
two types of stalk, peripheral or central, that connect the V1 and V0 domains. During 
rotation, hydrolysis of ATP induces conformational changes that drive clockwise 
rotation of the A/B hexamer. The central stalk couples the rotation of the V1 to the V0 
domain, whilst the peripheral stalks act as stators, maintaining the complex position 
during rotation (Forgac, 2007).  
The V0 domain of higher eukaryotes contains 7 different subunits designated a, 
d, e, c, c” and the accessory subunits, Ac45 and M8. There are 4-5 copies of subunit c 
and a single copy of c”. Both c and c” are proteolipid subunits formed of highly  
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hydrophobic proteins arranged in a ring, with each containing a single glutamic acid 
residue that undergoes reversible protonation (Wilkens and Forgac, 2001, Nishi and 
Forgac, 2002). Subunit d, located on top of the proteolipid ring, provides a connection 
Figure 1.10 Structural model of the mammalian V-ATPase. The complex is 
composed of at least 14 subunits which are organised into two distinct domains: 
The peripherally orientated V1 domain, which contains the site of ATP hydrolysis 
and is made up of subunits A-H; and the membrane-embedded proton-
translocating V0 domain, which is formed by subunits a, c, c”, d and e. There are 
also two accessory subunits, Ac45 and M8-9, associated with the V0 domain. 
Proton transport across membranes via hemi-channels in subunit a and the 
proteolipid c/c” ring is also shown. Taken from Qin et al. (2012b). 
48 
 
between V1 and V0 and participates in controlling the reversible assembly/disassembly 
of the V1 and V0 domains, a fundamental feature exclusive to the V-ATPases (Forgac, 
2007, Marshansky et al., 2014). The V0 domain also contains the 100 kDa subunit a that 
contains a hydrophilic N-terminal domain and a C-terminal containing 8 or 9 
transmembrane helices, one of which contains an arginine residue shown to be crucial 
for proton transport (Kawasaki-Nishi et al., 2001b). Subunit a provides entry and exit 
routes for protons via two hemi-channels that enable proton translocation. Protons enter 
one channel and are forcibly bound to the glutamic acid residues of the proteolipid ring 
subunits by the hydrophobic environment (Junge and Nelson, 2005, Marshansky et al., 
2014). Rotation of the stalk from ATP hydrolysis is coupled to rotation of the proteolipid 
ring relative to the subunit a, and on reaching the luminal hemi-channel, deprotonation 
of the buried glutamic acid residues occurs, induced by the crucial interaction with the 
arginine residue of subunit a (Junge and Nelson, 2005, Forgac, 2007). Rotation of the 
proteolipid ring relative to subunit a thus results in active transport of protons across 
membranes (Figure 1.10).  
In mammalian cells, almost all V-ATPase subunits exist as two or more isoforms 
that, to a certain extent, display tissue specific expression or differential membrane 
targeting (Table 1.2). In higher animals there are ubiquitous and tissue/cell-specific 
isoforms, the latter particularly associated with a subset of V-ATPases with specialised 
roles at the plasma membranes of cells, but which typically contain ubiquitous isoforms 
as well (Holliday, 2014).  Mammalian cells contain four isoforms of subunit a (a1, a2, 
a3 and a4) of the V0 domain, with the a4 isoform almost exclusively expressed in the 
apical membranes of epididymal clear cells and renal intercalated cells, where the V-
ATPase is responsible for acid balance and sperm maturation, respectively (Toei et al., 
2010). Mutations in this particular isoform have been shown to cause defective acid  
secretion, resulting in renal tubular acidosis (Smith et al., 2000). There are other 
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Table 1.2 Mammalian V-ATPase subunits, isoforms and proposed functions. 
Adapted from Forgac (2007) and (Cantrell et al., 2000), Qin et al. (2012b). 
50 
 
isoforms such as C2, G3 and d2, that are also shared between renal and epididymal cell 
types, suggesting the formation of V-ATPase complexes with unique subunit 
combinations in these and possibly other cell types (Nishi and Forgac, 2002, Smith et 
al., 2002, Pietrement et al., 2006).  
Localisations of isoforms can also be compartment-specific. In mouse kidney 
proximal tubes, all isoforms of a are expressed, but while a1, a3 and a4 are targeted to 
the plasma membrane a2 is targeted to early endosomes (Hurtado-Lorenzo et al., 2006). 
A further example can be seen with osteoclasts, where the a3 isoform is highly expressed 
and re-localised from lysosomes to the plasma membrane during bone resorption, whilst 
the a1 and a2 isoforms are localised at the Golgi complex (Toyomura et al., 2000, 
Toyomura et al., 2003). Mutations in the a3 subunit are shown to cause a defective bone 
resorption phenotype associated with osteopetrosis, which is characterised by excessive, 
dense bone formation (see Section 1.7.4) (Frattini et al., 2000). It is generally accepted 
that subunit a is crucial for trafficking and specific targeting of the V-ATPase complex 
in mammalian cells, which is also known from yeast and protists, but the underlying 
mechanisms are currently unresolved (Kawasaki-Nishi et al., 2001a, Wassmer et al., 
2006).  
 
1.6.2 Assembly and regulation 
 
Knockdown studies with the yeast V-ATPase have shown that all subunits of the 
V-ATPase are required for correct assembly and function (Kane and Parra, 2000, 
Graham et al., 2003). In yeast, the V0 domain is assembled in the endoplasmic reticulum 
and is dependent on a set of dedicated chaperones (Graham et al., 2003, Forgac, 2007). 
Assembly with either almost fully assembled V1 domains, or individual V1 subunits, 
occurs in the Golgi (Graham et al., 2003, Malkus et al., 2004). However, there are 
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alternative pathways to V-ATPase assembly in yeast that are still being resolved, 
including the role of RAVE (regulator of H+-ATPase of vacuolar and endosomal 
membranes), which is involved with yeast V-ATPase assembly, and possibly differential 
targeting, as well as the reversible disassembly of V-ATPase complexes (Kane, 2006, 
Smardon et al., 2014). Homologues for RAVE are also known from higher eukaryotes 
and implicated in defective organelle acidification, but V-ATPase assembly in mammals 
is otherwise understudied (Yan et al., 2009, Sethi et al., 2010, Einhorn et al., 2012).  
The reversible disassembly of the V-ATPase complex is one mechanism 
controlling the regulation of V-ATPase activity, and is known to occur for energy 
conservation in yeast in response to glucose depletion (Kane, 1995), as well as insects 
during moulting (Beyenbach and Wieczorek, 2006). Dissociation of the V-ATPase in 
yeast and humans is thought to be controlled by the direct interaction of the complex 
with cytosolic aldolase, an enzyme of the glycolytic pathway, which might be the 
glucose sensor that signals for V-ATPase dissociation (Lu et al., 2004). Whilst glucose 
was the paradigm signal for reversible V-ATPase disassembly, other signals such as pH 
are now indicated but there are likely to be other uncharacterised signals that also 
influence assembly/disassembly of the complex (Dechant et al., 2010, Diakov and Kane, 
2010). 
Modulation of V-ATPase activity can also occur through changes in the coupling 
efficiency between proton transport and ATP hydrolysis. In yeast, this is achieved 
through variations in the C-terminal domains of subunit a isoforms (Kawasaki-Nishi et 
al., 2001a). For example, the yeast V-ATPase complex found in the Golgi, has a much 
lower coupling efficiency than that found in the vacuole, and this is attributed to the 
different subunit a isoforms (Kawasaki-Nishi et al., 2001c). In mammals, mutations in 
other subunits, including d (Owegi et al., 2006), A (Shao et al., 2003), E (Sun-Wada et 
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al., 2002) and C (Sun-Wada et al., 2003) have all been proposed to have roles in 
regulating coupling efficiency.  
In cell types that have V-ATPase complexes targeted to the plasma membrane, 
the density of pumps at the cell surface is controlled through reversible exo- and 
endocytosis of intracellular vesicles which contain high densities of V-ATPases (Forgac, 
2007). In epididymal clear cells (Pastor-Soler et al., 2003), and possibly other secretory 
cells such as renal intercalated and osteoclasts (Geng et al., 2005, Geng et al., 2009), the 
recycling of V-ATPases to and from the plasma membrane is controlled by a novel 
soluble adenylyl cyclase (sAC), sensitive to cytoplasmic levels of bicarbonate. As 
bicarbonate and pH increase, sAC is activated, giving rise to increases in cyclic 
adenosine monophosphate (cAMP) that increase exocytosis and/or decrease endocytosis 
of V-ATPases via a currently unknown mechanism (Pastor-Soler et al., 2003).  
In most cells, V-ATPases are located only in membranes of acidic intracellular 
compartments such as lysosomes or vacuoles, where transcriptional control involves 
TATA-less, GC-rich regulatory regions containing multiple Sp1 or AP-2-like binding 
sites, as found with other housekeeping enzymes (Lee et al., 1997, Holliday, 2014). 
Expression of other cell-specific isoforms are controlled by transcription factors such as 
Foxi1 in kidney, epididymal and inner ear cells (Jouret et al., 2005, Blomqvist et al., 
2006, Vidarsson et al., 2009). In osteoclasts, the a3 isoform is induced by the receptor 
activator of NF-κB ligand (RANKL), a master regulator for osteoclast differentiation 
(see Section 1.7.2), with the d2 subunit also showing positive regulation by nuclear 
factor of activated T-cells, cytoplasmic 1 (NFATc1), in conjunction with 
microphthalmia-associated transcription factor (MITF) and myocyte enhancer factor 2 
(MEF2) (Lacey et al., 1998, Kim et al., 2008, Feng et al., 2009a). Beyond these 






The classical role of the V-ATPase is in pH homeostasis of intracellular 
compartments, but during the last two decades unconventional roles of V-ATPases in 
other cellular processes have also been described. 
1.6.3.1 The endocytotic pathway 
 
One of the most important roles concerning the V-ATPases is in the regulation 
of signalling, trafficking and degradation of cellular receptors and signalling molecules 
through the endocytotic pathway. Endocytosis is a fundamental cellular process that is 
used by all eukaryotic cells to communicate between the intra and extracellular 
environments and is responsible for internalising signalling molecules, nutrients, 
hormones, plasma membrane proteins, as well as cellular receptors via clathrin-
dependent endocytosis. The endocytotic pathway is a network of endosomes which, 
following internalisation of molecules, results in recycling them back to the surface 
membrane or to be sorted and degraded in late endosomes or lysosomes.   
There are two aspects to the endocytotic pathway that are known to be dependent 
on low endosomal pH: The dissociation of receptor-ligand complexes during recycling 
and the degradation of molecules in lysosomes (Mellman, 1992, Marshansky et al., 
2002, Forgac, 2007, Marshansky and Futai, 2008). V-ATPases are responsible for the 
generation of the required low endosomal pH, and additionally, across the pathway from 
early endosomes to lysosomes there exists a finely regulated, decreasing pH gradient 
generated by the actions of the V-ATPases which if disturbed using V-ATPase inhibitors 
results in improper endocytotic functioning (Clague et al., 1994, Xu et al., 2003, 




1.6.3.2 The exocytotic pathway 
 
Vesicular trafficking of the exocytotic pathway is essential for communication 
between organelles and involves a combination of two steps: The budding of vesicles 
from a donor and subsequent fusion with an acceptor compartment/membrane 
(Bonifacino and Glick, 2004). Studies in yeast have suggested that V-ATPases may be 
involved in fusion events where a direct role of the c-subunits of the V0 domain has been 
proposed (Peters et al., 2001). In this model, fusion pores were proposed to assemble 
from V0 domains in opposing membranes that pair, associated with SNARE (soluble N-
ethylmaleimide-sensitive factor attachment protein receptor) complexes (Strasser et al., 
2011).  
The process in yeast was regulated by a homologue of a subunit a isoform of the 
V-ATPase, which has also been observed in other organisms.  In Drosophilia 
melanogaster, for example, the neuron-specific a1 isoform interacts with SNARE and 
loss-of-function mutations were shown to block synaptic vesicle fusion with the 
presynaptic membrane (Hiesinger et al., 2005). In mammals, V-ATPases are believed to 
control the exocytotic trafficking and secretion of hormones, where knockout mice 
lacking the a3 isoform, which is highly expressed in endocrine tissues, show defective 
insulin secretion with no concordant alteration in the pH of the secretory cells (Sun-
Wada et al., 2006, Sun-Wada et al., 2007). This suggests that V-ATPases may have a 
role in membrane fusion that is independent of acidification. 
 
1.6.4 Inhibitors  
 
The involvement of the V-ATPase in numerous aspects of cellular physiology has 
led to efforts to identify and develop novel V-ATPase inhibitors for therapeutic purposes 
(Huss and Wieczorek, 2009). The bafilomycins (A1 (27), B1, C1, D1) were the first such 
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inhibitors discovered. These macrolide antibiotics were isolated from Streptomyces spp. 
(Werner et al., 1984) and bafilomycin A1 (27) was subsequently shown to inhibit V-
ATPases (Bowman et al., 1988). Concanamycin (28), another member of the same 
chemical family (plecomacrolides), was found to have similar activity and several 
groups have since identified subunit c of the V0 domain as being the primary binding 
site for the plecomacrolides, though there is some evidence that subunit a might also be 
involved (Kinashi et al., 1984, Bowman and Bowman, 2002, Huss et al., 2002, Bowman 
et al., 2006). These inhibitors function by perturbing the mechanical rotation of the V0 
domain proteolipid ring. 
Whilst other V-ATPase inhibitors such as archazolid (Huss et al., 2005), and 
salicylihalamide A (Boyd et al., 2001, Xie et al., 2004) have since been discovered, due 
to the ubiquitous occurrence of V-ATPases, inhibitors such as bafilomycin (27) and 
concanamycin (28) are found to cause off-target effects and systemic toxicity that 
impede use as therapeutics (Keeling et al., 1998). However, V-ATPases that perform 
specialist functions are known to contain distinct subunit isoforms, or combinations of 
subunits, that may permit specific pharmacological targeting. One example of this is the 
osteoclast where the plasma membrane V-ATPase is crucial to the function of bone 
resorption. The following sections introduce the processes involved in bone 
remodelling, in addition to further details regarding the osteoclast V-ATPase and its 
unique role in treating osteolytic diseases.  
 
1.7 Bone: Structure and cells 
 
Bone tissue is a porous, mineralised structure made up of an organic component 
(~25 %) consisting of a collagenous matrix (90 % type I collagen) plus cells and vessels, 
and an inorganic component (~75 %) containing hydroxyapatite crystals 
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(Ca10(PO4)6(OH)2). At the macroscopic level, there are two types of bone found in the 
adult human skeleton, cortical and trabecular (Figure 1.11). At the microscopic level, 
there are also two types of bone that are characterised by the orientation of their collagen 
fibres, lamellar or woven. Woven bone is laid down quickly in response to fracture or 
pathological states of high turnover, and is characterised by the disordered and random 
organisation of collagen fibres and hydroxyapatite crystals. This type of bone is 
ultimately replaced by lamellar bone, which has an organised structure of collagen and 
hydroxyapatite arranged in parallel or concentric sheets around blood vessels (Figure 
1.11) (Martini and Martini, 1992, Seeman and Delmas, 2006). 
Bone is a dynamic tissue that is constantly broken down and reformed in response 
to damage, as well as changes in mechanical loading and serum calcium levels (Sims 
and Gooi, 2008). The process by which this is achieved is known as bone remodeling, 
where 5-10 % of the skeleton is annually renewed with the equivalence of the entire 
adult human skeleton replaced in 10 years (Parfitt, 1982). Bone remodeling (see Section 
1.7.3) is primarily carried out by the actions of osteoclasts and osteoblasts but there are 
also other important cellular components of bone, including osteocytes and bone lining 
cells, which are members of the osteoblast lineage.  
 




Osteoclasts are large multinucleated cells derived from hematopoietic stem cells 
(HSC) of the monocyte/macrophage lineage. These cells carry out bone resorption, and 
are usually found in contact with the bone surface within a resorption pit, or lacuna, 























Figure 1.11 The structure of bone. A segment of bone from the wall of the humerus 
is shown, revealing the organisation of cortical and trabecular bone. Cortical bone 
comprises 80% of the skeleton and forms the outer part of all skeletal structures. It is 
dense and compact and functions to provide mechanical strength. The basic 
functional unit of cortical bone is the osteon, in which osteocytes are arranged and 
embedded in concentric layers (lamellae) of matrix around a central canal, called the 
Haversian canal. These canals contains one or more blood vessels carrying blood to 
and from the osteon and there are also perforating canals that extend perpendicular 
to the surface. Trabecular bone represents less of the skeletal mass but accounts for 
80% of the bone surface area, typically found at and within the ends of long bones, 
and within the interior of vertebrae. This type of bone is more elastic and vascular, 
with a higher turnover rate than cortical bone. In this type of bone, lamellae are not 
arranged in osteons but instead the bone matrix forms interconnecting struts and 
plates called trabeculae within which lies the bone marrow. Adapted from Martini 




Osteoclastogenesis begins when HSCs residing in the bone marrow or circulating 
peripheral blood mononuclear cells (PBMC) are committed to the 
monocyte/macrophage lineage, regulated by the myeloid and B cell transcription factor 
PU.1 (Figure 1.12). These cells (specifically cluster of differentiation (CD)14+, CD11b+ 
and CD61+ cells) are the progenitors of osteoclasts and mice lacking PU.1 lack myeloid 
cells and exhibit osteopetrosis, attributed to a lack of osteoclasts  (Tondravi et al., 1997, 
Tolar et al., 2004, Husheem et al., 2005).  
Studies on the naturally occurring osteopetrotic op/op mouse model led to the 
identification of other key factors in osteoclastogenesis, including macrophage colony 
stimulating factor (M-CSF), which is mutated in op/op mice. M-CSF binds to the 
colony-stimulating factor 1 receptor (c-Fms) on monocytes/macrophages and is essential 
in the generation of common progenitors for macrophages and osteoclasts (macrophage 
colony forming units or CFU-M), as well as an essential microenvironment factor for 
mature osteoclast generation (Wiktor-Jedrzejczak et al., 1990, Yoshida et al., 1990, 
Mossadegh-Keller et al., 2013). As such, during the first stage of osteoclast 
differentiation, M-CSF induces the proliferation and survival of osteoclast precursors 
(CFU-M), and also the expression of receptor activator of nuclear factor κB (RANK), 
which is a prerequisite for osteoclast precursors (Arai et al., 1999, Dougall et al., 1999). 
Other key molecules during this stage are the transcription factor MITF and the anti-
apoptotic protein Bcl-2, which are both downstream of M-CSF signalling and result in 
osteopetrosis and a lack of macrophages if targeted in vivo (Weilbaecher et al., 2001, 
McGill et al., 2002) (Figure 1.12).  
During the final stage of osteoclastogenesis, further molecular signalling result 
in the fusion of osteoclast precursors at the site of bone resorption to produce a mature 
multinucleated osteoclast, or polykaryon. This is mainly induced by RANKL, a member 
of the tumour-necrosis factor family that is essential for mature osteoclast differentiation 
59 
 
and survival, with co-stimulation by the adaptor proteins DAP12 and FcRγ (Anderson 
et al., 1997, Lacey et al., 1998, Yasuda et al., 1998, Humphrey et al., 2005). Deficiency 
in RANK (Li et al., 2000) or RANKL (Kong et al., 1999), as well as downstream 
molecules including TRAF6 (Lomaga et al., 1999, Kobayashi et al., 2001), c-Fos (Wang 
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Figure 1.12 Osteoclastogenesis. A schematic illustrating the differentiation of 
haematopoietic precursor cells into activated osteoclasts is shown, with the expressed 
traits of the monocyte/macrophage/osteoclast lineage shown below each stage. These 
include tartrate-resistant acid phosphatase (TRAP), calcitonin receptor (CTR) and the 
β3 integrin. M-CSF and RANKL are essential for osteoclastogenesis, and their 
involvement during differentiation is shown at the top of the figure. Osteoprotegerin 
(OPG) can bind RANKL and negatively regulate differentiation and activation of 
osteoclasts (see Section 1.7.3). Shown below are the key molecules needed for 
osteoclastogenesis and osteoclast activation. The first group induce differentiation of 
HSCs into macrophage colony-forming units (CFU-M). Defects in these molecules 
result in a lack of osteoclasts and macrophages. The second group induce the cellular 
fusion of precursors and the differentiation of multinucleated osteoclasts, mainly via 
RANKL. Defects here result in a lack of multinucleated osteoclasts. The third group 
induce the activation of osteoclasts and the commencement of bone resorption. 
Defects here result in non-functional, multinucleated osteoclasts. Adapted from 
Boyle et al. (2003) and Asagiri and Takayanagi (2007).  
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2002) and DC-STAMP (Kukita et al., 2004, Yagi et al., 2005), have all been shown to 
cause osteopetrosis due to a lack of multinucleated osteoclasts, despite normal or 
increased numbers of monocyte/macrophages (Asagiri and Takayanagi, 2007) (Figure 
1.12). 
A third set of key molecules determine the activation of mature osteoclasts, and 
the commencement of bone resorption. These include c-Src, a non-receptor tyrosine 
kinase, as well as ClC-7 (chloride channel), cathepsin K (protease) and Atp6i (V-
ATPase), which are directly involved with the bone resorption process (see Section 
1.7.1.2). Mice deficient in these molecules have severe osteopetrosis caused by non-
functioning osteoclasts (Soriano et al., 1991, Gowen et al., 1999, Li et al., 1999, Kornak 
et al., 2001). Both M-CSF and RANKL are now known to be necessary, and sufficient, 
to induce expression of genes that typify the osteoclast lineage, including tartrate-
resistant acid-phosphatase (TRAP), calcitonin receptor (CTR) and the β3-integrin (Lee 
et al., 1995, Lacey et al., 1998, Boyle et al., 2003) (Figure 1.12).  
Signalling is transduced via RANK through recruiting adaptor molecules such 
as the TRAF family (Inoue et al., 2000). Through knockout studies mentioned above, 
TRAF6 was identified as the major essential adaptor molecule, where the RANKL-
induced binding of TRAF6 to RANK induces the activation of upstream pathways that 
activate NF-κB, NFATc1 and AP-1, as well as mitogen-activated protein kinases 
(MAPK) ERK1/2, JNK1/2 and p38, and other protein kinases such as IKK, c-Src and 
AKT (Boyle et al., 2003, Teitelbaum and Ross, 2003, Asagiri and Takayanagi, 2007). 
Whilst RANKL is generally considered as the factor that directly controls 
osteoclastogenesis, M-CSF is also important for later differentiation stages through 
activation of AKT, ERK, c-Fos, and c-Src pathways (Ross and Teitelbaum, 2005). 
Activation of these important signalling cascades are thought to be crucial for osteoclast 
differentiation, survival, activation and function, though some require in vivo evidence 
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of involvement, and many other details of RANKL/M-CSF-induced signalling cascades 
are still under investigation. 
 
1.7.1.2 Osteoclast function 
 
Mature osteoclasts are polarised cells with specialised membrane domains 
including the sealing zone, ruffled border and the basolateral (upper) membrane which 
also contains the functional secretory domain (Väänänen and Laitala-Leinonen, 2008) 
(Figure 1.13 A). The sealing zone is a circular attachment of the plasma membrane to 
the underlying mineralised bone substrate, initiated and facilitated by the integrin 
receptors, such as αvβ3, which bind to amino acid motifs in bone matrix proteins (Nesbitt 
et al., 1993, McHugh et al., 2000).  
Bone resorption by osteoclasts involves the extracellular acidification of the 
sealing zone compartment adjacent to the substrate surface, which leads to the 
demineralisation and subsequent degradation of the bone matrix. Osteoclasts undergo 
several cycles of resorption before apoptosis, with each cycle lasting several hours, 
observed by monitoring phalloidin-stained actin ring formation and disappearance in 
vitro (Lakkakorpi et al., 1989, Lakkakorpi and Väänänen, 1996). During these cycles, 
the cytoskeleton undergoes dynamic rearrangement with the F-actin ring following the 
shape of the sealing zone during resorption. The sealing zone is initially marked by a 
belt of adhesion structures called podosomes, consisting of a core of F-actin bundles, 
covered by a vinculin-talin-β-integrin complex which anchors actin filaments to the 
membrane (Marchisio et al., 1988, Kanehisa et al., 1990). The function of the sealing 
zone is to form a tight seal between the substrate and the cell in order to isolate the 
resorptive space and prevent the loss of cellular secretory products during resorption 














































































































Channel 7  
Functional Secretory Domain 
Bone 
Resorption Pit (Lacunae) 
Basolateral Domain 









Figure 1.13 Overview of the activated osteoclast. A schematic cross-section of a 
polarised, resorbing osteoclast and the specialised membrane domains are shown (A). 
Initiation of bone resorption is dependent on the attachment of the osteoclast to the bone 
surface and the formation of a sealing zone which isolates the underlying resorption 
space. The ruffled border forms from the fusion of acidified vesicles containing V-
ATPases and proteolytic enzymes. The V-ATPases pump protons into the resorption 
space, generated by the activity of carbonic anhydrase II. Chloride ions, imported via 
HCO3
-/Cl- exchangers in the basolateral domain, are also pumped into the resorption 
space through ClC-7, thereby maintaining intracellular pH. The degradation of the 
mineralised component of bone by the acidic pH in the resorption space occurs 
alongside proteolytic degradation of the organic component of bone, ultimately leaving 
a resorption pit. Tartrate-resistant acid phosphatase (TRAP) stained mature osteoclasts 
are imaged on a substrate of dentin, with tailing tracks showing the result of their 
resorption activity (photo courtesy of Prof Tim Arnett) (B). Scanned electron 
micrograph of an osteoclast carrying out bone resorption (image courtesy of Prof Alan 




plasma membrane and contains the functional secretory domain, which has a slightly 
ruffled morphology and serves for the secretion of the digested bone matrix following 
transcytosis (Nesbitt and Horton, 1997, Salo et al., 1997). The basolateral membrane 
also contains a bicarbonate HCO3/Cl
- exchanger which is important in maintaining 
intracellular electron neutrality during bone resorption (Teti et al., 1989). 
The ruffled border is the most prominent feature of a resorbing osteoclast and 
serves two purposes: The secretion of protons and proteases to digest the bone matrix, 
and the endocytosis of digested material to be trancytosed across the cell and released at 
the functional secretory domain. It forms within the sealing zone of the osteoclast from 
the result of fusion with targeted transport vesicles, and is composed of numerous 
extensions and invaginations of the plasma membrane, giving it a ruffled appearance 
(Väänänen et al., 1990, Palokangas et al., 1997).  
The secretion of protons across the ruffled border and into the sealed 
extracellular space between the bone surface and the cell is carried out by the actions of 
V-ATPases localised to the ruffled border (Blair et al., 1989, Väänänen et al., 1990). 
Osteoclasts are the only cells with the ability to resorb bone and the osteoclast V-ATPase 
is crucial to this function. This was demonstrated by disruption of the osteoclast V-
ATPase by antisense DNA and small interfering RNAs, or by mutations in genes 
encoding specific V-ATPase subunits, all of which resulted in reduced resorption 
activity leading to osteopetrosis in both mice and humans (Laitala-Leinonen and 
Vaananen, 1999, Li et al., 1999, Frattini et al., 2000, Scimeca et al., 2000, Michigami et 
al., 2002, Hu et al., 2005b, Lee et al., 2006). Furthermore, bafilomycin (27), an 
established non-specific V-ATPase inhibitor, has been shown to reduce bone resorption 
in vitro, highlighting the potential of pharmacologically inhibiting the osteoclast V-
ATPase in order to treat osteolytic diseases characterised by excessive resorption (see 
Section 1.7.4) (Sundquist et al., 1990, Sundquist and Marks, 1994, Yuan et al., 2010). 
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Osteoclasts require a high efflux of protons across their plasma membranes 
during resorption, involving high densities of V-ATPases localised at the ruffled border. 
This is thought to be achieved by insertion of fully assembled V-ATPases derived from 
specialised populations of intracellular vesicles (Blair et al., 1989, Väänänen et al., 1990, 
Palokangas et al., 1997). Intracellular vesicles containing the V-ATPases are targeted to 
the ruffled border during resorption and then endocytosed during periods when 
resorption is not taking place, though the precise mechanisms regulating V-ATPase 
recycling have yet to be determined (Qin et al., 2012b). However, modulation of the 
actin cytoskeleton is thought to play an important role, as both isoforms of V-ATPase 
subunit B (B1, B2) have been shown to directly bind to actin in an association that is 
thought to facilitate recruitment of V-ATPases to the ruffled border, directed by PI3K 
signalling (Holliday et al., 2000, Chen et al., 2004, Zuo et al., 2006).  
The pool of cytoplasmic protons used for extracellular acidification are 
generated by carbonic anhydrases (Hall and Kenny, 1987) with the subsequent 
bicarbonate accumulation counteracted by bicarbonate/chloride exchangers on the 
basolateral domain (Teti et al., 1989). Also located at the ruffled border is the chloride 
channel, ClC-7, which enable a concurrent chloride ion flow alongside the protons, 
allowing for electroneutral secretion (Kornak et al., 2001). The resulting proton and 
chloride ions in the extracellular resorptive space form hydrochloric acid (HCl), 
producing an acidic pH of ~4.5, which dissolves the hydroxyapatite component the bone 
matrix, exposing the organic collagenous component (Qin et al., 2012b). This is then 
digested enzymatically by secreted cathepsin K and matrix metalloproteinases (MMPs) 
such as MMP-9 or MMP-13 (Nakamura et al., 2004, Everts et al., 2006). Osteoclasts 
also express and secrete TRAP (Figure 1.13 B), a marker for mature osteoclasts which 
is thought to be involved in dephosphorylating bone matrix proteins such as bone 
sialoprotein, a necessary step for integrin binding and generating reactive oxygen 
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species involved in matrix degradation (Halleen et al., 1999, Hayman and Cox, 2003, 
Vääräniemi et al., 2004). The combined actions of matrix demineralisation and 






Osteoblasts secrete the organic bone matrix that subsequently becomes 
mineralised. Osteoblasts are mature, cuboidal-shaped cells derived from mesenchymal 
stem cells (MSCs) that terminally differentiate to bone-lining cells and 
osteocytes(Figure 1.14). As the major bone-forming cells, osteoblasts produce a unique 
Figure 1.14 Osteoblastogenesis. A schematic illustrating the differentiation of 
osteoblasts from mesenchymal progenitors is shown. The process starts with the 
differentiation of preosteoblasts from MSCs, in which Runx2 plays an essential role. 
In the next step, preosteoblasts differentiate into osteoblasts, in which Osx is critical. 
Key inducers of osteoblast differentiation are shown above black arrows for each stage. 
The marker genes expressed by preosteoblasts and osteoblasts are shown below. These 
include collagen 1a (Col1a), alkaline phosphatase (ALP), bone sialoprotein (BSP) and 
osteocalcin. The terminally differentiated osteocytes and bone lining cells are also 





















Bone lining cell 
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combination of extracellular proteins such as osteocalcin, alkaline phosphatase (ALP) 
and type I collagen, which aid in their identification. Osteoblasts deposit osteoid, the 
organic, unmineralised extracellular matrix composed mainly of type I collagen, which 
is subsequently mineralised through the precipitation of hydroxyapatite crystals (see 
Section 1.7.2.2). Contrary to osteoblasts, the identities and molecular markers for the 
mesenchymal progenitors and preosteoblasts are less well defined and understood, as 
the heterogeneous preosteoblasts are represented by all cells transitioning from 
progenitors to mature osteoblasts (Long, 2012).    
Following bone-forming activity, a subset of osteoblasts can become embedded in 
the bone matrix as osteocytes. Osteocytes function as mechanosensors and are important 
regulators of osteoclasts and osteoblasts, responding to damage, hormonal signals, and 
changes in mechanical loading through the formation of an extensive network of 
cytoplasmic processes that extend throughout the bone matrix in tiny canals called 
canaliculi (Martini and Martini, 1992, Heino et al., 2002, Galli et al., 2010, Bonewald, 
2011) (Figure 1.11). Osteocytes secrete sclerostin, a negative regulator of osteoblast 
activity, which is also used as a marker for this cell type (Poole et al., 2005). Other 
osteoblasts undergo apoptosis or become the quiescent bone-lining cells that are found 
on the surfaces of newly formed bone structures, exhibiting a flattened and elongated 
morphology (Miller et al., 1989, Bonewald, 2011). Bone-lining cells are thought to have 
roles coupling bone resorption to bone formation (Everts et al., 2002, Andersen et al., 
2009) (see Section 1.7.3).  
Osteoblast differentiation begins with the local proliferation of MSCs residing in 
the marrow forming osteoblast progenitors (Robling et al., 2006). Only 15% of MSCs 
have the capacity to form bone (Wu et al., 2000) and they are directed towards the 
osteoblast phenotype, and away from adipocyte, myocyte and chondrocyte lineages by 
expression of the runt-related transcription factor-2 (Runx2) (Ducy et al., 1997). Mice 
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deficient in Runx2 lack osteoblasts and show skeletal abnormalities, demonstrating the 
importance of this factor in osteoblastogenesis (Komori et al., 1997, Otto et al., 1997). 
Further gene deletion studies have shown that the Runx2 pathway involves additional 
transcription factors, including distal-less homeobox-5 (Dlx5), muscle segment 
homeobox homologue-2 (Msx2) and basic helix-loop-helix transcription factors (Twist 
proteins) (Bendall and Abate-Shen, 2000, Robledo et al., 2002, Bialek et al., 2004). At 
this point the preosteoblasts express type I collagen and bone sialoprotein with further 
differentiation into a mature, bone-forming phenotype requiring the sustained 
expression of Runx2 as well as osterix (Osx), a zinc finger-containing transcription 
factor that is essential for osteoblast differentiation and bone formation, and activating 
transcription factor 4 (ATF4) (Nakashima et al., 2002, Yang et al., 2004) (Figure 1.14).  
Osteoblast differentiation is also indirectly modulated by components of the 
Wnt/β-catenin pathway, where a high level of β-catenin commits progenitors to 
osteoblast differentiation whilst low expression is important for chondrogenesis (Hu et 
al., 2005a, Milat and Ng, 2009). Other important factors for osteoblast differentiation 
are bone morphometric protein (BMP) signalling (Bandyopadhyay et al., 2006), 
Hedgehog signalling (Long et al., 2004), Notch signalling (Hilton et al., 2008) and 
fibroblast growth factors (FGF) (Montero et al., 2000).  Once mature, osteoblasts 
express type I collagen and osteocalcin, as well as alkaline phosphatase (ALP), a key 
enzyme in the mineralisation process (Robling et al., 2006). 
 
1.7.2.2 Osteoblast function 
 
Osteoblasts have abundant mitochondria, enlarged Golgi and extensive 
endoplasmic reticulum, all of which are consistent with the capacity to synthesise 
collagen and other extracellular matrix (ECM) proteins. These cells are also rich in 
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secretory vesicles containing the ECM proteins which form osteoid. Mineralisation of 
the osteoid occurs after a time lag of approximately 10 days and begins with nucleation, 
the formation of an initial hydroxyapatite crystal. The exact mechanisms of this process 
are still not clear with three modes of nucleation having been proposed. One theory 
suggests that crystals are actively nucleated from solution by charge proteins in the 
collagen gap zones without any intervention from cellular processes (Glimcher and 
Muir, 1984). Another theory suggests that initial nucleation takes place in the 100 nm-
wide extracellular matrix vesicles that bud from the plasma membrane of osteoblasts 
and are seeded within the ECM. Initial crystals are generated inside the vesicles, 
controlled by alkaline phosphatase (ALP) and calcium binding proteins (Ali et al., 1970), 
before the breakdown of the vesicular membrane and further crystal proliferation is 
governed by extracellular conditions (Anderson, 1995).  
A more recent theory suggests that disordered calcium phosphate material is 
formed in matrix vesicles intracellularly before being exocytosed and deposited in the 
collagen gap zones where it crystallises, a strategy known to be employed in the 
formation of fish fin-bones and by various invertebrates (Mahamid et al., 2011). Several 
proteins secreted by osteoblasts are required for proper mineralisation, including ALP 
and osteocalcin, the ablation of which results in hypomineralisation of the skeleton 
(Tesch et al., 2003) and impaired mineral maturation (Boskey et al., 1998) respectively. 
ALP and osteocalcin are therefore used as markers for osteoblastic activity.  
 
1.7.3 Bone remodeling and coupling factors 
 
Bone remodeling is carried out by the coordinated actions of osteoclasts and 
osteoblasts, together known as the “Basic Multicellular Unit” (BMU). Bone remodeling 
takes place asynchronously throughout the skeleton with resorption activity in an adult 
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BMU taking approximately 3 weeks, and the formation response 3 to 4 months (Sims 
and Martin, 2014). The dynamics of bone remodelling were first described by Frost 
(1964) over 50 years ago, in which the BMU was thought to consist of two cell types, 
osteoclasts and osteoblasts, that act in close apposition and regulate the function of each 
other through production of inhibitory and stimulatory factors. The different processes 
of bone remodeling in cortical and trabecular bone are shown in Figure 1.15.   
The coupling of a BMU is tightly controlled, coordinated by signalling cross-talk 
between the relevant cell types via local factors, as well as matrix-derived signals and 
systemic hormones, which together ensure that the removal of old bone is always 
followed by the formation of new bone (Parfitt, 2000, Sims and Gooi, 2008). In healthy 
individuals, coupling is a finely balanced process but any disruptions to this balance can 
lead to metabolic bone diseases characterised either by low bone mass such as 
osteoporosis, attributed to excessive resorption by osteoclasts leading to increased 
fracture risk, or by high bone mass such as osteosclerosis or osteopetrosis, attributed to 
a net imbalance favouring bone formation (Zaidi, 2007).  
The application of an in vitro method of osteoclast generation involving the co-
culture of bone marrow cells with osteoblasts demonstrated the importance of cellular 
contact between osteoclast precursor cells and osteoblasts, and led to the identification 
of RANKL (Jimi et al., 1996, Suda et al., 1999). The discovery of RANKL represented 
a major advance in bone biology and has greatly facilitated in vitro osteoclastogenesis, 
where it is now well established that cells of the monocyte/macrophage lineage, obtained 
from bone marrow or peripheral blood, can be differentiated into mature, functional 
osteoclasts by adding recombinant M-CSF and RANKL to the culture medium (Yasuda 
et al., 1998, Suda et al., 1999). Both M-CSF and RANKL are primarily produced by 
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Figure 1.15 Cells of basic multicellular units (BMU) during bone remodeling. Bone 
remodeling is initiated beneath a canopy of bone lining cells in trabecular bone (upper 
panel) and within cortical bone Haversian canals (lower panel) (A). Osteoclasts are 
derived from hematopoietic stem cells (HSC), osteoblasts are derived from 
mesenchymal stem cells (MSC), both via the marrow and blood. Lining cells may also 
differentiate into active osteoblasts and vice versa. A scheme representing the bone 
remodeling cycle is also shown (B): 1. Bone lining cells cover the quiescent surface of 
bone. 2. Upon signals derived from apoptotic osteocytes, preosteoclasts are recruited to 
the bone surface. 3. Mature osteoclasts form and perform bone resorption. 4. A group 
on mononuclear cells, believed part of the osteoblast lineage, line the resorptive cavity 
during the reversal phase. The exact function of these cells is unknown but may smooth 
the cavity in preparation for the deposition of new bone matrix. 5. Osteoblasts secrete 
matrix proteins in the form of osteoid which subsequently mineralises to become new 
bone. 6. Osteoblasts become apoptotic or differentiate into osteocytes or bone lining 
cells and the bone surface is again quiescent. Adapted from Sims and Martin (2014) and 
Burr and Allen (2013). 
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stimulates osteoclast differentiation (Wiktor-Jedrzejczak et al., 1990, Kong et al., 1999, 
Pixley and Stanley, 2004, Nakashima et al., 2011). At the same time RANKL was 
discovered, the soluble decoy receptor osteoprotegerin (OPG) was also found to be 
produced by osteoblastic cells, which inhibits osteoclastogenesis by competitively 
binding to RANKL preventing the induction of RANK-signalling in osteoclasts 
(Simonet et al., 1997, Yasuda et al., 1998). Bone remodeling is thus coordinated by 
RANKL:OPG expression in osteoblastic cells, stimulating osteoclastogenesis and bone 
resorption by increasing RANKL expression and decreasing OPG, which is then closely 














Figure 1.16 Regulation of osteoclast differentiation by the osteoblast lineage. The 
release of M-CSF by osteoblastic cells stimulates osteoclast precursors to express 
RANK. RANKL is also secreted by osteoblastic cells and can either bind to RANK on 
the surface of osteoclast precursors to promote osteoclast differentiation, or it can bind 
to the decoy receptor OPG, impeding osteoclast differentiation. OPG is also secreted by 
cells of the osteoblast lineage and so the ratio of RANKL to OPG is critical for 
determining in vivo osteoclast numbers and bone resorption, as shown by the schematic 




Various local and systemic factors, including cytokines and paracrine signals, 
exhibit an effect on bone remodeling via signals to the osteoblast/stromal cell, which are 
then transduced into the appropriate ratio of RANKL:OPG (Hofbauer et al., 2000, 
Martin, 2004). Parathyroid hormone (PTH), for example, is classically regarded as a 
hormone that stimulates bone resorption, mediated by the ability to induce production 
of RANKL by the osteoblast lineage (Fu et al., 2002). Other factors that have been 
shown to upregulate RANKL-induced bone resorption include TNF-α, vitamin D3, PTH-
related peptide (PTHrP), glucocorticoids, prostaglandin E2, insulin-like growth hormone 
1 (IGF-1) and interleukins (IL), such as IL-1, IL-6 and IL-17 (Hofbauer et al., 1999, Li 
et al., 2000, Ma et al., 2001, Liu et al., 2005, Lee et al., 2008). Conversely, oestrogen 
negatively regulates bone resorption by increasing OPG and decreasing RANKL 
expression in osteoblastic cells, as well as reducing osteoclast survival and stimulating 
osteoblast proliferation (Kameda et al., 1997, Saika et al., 2001, Srivastava et al., 2001, 
Eghbali-Fatourechi et al., 2003, Nakamura et al., 2007). The loss of oestrogen in 
postmenopausal women therefore results in increased osteoclast survival and resorption, 
ultimately leading to osteoporosis. Another negative regulator of bone resorption is 
calcitonin, which directly inhibits resorption through specific receptors on the 
osteoclasts (Zaidi et al., 2002).   
However, in contrast to the catabolic effect of PTH, intermittent administration 
of PTH can be used therapeutically to increase bone formation and bone mass in 
menopausal women (Neer et al., 2001). This is due to the direct effects of PTH on the 
osteoblast lineage where it promotes osteoblast differentiation (Dobnig and Turner, 
1995), inhibits osteoblast apoptosis (Jilka et al., 1999, Stanislaus et al., 2000) and 
reduces the production of the bone formation inhibitor sclerostin (Keller and Kneissel, 
2005). As PTH appears to stimulate both bone formation and resorption, it has been 
suggested that the anabolic effect of PTH is dependent on the ability to stimulate 
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osteoclast activity, implying that osteoclasts are an essential intermediate for the 
anabolic effect (Koh et al., 2005). Furthermore, the anabolic effect of intermittent PTH 
therapy was reduced when bisphosphonates were used concomitantly, also indicating 
the required presence of osteoclasts for the anabolic effect of PTH (Delmas et al., 1995, 
Coxon et al., 2006). The anabolic effects of intermittent PTH therapy therefore suggest 
the involvement of osteoclast-derived coupling factors that function to stimulate bone 
formation. Work by Karsdal et al. (2008) and Henriksen et al. (2012a) also presented 
compelling evidence for the existence of an osteoclast-derived coupling factor, as 
conditioned media from human osteoclasts, cultured on either bone or plastic, led to a 
dose dependent increase in bone nodule formation by primary osteoblasts, indicating the 
presence of stimulatory factor(s) produced by the osteoclasts independent of bone 
resorption.  
Whilst the major osteoblast-derived coupling factors have been understood for 
many years now, in recent years there has been great interest in identifying the putative 
osteoclast-derived coupling factors. Such candidates have included factors that are 
released from the bone matrix during bone resorption such as IGF-1 or TGFβ (Hayden 
et al., 1995, Tang et al., 2009), as well as other factors secreted by both inactive and 
active osteoclasts which are shown to have positive effects on osteoblasts. These include 
cardiotrophin-1 (Walker et al., 2008), ephrinB ligands (Zhao et al., 2006, Sims, 2010), 
sphingosine-1-phosphate, BMP6 and Wnt10b (Ryu et al., 2006, Pederson et al., 2008, 
Ishii et al., 2009), collagen triple helix repeat containing 1 (CTHRC1) (Takeshita et al., 
2013) and semaphorin 4D (Negishi-Koga et al., 2011). None of these are exclusively 
expressed by osteoclasts and further in vivo studies are needed to determine their roles 
as coupling factors. However, the implication of an osteoclast-derived coupling factor 
has significant consequences for treating imbalances in bone remodeling and for 
developing novel effective therapeutics, as discussed in the following section. 
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1.7.4 Osteolytic bone diseases and the osteoclast V-ATPase 
 
Osteolytic bone diseases are caused by disturbances to bone remodeling in the 
form of enhanced osteoclast activity, leading to increased bone resorption, 
hypercalcemia and a loss of bone mass. This activity is observed in osteopathic disorders 
such as osteoporosis, Paget’s disease, primary bone tumours, multiple myeloma as well 
as lytic bone metastases (Goltzman, 2001, Heymann et al., 2005, Guise et al., 2006, 
Chamoux et al., 2009). Osteoporosis, specifically, represents a serious worldwide health 
problem, as the consequent increase in bone fragility leads to increased risk of fracture, 
particularly in the hip, wrist and vertebrae (Seeman, 2003, Johnell and Kanis, 2005). In 
the UK, the lifetime risk of an osteoporotic fracture at age 50 is 53 % and 21 % for 
women and men respectively, with the increased risk of hip fracture a major concern 
due to the associated high morbidity, mortality and loss in quality of life (Van Staa et 
al., 2001). Global estimates suggest there are 1.25 million osteoporotic hip fractures each 
year, predicted to increase by 310 % in men and 240 % in women due to the aging of 
the population, and leading to predicted costs of $131.5 billion by 2050 (Gullberg et al., 
1997, Johnell, 1997). It is thus worthwhile and important to prevent osteoporotic 
fractures, and treating high risk osteoporotic patients with drugs known as 
antiresorptives has been shown to be a cost-effective solution (Johnell and Kanis, 2005).  
 Currently the most widely used treatments for osteolytic diseases are the 
bisphosphonates, such as alendronate and zoledronate (Chen and Sambrook, 2012). 
Bisphosphonates are synthetic analogues of inorganic pyrophosphate and bind to bone 
mineral surfaces in vivo. Upon release following bone resorption, bisphosphonates 
inhibit the formation, activity and survival of osteoclasts through disruption of key 
enzymes involved in the isoprenylation of small GTPases, which are required for 
osteoclast polarisation and vesicular trafficking (Coxon et al., 2006). In addition to 
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bisphosphonates, there are also other antiresorptive compounds such as selective 
oestrogen receptor modulators (SERMS), denosumab (monoclonal antibody to 
RANKL) and calcitonin (Chen and Sambrook, 2012). However, whilst all of these 
treatments have been shown to be effective inhibitors of bone resorption, a common 
secondary effect is the suppression of bone turnover and a decrease in bone formation 
that can lead to atypical bone fractures and osteonecrosis (Ott et al., 2002, Odvina et al., 
2005, McClung et al., 2006, Karsdal et al., 2007, Lenart et al., 2008). The cause of 
reduced bone formation is likely a result of the inhibitory mechanisms of the 
antiresorptives, which involve eliminating or reducing the number of osteoclasts leading 
to decreased bone formation due to coupling with osteoblasts (Karsdal et al., 2007, 
Henriksen et al., 2011a).  
An ideal treatment for osteolytic diseases is the use of an antiresorptive that 
uncouples bone remodeling so that bone formation can occur independently of bone 
resorption, leading to a net gain in bone tissue (Thudium et al., 2012). Analyses of the 
phenotypic characteristics of osteopetrosis mutations in humans has indicated that the 
osteoclast ruffled border V-ATPase may be a promising target to uncouple bone 
resorption from bone formation. Osteopetrosis is divided into three groups based on 
severity: Autosomal dominant osteopetrosis (ADO), where the phenotype ranges from 
mild to asymptomatic; autosomal recessive osteopetrosis (ARO), the most severe group; 
and intermediate autosomal recessive osteopetrosis (IARO). ADO is caused by 
dominant negative mutations in ClC-7, the chloride ion-proton antiporter that ensures 
ion homeostasis in resorbing osteoclasts (Cleiren et al., 2001, Del Fattore et al., 2008). 
ARO on the other hand is caused by homozygous mutations in either CIC-7 (Kornak et 
al., 2001, Frattini et al., 2003), RANK/RANKL (Sobacchi et al., 2007, Guerrini et al., 
2008) or the a3 subunit of the V-ATPase (Frattini et al., 2000, Kornak et al., 2000). Of 
all the mutations causing osteopetrosis, mutations in the a3 isoform gene (TCIRG1) are 
76 
 
responsible for approximately 50% of cases of malignant osteopetrosis, resulting in 
symptoms that include high bone density, propensity to fractures and no marrow cavity 
(Frattini et al., 2000, Michigami et al., 2002).  
Interestingly, mutations of the a3 V-ATPase subunit or ClC-7, were found to 
cause uncoupling of bone remodelling, where resorption was inhibited but bone 
formation was normal or increased. Observations at the cellular level showed that 
patients with defects in acid secretion had high numbers of osteoclasts that showed 
normal polarisation and interaction with the bone surface, but no bone resorption due to 
inhibited extracellular acidification (Flanagan et al., 2000, Frattini et al., 2000, Del 
Fattore et al., 2006). These patients were also found to have correlating numbers of 
osteoblasts resulting in normal or increased bone formation, demonstrating the 
uncoupling of bone remodeling (Bollerslev et al., 1993, Del Fattore et al., 2006, Karsdal 
et al., 2007). In contrast to the osteoclast-rich osteopetrosis models are the osteoclast-
poor osteopetrosis models where mutations in RANK/RANKL, or M-CSF  lead to low 
numbers of osteoclasts, causing patients to have both lowered bone resorption and 
formation with no uncoupling of bone remodeling (Dobbins et al., 2002, Dai et al., 2004, 
Sakagami et al., 2005, Segovia-Silvestre et al., 2009).  
These observations support the evidence that osteoclasts mediate anabolic 
signals to osteoblasts, emphasising the importance of sustaining osteoclast populations 
during treatment of bone remodeling disorders. Additionally, they suggest that 
attenuating the acid secretion machinery of osteoclasts is a way to uncouple bone 
resorption from bone formation, providing the ideal therapeutic scenario for osteolytic 
diseases. This uncoupling was observed in the oc/oc mice, which have a natural mutation 
in the a3 subunit of the V-ATPase, and in vitro effects mimicking the phenotype of 
osteoclast-rich osteopetroses have also been observed using inhibitors of V-ATPases (Li 
et al., 1999, Karsdal et al., 2005, Sorensen et al., 2007). It was also shown that if 
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osteopetrosis was induced in wild-type mice using fetal liver-derived HSCs from the 
oc/oc mice, bone formation and bone strength were increased, confirming that 
attenuation of acid secretion through targeting the V-ATPase can lead to uncoupling and 
anabolic activity (Henriksen et al., 2011b). 
Interestingly, ex vivo-generated osteoclasts from a3-mutant mice, as well as 
osteoclasts with siRNA mediated knockdown of a3 had defective extracellular 
acidification but showed normal osteoclastogenesis and normal intracellular pH 
homeostasis, suggesting that the a3 isoform is not involved in the latter processes (Li et 
al., 1999, Hu et al., 2005b). Whilst osteoclasts are known to contain subunit isoforms 
a1, a2 and a3, only a3 has been shown to be crucial for osteoclast resorption despite also 
being expressed in other tissues, as this isoform is dramatically upregulated during 
osteoclastogenesis and re-localised from lysosomes to the ruffled border during 
osteoclast activation (Scott and Chapman, 1998, Li et al., 1999, Manolson et al., 2003, 
Toyomura et al., 2003).  
Other V-ATPase subunits of importance in the osteoclast are B2, C1, d2 and the 
accessory subunit Ac45. There are two isoforms of subunit d found in humans but d2 is 
expressed 5-fold higher that d1 in human osteoclasts (Smith et al., 2005, Lee et al., 2006, 
Wu et al., 2009a) and like a3, expression is highly induced by RANKL (Feng et al., 
2009b, Wu et al., 2009a). Ablation of the d2 gene in mice was found to cause 
osteopetrosis, with osteoclasts from those mice showing defects in the formation of 
fused multinucleated cells suggesting a role for this subunit in pre-osteoclast fusion (Lee 
et al., 2006). The subunit isoform C1 is also highly induced by RANKL, with a role that 
is thought to involve actin-binding to facilitate the recruitment of V-ATPases at the 
ruffled border, also attributed to the B2 subunit. In osteoclasts, both C1 and B2 are 
expressed exclusively and localised to intracellular vesicles and the ruffled border 
(Bartkiewicz et al., 1995, Lee et al., 1996, Feng et al., 2009b), and depletion of C1 caused 
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impaired osteoclast resorption and disrupted actin ring formation but otherwise normal 
differentiation (Feng et al., 2009b). The precise physiological role of Ac45 is still 
unclear, though studies have shown that this subunit is essential for osteoclast-mediated 
bone resorption as well as osteoclast formation and maturation (Feng et al., 2008, Qin et 
al., 2011, Yang et al., 2012). In summary, there are specific V-ATPase subunits 
expressed in osteoclasts (a3, B2, C1, d2, Ac45), which have all been shown to localise 
at the ruffled border. Whilst a3, B2 and C1 have been shown to have roles in osteoclast 
activation and resorption only, d2 and Ac45 have shown dual roles, involved in both 
osteoclast differentiation and activation.  
The crucial and specific involvement of the a3 isoform in the function of bone 
resorption, coupled with the knowledge that certain other subunit isoforms are highly 
expressed and localised to the ruffled border, has led to the suggestion that the osteoclast 
ruffled border V-ATPase is structurally distinct from V-ATPases involved in other 
cellular processes. This permits the intriguing possibility of specifically targeting 
subunits of the ruffled border V-ATPase with inhibitors in order to attenuate osteoclast 
function without causing off-target effects. As seen with the osteoclast-rich 
osteopetroses, this should then lead to the uncoupling of bone remodeling and a net gain 
in bone density. As such, examination of the effects of uncharacterised V-ATPase 
inhibitors on osteoclasts is thus a worthwhile endeavour in the search for novel osteolytic 









1.8 Research aims 
 
This thesis addressed two general aims concerning the study of the sponge-derived 
compound 73-DOC (22). The V-ATPase is crucial to the bone resorptive function of 
osteoclasts as well as the pathogenesis of osteolytic diseases such as osteoporosis, which 
is characterised by effects on both osteoclasts and osteoblasts. Previous work with 73-
DOC (22) demonstrated V-ATPase inhibitory activity, but the effects of the compound 
on osteoclasts and osteoblasts have never been investigated.  
Using the hypothesis that 73-DOC (22) will cause specific V-ATPase-mediated 
inhibition of osteoclastic bone resorption, the first aim of this thesis was to evaluate 73-
DOC (22) as a novel bone resorption inhibitor and to characterise differential activity 
between osteoclasts and osteoblasts. This was achieved by: 
 Extracting a stock of 73-DOC (22) from the sponge I. ramosa for in vitro testing 
and establishing biological activity against an osteoblastic cell line (Chapter 3). 
 Determining the effects of 73-DOC (22) on primary osteoclast/osteoblast 
precursor proliferation, differentiation and mature cell viability (Chapter 4). 
 Examining the effects of 73-DOC (22) on osteoclast activation, bone resorption 
and osteoblast mineralised bone nodule formation (Chapter 5). 
The second aim of this thesis sought to provide a long-term solution to the supply 
problem of natural products alongside in vitro experimentation with 73-DOC (22). 
Using the hypothesis that 73-DOC (22) biosynthesis involves a type I hybrid 
PKS/NRPS, which implies that the cloned biosynthetic genes may ultimately be 
expressed in a fermentable bacterial species, the second aim was to clone and sequence 
the PKS/NRPS gene cluster responsible for 73-DOC (22) biosynthesis from the sponge 




 Screening a metagenomic clone library for conserved features of PKS/NRPS 
biosynthesis, in addition to direct sequencing of sponge-derived metagenomic 
DNA (Chapter 6).  
 Comparison of annotated PKS sequences with a predicted model of 73-DOC 
























Chapter 2: Materials and Methods 
 




Samples of I. ramosa were collected from the central region of the Great Barrier 
Reef by AIMS by scuba diving at a depth of approximately 15 m. Immediately after 
collection, the sponges were either flash-frozen in liquid nitrogen, stored and shipped to 
KCL at -80 °C for DNA extractions described in Section 2.3.3, or freeze-dried for the 
extraction of 73-DOC and shipped at -80 °C with the flash-frozen samples. All 
specimens were verified to contain 73-DOC by AIMS using published methods (Rashid 
et al. 2001b). A 2.5 mg authentic sample of 73-DOC was also supplied by AIMS, 
prepared by Dr. M. Freckelton and Dr. C. Motti from the Bio-Analytical Facility, and 
shipped as a dry residue. The concentration was estimated with UV spectroscopy as 
detailed in Section 2.1.4. All solvents were sourced from Fisher Scientific 
(Loughborough, UK).  
 
2.1.2 Preparation of semi-crude extract 
 
Preparation of the semi-crude extract was carried out according to procedures 
previously optimised by Dr. Walt Dunlap of AIMS. Freeze-dried whole I. ramosa tissue 
(10 g) was cut up into small pieces using a disposable scalpel. The tissue was placed into 
50 ml tubes and extracted with 20 % methanol for 2 hours using mild sonication. This 
was repeated using the same tissue 4 times, with the extracts combined after removing 
gross particulates by centrifugation at 4000 x g. The extract was then filtered through a 
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glass-fibre filter with a 1.5 cm bed of celite. A C18-E solid phase extraction (SPE) 
column from Phenomenex (Macclesfield, UK) was prepared by washing with 1 volume 
(50 ml) of 100 % methanol followed by water. The celite filtered extract was then 
applied to the column followed by 2x 50 ml washes of water and then eluted successively 
with 3 volumes of 90% methanol. The eluate was dried using a rotary evaporator and 
the residue was resuspended in 50 ml 20 % methanol. Another SPE column was prepared 
with 1 volume of 100 % methanol followed by 20 % methanol, before the resuspended 
sample was applied to the new column. This column was washed with 1 volume of 20 
% methanol and then eluted with 2 volumes of 90 % methanol. This eluate represented 
the semi-crude 73-DOC extract and was dried using a rotary evaporator.  
 
2.1.3 Chromatography procedures  
 
Reversed-phase high performance liquid chromatography (HPLC) was carried 
out using an Agilent Technologies system (Stockport, UK). The HPLC system involves 
the interaction of the analyte with the stationary phase and the mobile phase, constituted 
of a mixture of solvents. Reversed-phase HPLC has a non-polar stationary phase and an 
aqueous, moderately polar mobile phase. A Phenomenex C18 Jupiter column (300Å, 5 
µm, 150 x 2 mm) was used for the analytical work, using a flow rate of 0.2 ml/min and 
a 30 minute gradient of 10-90 % acetonitrile in water. Both the acetonitrile and water 
were supplemented with 0.1 % trifluoroacetic acid. Samples (10 µl) were auto-injected 
into the system and the UV signal was monitored at 216, 226 and 261 nm using a diode 
array detector and Agilent’s ChemStation software, based on spectral data reported by 
Rashid et al. (2001b). Preparative reversed-phase HPLC was performed using the same 
equipment but with a preparative Whatman Partisil (GE Healthcare, Little Chalfront, 
UK) C18 column (10 µm, 500 x 9.4 mm) and a flow rate of 5 ml/min. Semi-crude 73-
83 
 
DOC was resuspended in 10 ml of 10 % acetonitrile at a concentration of 10 mg/ml, and 
injected manually. The gradient and detection conditions were the same as for the 
analytical column, the UV signals (216, 226 and 261 nm) were monitored during each 
run and the relevant peak corresponding to 73-DOC was collected in 15 ml tubes. The 
solvents were then removed using a freeze-drier, leaving a white powder.   
Liquid chromatography-mass spectrometry (LC-MS) was performed using a 
Thermo Accela LC system interfaced directly to a Thermo LTQ XL linear ion trap mass 
spectrometer, running in full scan positive ion electrospray mode (ThermoFisher 
Scientific, Massachusetts, USA). The chromatography column was a Hypersil Gold (1.9 
µm, 50 x 2.1 mm) from Phenomenex and a flow rate of 0.2 ml/min was used. 1 mg of 
material was resuspended in 1 ml of 50 % methanol which was further diluted to 0.1 
mg/ml before injection.  
 
2.1.4 Spectrometry and spectroscopy procedures  
 
Nuclear magnetic resonance spectra were recorded using a Brucker Advance 
DPX-400 spectrometer (Coventry, UK). The spectra were obtained from 2.5 mg of 73-
DOC resuspended in deuterated methanol at 400 MHz.  
UV spectroscopy was used to determine the concentration of 73-DOC. Dried 73-
DOC was resuspended in 1 ml methanol, loaded into a Hellma-Analytics (Müllheim, 
Germany) quartz cuvette, and the absorbance of the solution at 261 nm was obtained 
using a spectrophotometer. Using the absorbance value and the coefficient of extinction 
(ε = 36308) reported by Rashid et al. (2001b) for 73-DOC at 261 nm, the concentration 
of the sample was calculated using the formula: 
A = ε L c 
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Where A is absorbance, ε is the coefficient of extinction, L is the light path length 
through the cuvette (10 mm) and c is the concentration of the sample in mol/L. The 
solution of 73-DOC in methanol was then dried down and the compound was 
resuspended in 1 ml sterile water, aliquoted at concentrations of 1-10 µM and stored at 
-20 °C.     
 High resolution mass spectrometry (HRMS) was performed using an Exactive™ 
Plus Orbitrap Mass Spectrometer (ThermoFisher Scientific) running in full scan positive 
ion electrospray mode. The sample was delivered by direct infusion at a concentration 
of 1 µg/ml. Mass error estimates in parts per million (ppm) were calculated using the 
formula: 
Ppm = 106 x measured mass – theoretical mass  
                theoretical mass 
 




All cells were cultured in minimum essential medium, alpha modification (α-
MEM) (Lonza, Basel, Switzerland), supplied with ribonucleosides, 
deoxyribonucleosides and 2 mM L-glutamine. Cells were cultured in α-MEM containing 
100 U penicillin and 100 µg/ml streptomycin from Sigma-Aldrich (Gillingham, UK),  
and 10 % heat-inactivated fetal bovine serum (FBS) (Lonza), batch-tested for osteoclast 
and osteoblast differentiation (complete culture medium). Murine recombinant RANKL 
and human recombinant M-CSF were purchased from R&D Systems (Bio-Techne, 
Abingdon, Oxford, UK). All cells were cultured at 37 °C in 5 % CO2 in air, and media 
were replaced every 2-3 days.  
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Acridine orange was obtained from Fisher Scientific. Enzymes including trypsin, 
dispase and collagenase A were all obtained from Roche (Basel, Switzerland). 
Bafilomycin (bafilomycin A1 - Sigma-Aldrich) was resuspended in dimethyl sulfoxide 
(DMSO) and stored at -20 °C in 5 µM aliquots.  
All mice used were from the CD-1 strain and were housed and maintained in 
accordance with Home Office guidelines. Human peripheral blood was obtained from 
healthy adult male volunteers with approval from the KCL ethics committee (Dr Valerie 
Corrigall, Rheumatology, Centre for Molecular & Cellular Biology of Inflammation 
(CMCBI)).  
Dentin slices were obtained from elephant ivory (HM Customs and Excise, 
Heathrow, London, UK). The ivory was cut into 250 µm-thick wafers using a diamond 
coated wafering blade (Buehler, Coventry, UK) and a standard hole-punch was used to 
produce 5 mm-diameter discs of dentin which could fit into 96-well culture plates. The 
dentin discs were sonicated in multiple changes of deionised water for a minimum of 3 
hours before being washed in ethanol and dried in a laminar-flow cabinet.  
 
2.2.2 MG-63 culture 
 
The human osteosarcoma cell line, MG-63, was obtained from the American 
Type Culture Collection, and was used to determine the antiproliferative activity of the 
newly prepared 73-DOC stock using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay (see Section 2.2.11). 
MG-63 cells were maintained in 75 cm2 culture flasks using α-MEM and 10 % FBS, and 




2.2.3 Osteoclast culture 
 
2.2.3.1 Murine osteoclast culture 
 
Murine primary osteoclast precursors were obtained from bone marrow 
macrophages (BMMs) of 6-8 week old male mice as described by Orriss and Arnett 
(2012). Mice were killed by cervical dislocation with the femora and tibiae dissected 
and scraped cleaned of adherent tissue. Under sterile conditions, a 25-gauge needle was 
used to bore into the ends of each bone. The bone marrow of all bones was flushed out 
into 1 ml of α-MEM with 10 % FBS to create a single-cell suspension, and cultured 
overnight in complete culture medium containing 50 ng/ml M-CSF in a 75 cm2 flask. 
The following day, non-adherent cells were poured through a 40 µm cell strainer and 
counted using a heamocytometer. These precursor cells were then either used in 
proliferation assays (see Section 2.2.11) or to generate mature osteoclasts.  
For osteoclast differentiation, M-CSF-dependent done marrow cells were plated 
at 150,000 cells/cm2 either on tissue culture plastic or directly on dentin discs in 
complete culture medium containing 50 ng/ml M-CSF. After 2 days, medium was 
changed to contain M-CSF (25 ng/ml) and RANKL (5 ng/ml). Media were replaced 
every 2-3 days and multinucleated osteoclasts typically formed within 3-4 days 
following the addition of RANKL.  
For resorption analysis of mature osteoclasts, M-CSF-dependent bone marrow 
precursors were cultured in 24-well plates as described above. Once multinucleated 
osteoclasts were present, the cells were detached using Accutase® (Sigma-Aldrich) and 
seeded onto pre-soaked dentin discs in 100 µl of complete culture medium containing 
M-CSF (25 ng/ml) and RANKL (5 ng/ml), at an average of 1 well to 2 discs with 
treatment groups arranged in triplicate. The cells were left to adhere for 2-3 hours before 
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test compounds were added in an additional 100 µl of medium at 2x the desired final 
concentration. The cells were cultured for a further 48 hours before the experiment was 
terminated.  
 
2.2.3.2 Human osteoclast culture 
 
Human peripheral blood mononuclear cells (PBMCs) obtained from male 
volunteer donors were used to generate human osteoclasts using procedures similar to 
those described by Henriksen et al. (2012b). To isolate mononuclear cells from 
peripheral blood, the density gradient medium, LymphoprepTM, from Axis-Shield (Oslo, 
Norway) was used. Undiluted blood from a healthy volunteer was carefully layered over 
20 ml of LymphoprepTM in 4 x 50 ml tubes. The tubes were centrifuged for 20 minutes 
at 800 x g with no stopping brake. The mononuclear cell layer was removed from the 
LymphoprepTM/plasma interface, combined, and washed with PBS before being 
centrifuged at 250 x g for 10 minutes. This washing step was then repeated. In order to 
produce a more homogenous population of monocyte cells and to remove other 
contaminating cell types such as red blood cells, the PBMCs were sorted for CD14+ 
monocytes using a Dynabeads® Untouched™ Human Monocytes Kit from Life 
Technologies (California, USA). The kit protocol was followed, monocytes following 
isolation were resuspended in 10 ml of isolation buffer (PBS, 0.1% BSA and 2 mM 
EDTA). 
The purified monocytes were then counted using a haemocytometer and cultured 
in 75 cm2 flasks at a concentration of 3 x 106 cells/flask in complete culture medium 
containing 50 ng/ml M-CSF. After 2-4 days in culture, the M-CSF concentration was 
reduced to 25 ng/ml and RANKL was added at a concentration of 10 ng/ml. Culturing 
continued until mature osteoclasts were observed, usually after 7-10 days in culture. 
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Once present the cells were detached from the flasks using Accutase®, counted, and re-
pated onto pre-soaked dentin discs in 100 µl of complete culture medium containing M-
CSF (25 ng/ml) and RANKL  (10 ng/ml), at a concentration of approximately 80,000 
cells per disc. The cells were left to adhere for 2-3 hours before test compounds were 
added in an additional 100 µl of medium at 2x the desired final concentration. The cells 
were cultured for a further 72 hours before the experiment was terminated.        
 
2.2.4 TRAP staining 
 
Osteoclasts were fixed in 4 % paraformaldehyde and stained for Tartrate-
Resistant Acid Phosphatase (TRAP) using the Acid Phosphatase, Leukocyte Kit (387A; 
Sigma-Aldrich), in the presence of 50 mM sodium-tartrate. Mature osteoclasts, defined 
as TRAP-positive cells with more than 3 nuclei, were either counted using bright-field 
microscopy with a graticule, or from images acquired using a stereomicroscope followed 
by ImageJ (http://imagej.nih.gov/ij/) quantification. All cell counts were made from 
triplicate wells in each treatment group, expressed as a percentage of the control group.  
 
2.2.5 Actin staining 
 
Staining of actin rings using phalloidin-TRITC (Sigma-Aldrich) was used for 
quantifying human osteoclasts cells. Following fixation with 4 % paraformaldehyde, 
cells were permeabilised with 0.1 % Triton X-100 in PBS for 5 minutes and stained with 
phalloidin-TRITC (1 µg/ml in PBS) for 30 minutes. Cells were visualised and imaged 
using a Leica fluorescence microscope (Wetzlar, Germany) with a TRTIC filter, set for 
emission wavelengths of 570 nm. Actin ring morphology was also used to quantify the 
activation state of mature osteoclasts during resorption. The number of osteoclasts 
89 
 
showing the actin ring morphology characteristic of resorbing osteoclasts  were counted 
and expressed as a proportion of the total number of actin ring-positive cells (Lakkakorpi 
and Väänänen, 1996).   
 
2.2.6 Acridine orange staining 
 
Acridine orange was used to examine the extent of cellular acidification of 
osteoclasts in response to test conditions. Murine osteoclasts were cultured on dentin 
discs as described in Section 2.2.3.1 in the absence or presence of test compounds for a 
period of 24 hours. Thirty minutes before analysis, the culture medium was 
supplemented with 15 µg/ml of acridine orange, after which slices were washed and 
mounted on concave microscope slides for visualisation. Live cells were imaged using 
a Leica confocal microscope (Wetzlar, Germany), using a 63x lens and an excitation of 
480 nm. Emissions in two channels set to 525 nm (green) and 650 nm (red) were 
captured. Image stacks were obtained for randomly chosen fields from duplicate test 
slices in each test group, with microscope settings maintained between test groups. The 
ImageJ software was then used to combine channels and produce final images.     
 
2.2.7 Osteoclast resorption quantification 
 
Following TRAP staining of osteoclasts, the cells were removed from the dentin 
discs using sonication and light brushing with a toothbrush. The dentin discs were then 
stained for 1 minute using a 1 % (w/v) toluidine blue in 1 % (w/v) sodium borate solution 
to aid visualisation. Resorption pits were imaged across the entire surface of the dentin 
disc using reflected light microscopy and a point-counting method was used to quantify 
the surface area of resorption pits (Orriss and Arnett, 2012). Resorption area estimations 
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were made from triplicate dentin discs for each treatment group with the data expressed 
as an average of total surface area or, by using matched cell count data, as an average of 
resorption area per cell.       
The depth of resorption pits was also estimated using reflected light microscopy 
using the fine focus wheel of the microscope which was calibrated in microns. The 
maximum depth of an individual resorption pit could therefore be estimated by 
quantifying the distance in focus between the surface of the dentin disc and the bottom 
of the resorption pit. Ten randomly chosen pits per disc from triplicate samples were 
quantified. 
 
2.2.8 Osteoblast culture 
 
Primary murine osteoblast precursors were obtained from the calvaria of 4-5 day 
old CD-1 mice of mixed sex, as previously described Harmey et al. (2004). For each 
isolation, a whole litter of pups was used. Following cervical dislocation, the calvaria 
(frontal and parietal bones) were carefully dissected from the skulls of the mice and 
cleaned of any adherent tissue. The calvaria were then combined and subjected to 
successive enzymatic digestions of trypsin (1 mg/ml; 10 minutes), dispase (2 mg/ml; 20 
minutes) and 3 successive rounds of collagenase A (2 mg/ml; 30 minutes each). All 
enzymes were resuspended in 5 ml pre-warmed Tyrode’s solution and the digestions 
took place in a shaking water bath at 150 rpm and 37°C. 
Cells harvested from the dispase and the three collagenase digestions were each 
centrifuged at 250 x g for 5 minutes, and cultured separately overnight in complete 
culture medium. The following day, the dispase population was discarded and the three 
collagenase populations were combined, passed through a 70 µm cell strainer and 
counted using a haemocytometer. These cells would then either be used in MTS 
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proliferation assays (see Section 2.2.11) or differentiation assays to yield mature 
osteoblasts capable of forming mineralised bone nodules.  
For differentiation assays, precursor cells were seeded in 24-well plates at 10,000 
cells/well in complete medium containing 50 µg/ml ascorbic acid and 10 mM β-
glycerophosphate (βGP). Triplicate wells were used for each test group and culturing 
continued until the presence of mineralised bone nodules were evident in control wells, 
usually within 14-21 days. Test compounds were added and maintained in the culture 
medium at two different stages: at the time of the first media change (day 2-3), or once 
precursor cells were confluent (day 7-10).      
 
2.2.9 Alkaline phosphatase (ALP) staining 
 
Osteoblasts differentiation cultures were stained for ALP activity, a marker of 
osteoblast differentiation. Cells were fixed with 4 % paraformaldehyde. The ALP 
staining solution consisted of 0.1 M Tris-HCl (pH 8.3), 5 mg naphthol AS-MX 
phosphate, dissolved in 200 µl of dimethylformamide, and 30 mg red violet LB salt. The 
solution was filtered and then added to cells. Once developed, the stain was removed 
and cells were washed with water and stored dry. Stained cultures were imaged using a 
stereomicroscope and the area of positive red ALP staining per well was quantified using 
ImageJ. All ALP area measurements were obtained from triplicate wells. 
 
2.2.10 Von Kossa staining 
 
To visualise mineralised bone nodules, von Kossa staining was used. Following 
ALP staining, osteoblast differentiation cultures were washed with water and incubated 
in 2.5 % (w/v) silver nitrate in the dark at room temperature for 30 minutes. The silver 
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nitrate was removed and the cells were washed. The stain was developed in a sodium 
carbonate formaldehyde solution (0.05 g/ml sodium carbonate, 20 % formaldehye in 
water) for 2 minutes. Cells were washed with water and black areas corresponding to 
mineralised bone nodules were visualised and imaged using a stereomicroscope. The 
total von Kossa-positive area was quantified by ImageJ from triplicate wells for each 
group. 
 
2.2.11 MTS Assay for proliferation 
 
To measure cell proliferation, the MTS assay was used, which measures cellular 
metabolic activity (CellTiter 96®AQueous One Solution Cell Proliferation kit, Promega, 
Southampton, UK). MG-63 cells (30,000 cells/cm2), osteoclast bone marrow precursors 
(150,000 cell/cm2) and osteoblast calvarial precursors (30,000 cells/cm2) were seeded 
into 96-well plates and treated the following day with test compounds as indicated. After 
48 hours, the tetrazolium compound was added to each well for 3 hours, according to 
the manufacturer’s instructions. The resulting absorbance at 490 nm was then measured 
using a Multiskan 96-well plate reader (ThermoFisher Scientific). Absorbance values 




All data are expressed as a percentage of control values, shown using standard 
error of the mean (SEM) error bars for when n = 3 and standard deviation (SD) error 
bars for when n = 1. All statistics shown are the results of one-way ANOVAs, calculated 
using the statistics software, SPSS (IBM, New York, USA). All data were confirmed to 
be normally distributed and with equal variances before the test was run. The Tukey’s 
93 
 
post-hoc test was used to determine any significant differences between test groups and 
the control group.   
 
 





Samples of frozen I. ramosa tissue for DNA extractions were obtained as 
described in Section 2.1.1. Genomic DNA samples of E. coli (JM109), Nostoc sp. (PCC 
7120) and Streptomyces rimosus were provided by Dr Edward Spence (KCL). All 
culturing reagents, standard laboratory chemicals and solvents were sourced from Fisher 
Scientific unless otherwise stated. The CopyControl™ Fosmid Library Production Kit 
from Epicentre (Cambridge, UK) was used for fosmid library construction. This 
included the pCC2FOS vector and the host E. coli strain EPI300™-T1R (genotype: F- 
mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 recA1 endA1 araD139 Δ(ara, 
leu)7697 galU galK λ- rpsL (StrR) nupG trfA tonA). The pGEM®-T Easy vector from 
Promega (Southampton, UK) was used for TA cloning of PCR products with the K12 
JM109 strain of E. coli (genotype: endA1, recA1, gyrA96, thi, hsdR17 (rk
–, mk
+), relA1, 
supE44, Δ( lac-proAB), [F´ traD36, proAB, laqIqZΔM15]), also from Promega.  
 
2.3.2 Microbiological culturing 
 
Microbiological culturing of E. coli was performed in lysogeny broth (LB; 10g 
NaCl, 10g tryptone, 5 g yeast extract, per litre water), either in liquid cultures or 
supplemented with 12 g/l agar for plate cultures. For EPI300™-T1R cells containing 
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fosmids, all culture media was additionally supplemented with 12.5 µg/ml 
chloramphenicol. For JM109 cells containing the pGEM®-T Easy vector, the culture 
medium was supplemented with 100 µg/ml ampicillin. Liquid cultures were incubated 
at 37 °C using a shaking incubator set to 150 rpm. Plate cultures were incubated statically 
at 37 °C. All media and consumables were autoclaved at 120 °C for 15 minutes prior to 
use and standard aseptic techniques were used to prevent contamination of cultures. 
Overnight cultures of fosmid or plasmid containing E. coli colonies were generated by 
inoculating 10 ml of LB media with either single colonies from plates using sterile 
pipette tips, or from frozen aliquots of cultures using a sterile inoculation loop. 
In order to ensure high cloning efficiency and maintain stability of inserted 
sequences, clones transformed using the pCC2FOS vector were initially grown at single 
copy. However, for colony blot hybridisation screening and when positive clones were 
identified, fosmids were induced to high copy number in order to increase DNA yield. 
This was carried out using the CopyControl™ Fosmid Autoinduction Solution from 
Epicentre, which was added to overnight liquid or plate cultures at a 1x concentration.   
Electrocompetent E. coli JM109 cells were generated from a 50 ml culture with 
an optical density of 0.4, measured using a spectrophotometer set to 600 nm and then 
immediately placed and kept on ice. The culture was then centrifuged at 4,000 x g, the 
supernatant was removed and the cell pellet was resuspended in 10 ml of ice-cold 10 % 
(v/v) glycerol in water. This process was repeated a further three times. After the final 
wash, the supernatant was removed and the cells were resuspended in 0.5 ml 10 % 






2.3.3 DNA extraction 
 
The metagenomic DNA used for KS cloning and fosmid library construction was 
extracted using a protocol from Dunlap et al. (2007). Whole sponge material (1 g), stored 
at -80 °C, was ground to a powder in a mortar and pestle under liquid nitrogen. The 
powder was transferred to a 15 ml tube and 10 ml of lysis buffer containing 100 mM 
Tris, 100 mM EDTA, 100 mM NaCl, 2 % sodium dodecyl sulphate (SDS) and 400 g/ml 
proteinase k was added. The solution was incubated at 55 C for two hours before 
particulate material was pelleted under centrifugation and the supernatant removed. 
DNA was purified from the supernatant with 2 rounds of phenol-chloroform extraction, 
where an equal volume of phenol/chloroform/isoamyl (25:24:1 v/v, pH 8) was added to 
the aqueous supernatant from the previous step. The mixture was inverted several times 
and centrifuged at 12,000 x g.  The aqueous upper phase was removed and the process 
was repeated once more. DNA was then precipitated from solution using an equal 
volume of isopropanol at room temperature. The precipitated DNA was removed using 
a wide-bore pipette, washed in 70 % ethanol, dried and resuspended in TE buffer (10 
mM Tris, 1 mM EDTA). The concentration of DNA was estimated using a NanoDrop 
spectrophotometer (Fisher Scientific) and aliquoted at 100 ng/µl. All DNA was kept at 
4 °C when in regular use and -20 °C for long term storage. 
The extraction of metagenomic DNA used for next generation sequencing 
involved a cell separation step to reduce the presence of sponge cells and enrich for 
microbial symbionts from Thomas et al. (2010). Whole frozen sponge tissue (1 g) was 
ground to a powder in a mortar and pestle under liquid nitrogen. To release embedded 
symbionts from sponge tissue, the powder was transferred to a 50 ml tube and incubated 
at 37 °C for 30 minutes, plus agitation at 150 rpm, in a solution of calcium, magnesium 
free seawater (CMFSW; 25 g NaCl, 0.8 g KCl, 1 g Na2SO4, 0.04 g NaHCO3 per litre) 
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with 500 µg/ml collagenase A (Roche). The supernatant was then passed through a 40 
µm cell strainer then centrifuged at 100 x g for 20 minutes to remove the heavier sponge 
cells. The new supernatant was then centrifuged at 4000 x g to pellet all remaining cells. 
Metagenomic DNA was extracted from the cell pellet using the same protocol detailed 
above, re-suspending the dried DNA in 10 mM Tris buffer, quantifying, aliquoting and 
storing as described above.  
Plasmid and fosmid DNA were extracted from overnight liquid cultures using 
the PureYield™ Plasmid MiniPrep System (Promega), according the manufacturer’s 
instructions. Extracted fosmid DNA was further purified by incubating with Plasmid-
Safe™ (Epicentre), an ATP-dependant DNase that digests contaminating host 
chromosomal DNA from fosmid extractions, leaving circular DNA untouched. Fosmid 
DNA was incubated with the enzyme at 37 °C according to the manufacturer’s 
instructions.   
 
2.3.4 Agarose gel electrophoresis 
 
Metagenomic sponge DNA, fosmid DNA and PCR products were visualised and 
sized using agarose gel electrophoresis. For metagenomic and fosmid DNA, 0.8 % (w/v) 
agarose was dissolved by boiling in 1x TBE (Tris/Borate/EDTA) buffer and 
supplemented with 0.5 µg/ml ethidium bromide. For PCR products, 1.6 % agarose gels 
were used. Once loaded with DNA dyes and 100 bp or 1 kb Plus DNA ladders from 
ThermoFisher Scientific, the gels were run at a voltage of 150 V and a UV light from a 





2.3.5 Fosmid library construction 
 
Fosmid vectors  can accommodate 30-40 kbp sized inserts and contain an F-
plasmid origin of replication which enables the fosmid to be maintained at single-copy 
levels in E. coli (Kim et al., 1992). Metagenomic sponge DNA was used to generate a 
fosmid clone library using the CopyControl™ HTP Fosmid Library Production Kit from 
Epicentre, according to the manufacturer’s instructions. Briefly, metagenomic DNA was 
blunt-ended and size selected to 30-40 kbp using agarose gel electrophoresis and kit 
reagents. Once gel-purified, the DNA was ligated into the pCC2FOS vector in an 
overnight reaction and packaged using MaxPlax Lambda packaging extracts, according 
to the manufacturer’s instructions. Packaged phage particles were then used to transform 
EPI300™-T1R E. coli cells by incubating together at 37 °C. The titer of the fosmid-
containing phage particles was determined through transforming E. coli cells with serial 
dilutions of the packaged phage and counting the colonies that grew overnight on LB 
agar plates supplemented with 12.5 µg/ml chloramphenicol. To confirm fosmid library 
construction, a selection of single colonies were induced to high copy number overnight 
(see Section 2.3.2) before fosmid DNA was extracted (see Section 2.3.3). A restriction 
enzyme digest was performed using the BamHI enzyme (Promega) and fosmid DNA, 
according to the manufacturer’s instructions. This enzyme released the inserted 
sequence from pCC2FOS producing an expected band pattern consisting of a ~8 kbp 
vector fragment and fragments representing the 30-40 kbp insert, which were confirmed 
for the selected clones using agarose gel electrophoresis (see Section 2.3.4). 
 
2.3.6 Polymerase chain reaction (PCR) 
 
To amplify type I KS domains from metagenomic sponge DNA using PCR, the 
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degenerate primers KSDPQQF (5’-MGNGARGCNNWNSMNATGGAYCCNCARC- 
ANMG-3’) and KSHGTGR (5’-GGRTCNCCNARNSWNGTNCCNGTNCCRTG-3’) 
were used, designed from universally conserved motifs of KS domains (Piel, 2002). To 
amplify adenylation domains from fosmid DNA using PCR, the degenerate primers NP1 
(5’-CCTAATTCAATACGAAAACCACGAADYTTNAYYTG-3’) and NP2 (5’-
TGTATGTTATTTATACTTCTGGTTCTACTGGTMRNCCANARGG-3’) were used 
(Zhang et al., 2009). Typical PCR volumes of 25 l for both primer sets contained 100 
ng of DNA, 0.4 M of each primer, 0.2 mM deoxynucleotide triphosphates, 6 mM 
magnesium chloride, 5 % DMSO and 2 U of a Hot-start Taq DNA polymerase. All PCR 
reagents were obtained from Promega. Thermal cycling conditions consisted of 5 
minutes at 95C followed by 35 cycles of 30 seconds at 95C, 60 seconds at annealing 
temperature and 60 seconds at 72C, with a final step of 5 minutes at 72C. Annealing 
temperatures (55 C for KS and 52 C for adenylation domains) were determined using 
gradient PCR, where positive control DNA (S. rimosus for KS domains, Nostoc sp. for 
adenylation domains) was used in 12 identical PCRs and the annealing temperature was 
varied for each within the range of 48 to 58 C using a specialised PCR program. The 
annealing temperature producing the optimum band at the expected size was then used 
in subsequent test PCRs. All PCR products were checked and sized using agarose gel 
electrophoresis (see Section 2.3.3).  
 
2.3.7 TA cloning of PCR products 
 
TA cloning is a useful method for cloning PCR products where, during PCR, the 
single nucleotide A is naturally added to the 3’ end of a PCR product, resulting in an A’ 
overhang terminus that hybridises with the 3’-T overhangs of the pGEM®-T Easy 
vector. Plasmids are then transferred to host E. coli cells using electroporation. KS and 
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adenylation domain PCR fragments of approximately 700 and 850 bp in length, 
respectively, were excised from agarose gels following electrophoresis and purified 
using the QIAquick Gel Extraction Kit from Qiagen (Manchester, UK). The PCR 
products were then ligated into pGEM®-T Easy in an overnight reaction according to 
the manufacturer’s instructions. A 50 µl aliquot of electrocompetent JM109 cells on ice 
was mixed with 10 µl of the vector ligation reaction and transferred to an ice-cold 
electroporation cuvette. Electroporation was performed using an electroporator set at 2.5 
kV for 6 ms. Immediately after electroporation, 1 ml of LB medium was added to the 
cuvette and then transferred to a 1.5 ml tube. The cells were incubated at 37 °C with 
shaking at 150 rpm for 1 hour. The cells were then pelleted using centrifugation (11,000 
x g) and then resuspended in 100 µl LB medium and spread onto agar plates containing 
100 µg/ml ampicillin, 0.1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 40 
µg/ml X-gal. Following an overnight incubation at 37 °C, white colonies indicating 
successful transformation by plasmids containing an inserted sequence were identified. 
Overnight cultures of 5-20 white colonies per PCR product were performed before 
plasmid DNA was extracted as described in Section 2.3.3. To check the size of inserted 
PCR product sequences, samples of plasmid DNA were digested with the EcoRI enzyme 
(Promega), according to the manufacturer’s instructions. This digestion released the 
inserted sequence from the pGEM®-T Easy vector, the size of the insert was estimated 
using agarose gel electrophoresis (see Section 2.3.4). 
 
2.3.8 Colony blot hybridisation screening of fosmid library 
 
All reagents and materials for this task were obtained in kits from Roche unless 
stated otherwise. A DIG-labelled KS probe was first produced using the PCR DIG Probe 
Synthesis Kit according to the manufacturer’s instructions. Plasmid DNA (100 ng) 
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encoding a KS sequence was used as a template in a PCR reaction along with a 
nucleotide mixture containing DIG-dUTP (0.2 mM), kit buffer plus 6 mM magnesium 
chloride, 3 U of the kit’s high fidelity Taq DNA polymerase and 0.4 µM each of the 
KSDPQQF and KSHGTGR primers. The PCR conditions were the same as described in 
Section 2.3.6. Following the reaction, the DIG-labelled PCR product was stored at -20°C 
until needed. 
Transformed fosmid-containing E. coli were induced to high copy number in 
patches on LB agar plates. A total of 1200 individual colonies were prepared in this way 
on large plates at approximately 80-100 colony patches per plate. Colony patches were 
blotted onto large nylon membranes for 1 minute. As a positive control for the 
hybridisation process, E. coli cells containing the plasmid used as a template for the DIG 
probe were also scratched onto the top of the membranes in a cross shape using a sterile 
pipette tip. The membranes were then incubated successively at room temperature in a 
denaturation solution (0.5 M NaOH, 1.5M NaCl), a neutralisation solution (1.5 M NaCl, 
1 M Tris-HCl, pH 7.4) and 2x SSC (30 mM saline-sodium citrate, pH 7.0, 0.3 M NaCl), 
each for 15 minutes with blotting on Whatman 3MM filter paper between each step. The 
DNA was then crosslinked to the membrane by illuminating the disc with UV light 
(UVA, 1.8 mW cm-2, Philips TL-20/05 lamps) for 90 seconds. Cell debris was removed 
from the membranes by incubating with proteinase K (140 mg/ml) diluted in 2x SSC for 
1 hour at 37 °C, followed by blotting onto Whatman 3MM paper soaked in sterile water. 
Hybridisation of the KS DIG probe to the nylon membranes was carried out 
using a hybridisation oven (GE Healthcare, Little Chalfont, UK) with single membranes 
placed in bottles on a rotisserie. A standard hybridisation buffer was used consisting of 
5x SSC, 0.1 % (w/v) N-lauroylsarcosine, 0.02 % (w/v) sodium dodecyl sulphate (SDS) 
and 1 % (v/v) blocking solution from the Roche DIG Wash and Block Buffer Set. The 
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hybridisation temperature (Thyb) was calculated to be 80.6 °C using formulas from the 
DIG Application Manual for Filter Hybridisation (Roche-https://lifescience.roche.com):  
Thyb = Tm - 25°C  
Tm = 16.6 log [Mol. Na+] + 0.41(%GC) + 81.5  
Where [Mol. Na+] for 5x SSC is 0.75 and the GC content of the probe was determined 
to be 64%. 
The DIG-labelled probe was first denatured by boiling at 95 °C for 5 minutes 
and then placed immediately on ice, after which it was diluted to approximately 25 ng/ml 
in hybridisation buffer. The membranes were initially incubated with 60 ml 
hybridisation buffer for 1 hour at 81 °C. The buffer was then poured away before being 
quickly replaced with 15 ml per tube of pre-warmed hybridisation buffer containing the 
DIG labelled probe. The membranes were then left overnight at 81 °C with gentle 
rotation. 
 The following day the probe was removed and stored at -20 °C to be re-used for 
up to 4 additional rounds of hybridisation. The membranes were washed twice for 5 
minutes with gentle shaking at room temperature using 2x SSC plus 0.1 % sodium 
dodecyl sulphate (SDS). Two high stringency washes were then performed using 0.1x 
SSC plus 0. 1% SDS at 68°C with gentle shaking for 15 minutes each. Detection of 
probe-target hybrids was then immediately performed on wet membranes using buffers 
and solutions from the DIG Wash and Block Buffer Set. 
 The membranes were first washed for 5 minutes with a washing buffer 
containing maleic acid and 0.3 % (v/v) tween 20, and then blocked for 30 minutes using 
a kit blocking solution. The membranes were then incubated for 30 minutes at room 
temperature with an anti-DIG-AP conjugate antibody, diluted 1:10,000 in blocking 
solution. Two washes for 15 minutes each with washing buffer were then performed 
before the membranes were equilibrated with detection buffer (100 mM Tris-HCl, pH 
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9.5, 100 mM NaCl) for 5 minutes at room temperature. Each membrane was then 
covered with a solution containing 34 µl of NBT (100 mg/ml 4-nitroblue tetrazolium 
chloride in 70 % DMF) and 35 µl of BCIP (50 mg/ml 5-bromo-4-chloro-3-indolyl 
phosphate in DMF) in 10 ml of detection buffer. The membranes were incubated at room 
temperature in the dark for 5-6 hours until hybridisation signals from the control were 
evident. The reaction was then stopped by incubating the membranes in TE buffer (10 
mM Tris-HCl, 1 mM EDTA, pH 8.0). The membranes were then dried and stored.     
Colonies producing strong, positive hits were identified back to their original 
low copy number colony and then cultured overnight both at low and high copy numbers 
(see Section 2.3.2). Fosmid DNA was extracted from overnight, high copy number 
liquid cultures (see Section 2.3.3), whilst 1 ml aliquots were taken from the low copy 
number cultures, diluted with glycerol to achieve a final concentration of 20 % (v/v) and 




PCR products amplified from metagenomic sponge DNA, or subcloned from 
fosmid DNA were sequenced from pGEM®-T Easy vectors using the M13 binding site. 
This was carried out by Source Bioscience (Nottingham, UK) using the method of chain-
terminating dideoxynucleotides (Sanger et al., 1977). Source Bioscience were also used 
to partially sequence fosmid DNA using primer-walking, where initial insert sequence 
was obtained using the forward sequencing primer binding site on the pCC2FOS vector, 
which was then used to design a new primer in order to extend the sequence.  
Next generation sequencing of microbially enriched metagenomic DNA from I. 
ramosa and fosmid DNA was carried out using the Nextera DNA Sample Preparation 
Kit and the MiSeq platform from Illumina (California, USA), according to the 
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manufacturer’s instructions. First, DNA was accurately quantified using a Qubit dsDNA 
HS Assay and the Qubit 2.0 fluorometer (Life Technologies, California, USA). The 
DNA was then enzymatically ‘tagmented’ (tagged and fragmented) into 300 bp 
fragements using kit reagents. A clean-up procedure was followed before sequencing 
primers and indexers were then appended to the sequences in a PCR amplification step. 
The kit consisted of 6 unique indexers, 1 was assigned to the metagenomic sponge DNA, 
the other 5 to fosmid libraries. A further clean-up step was performed before the 
sequencing libraries were size-validated using an Agilent Technologies 2100 
Bioanalyzer and a High Sensitivity DNA chip (California, USA). The sequencing 
libraries were also quantified using Qubit. Once sequencing libraries for the fosmids and 
metagenomic DNA were validated and quantified, the libraries were pooled so that 94 
% consisted of the metagenomic sponge DNA, 1 % for each of 5 fosmid libraries and 1 
% for the PhiX control library supplied with the kits. The final library was denatured 
using 0.2 M NaOH before hybridisation buffer was used to dilute the library to a 
concentration of 16 pM, according to the manufacturer’s advice. This library was loaded 
onto a standard MiSeq flow cell before 300 bp paired-end sequencing was carried out 
using MiSeq platform and 600 cycles of the v.3 MiSeq sequencing reagents.      
 
2.3.10 Sequence assembly 
 
Primer-walking sequences for fosmid DNA were assembled using pair-wise 
alignments and the MEGA software, version 6.06 (Tamura et al., 2013). Following the 
MiSeq run, all data was instantly uploaded to Illumina’s cloud-based, genomics 
computing environment, BaseSpace (https://BaseSpace.Illumina.com). This platform 
contains numerous applications and tools for the analysis and management of NGS data. 
Assembly of all the fosmid reads was carried out using an automated, integrated 
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sequence assembly program on BaseSpace called DNASTAR SeqMan NGen 
(Wisconsin, USA). This program successfully assembled the sequencing reads from 
each fosmid sample into a single contiguous sequence (contig) representing the complete 
pCC2FOS vector and inserted sequence. The fosmid vector sequences were then 
removed to leave only the insert sequence using the MEGA software. 
For the sequencing reads obtained from the metagenomic sponge DNA sample, 
metagenomic de novo assembly was carried out by Ranko Gacesa using the software, 
Velvet (Zerbino and Birney, 2008). The sequencing reads were first assessed for quality 
using the FastQC tool. This provided an overview of the quality of the sequencing reads, 
showing any regions of the reads that have recurrent drops in phred quality scores. Phred 
quality scores are logarithmically related to the base-calling error probabilities, so that a 
score of 10 means a 1 in 10 probability of an incorrect base call, a score of 20 means a 
1 in 100 probability, a score of 30 means a 1 in 1000 probability. The FASTX-Toolkit 
was then employed to pre-process the sequencing reads before assembly was attempted, 
which removed all reads less than 100 bp as well as any detectable artefacts in the 
sequencing reads. The FASTX-Toolkit was also used to trim the first 20 base pairs from 
the start and end of every sequence as these were found to have phred quality scores 
below the commonly used threshold of 20. The processed reads were then assembled 
using the Velvet software, which is an algorithm package designed to deal with de novo 
assembly from short read sequences. The program takes all the sequencing reads and 
forms strings of sequences of length k, called k-mers. The algorithm then uses de Bruijn 
graphs to analyse and assemble the overlapping regions of k-mers, ultimately leading to 
assembled sequence data. The assembly of the metagenomic sponge DNA reads was 
carried out by running the Velvet algorithm, varying the length of k-mers used until an 
optimum was reached based on the proportion of sequences assembled and the length 
and number of contigs generated.  
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2.3.11 Sequence annotation 
 
KS and adenylation domain nucleotide sequences were identified using the Basic 
Local Alignment Search Tool (BLAST - http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
(Camacho et al., 2009), searching against the non-redundant database with default 
parameters. Nucleotide sequences were translated into amino acid sequences in all 6 
reading frames using the European Molecular Biology Open Software Suite (EMBOSS) 
Transeq tool (Rice et al., 2000). Translated amino acid sequences were identified using 
BLAST or Pfam (http://pfam.xfam.org/) searches against non-redundant databases and 
default parameters. Pfam contains a large collection of protein families represented by 
sequence alignments and HMMs (Finn et al., 2011). Multiple sequence alignments of 
amino acid sequences were performed and used to construct phylogenetic trees using 
the MEGA software, version 6.06, and the ClustalW algorithm (Larkin et al., 2007). 
Other reference KS sequences used in the alignments were obtained from the National 
Center for Biotechnology Information (NCBI) GenBank database 
(http://www.ncbi.nlm.nih.gov/genbank/) (Benson et al., 2013). The Neighbour-Joining 
method (Saitou and Nei, 1987) was used for phylogenetic tree construction with the 
evolutionary distances estimated using the Poisson correction method (Zuckerkandl and 
Pauling, 1965) and robustness estimated using the bootstrap test (Felsenstein, 1985).  
To predict the substrate specificity of adenylation domains from their nucleotide 
sequences, a web-based program designed by Baranasic et al. (2014) was used. This 
program detects adenylation domain binding pockets from amino acid sequences based 
on an alignment to a hidden markov model (HMM) of adenylation domains. The 
software then analyses the binding pocket residues with a latent semantic indexing 
model and provides predictions of amino acid substrate specificity along with a precision 
score showing the quality of the prediction. 
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Assembled NGS contigs from fosmid and metagenomic sponge DNA were 
automatically screened for the presence of secondary metabolite biosynthetic genes 
using the Antibiotics & Secondary Metabolite Analysis Shell software (antiSMASH 2.0) 
(Blin et al., 2013). This program allows the rapid genome-wide identification, annotation 
and analysis of secondary metabolite gene clusters from nucleotide sequences and 
integrates common bioinformatic tools such as NCBI’s BLAST, Glimmer (Delcher et 
al., 2007), Muscle (Edgar, 2004) and HMMer (Finn et al., 2011) to identify biosynthetic 
genes and align identified regions with nearest relatives from databases containing all 
other known gene clusters. The program also integrates a suite of in silico secondary 
metabolite analysis tools such as PKS/NRPS domain detection using ClustScan 
(Starcevic et al., 2008) and CLUSEAN (Weber et al., 2009). The annotation of detected 
PKS genes by antiSMASH was also manually confirmed using ClustScan. This program 
annotates the domain architecture of PKS genes from nucleotide sequences, as well as 
the activity of reductive domains (ER/KR/DH), through comparative alignments with 
HMM profiles of individual domains. A prediction of AT domain specificity is also 
determined by HMM alignment, with the diagnostic amino acid residues extracted and 
compared with fingerprints corresponding to different specificities or activities 
















The first aim of this thesis was to investigate in vitro effects of 73-DOC on the 
bone remodeling cell types, osteoclasts and osteoblasts. However, in order to achieve 
this aim, a stock of 73-DOC was first needed. Once a purified sample of 73-DOC was 
obtained, the biological activity of the compound also needed confirming before 
commencement of in vitro testing with bone cells. The objectives for this chapter were 
therefore: To extract a stock of 73-DOC for in vitro testing; and confirm biological 
activity of the new extract.  
The only examples of 73-DOC extraction in the scientific literature are that of 
Rashid et al. (2001b), following the original discovery of the compound and Chevallier 
et al. (2004). 73-DOC was originally discovered in the Australian sponge species, I. 
ramosa, samples of which were also found to contain chondropsin A (Cantrell et al., 
2000), which has a chemical structure almost identical to 73-DOC, but differs by a single 
oxygen atom (Figure 3.1). The extraction procedures detailed by Rashid et al. (2001b) 
showed that 73-DOC could be isolated through fractionation of an aqueous sponge tissue 
extract on a C18 chromatography column, using reverse-phase HPLC. As well as 
guiding extracting procedures used in this chapter, Rashid et al. (2001b) also provided 
spectral characteristics of 73-DOC, such as UV absorbance peaks, that will enable 
detection of the compound during HPLC-based fractionation, as well as quantification 
of the isolated compound using UV spectroscopy.   
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Samples of I. ramosa, from which 73-DOC could be extracted, were collected by 
Dr Paul Long (KCL) and Dr Walt Dunlap (AIMS) from the Great Barrier Reef with the 
support of AIMS. These were freeze-dried and shipped frozen to KCL along with an 
authentic sample of 73-DOC, prepared by Dr Marnie Freckelton and Dr Cherie Motti at 
AIMS, which was provided for comparison with the newly extracted material. Dr Walt 
Dunlap also assisted with work in this chapter by optimising the procedures for obtaining 
the semi-crude extract of 73-DOC, as described in the next section. Work presented in 
this chapter was also assisted by Miss Priyanka Rajeevkumar (KCL masters student). 
73-Deoxychondropsin A 
Chondropsin A 
Figure 3.1 Chondropsin metabolites present in I. ramosa. The 
chemical structures of 73-DOC and chondropsin A are shown, as reported 
by Rashid et al. (2001b) and Cantrell et al., (2000), respectively. The 
additional oxygen present in chondropsin A is highlighted in red.  
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3.2.1 Extraction of semi-crude 73-deoxychondropsin A 
 
Freeze-dried samples of I. ramosa, collected from the Great Barrier Reef, were 
confirmed by Dr Walt Dunlap at AIMS to test positive for the presence of both 73-DOC 
and chondropsin A using LC-MS according to published procedures (Rashid et al., 
2001b). A protocol for producing a semi-crude extract of 73-DOC was followed, using 
disposable SPE columns which separate compounds in an aqueous mixture according to 
their physiochemical properties. This protocol was optimised to produce a mixture that 
retains 73-DOC, as well as chondropsin A and other unwanted compounds, but which 
is much less heterogeneous than the raw extract. The semi-crude extract is thus more 
suitable for the improved accuracy and resolution offered by HPLC partitioning, which 
operates using the same physiochemical principles as SPE columns. 
Images showing the procedures used for obtaining the semi-crude extract of 73-
DOC from I. ramosa are shown in Figure 3.2. The protocol started with 4 successive 
rounds of extraction from shredded sponge tissue using 20 % methanol and mild 
sonication. Each round lasted 2 hours producing an aqueous solution containing soluble 
compounds present in the sponge. The combined extracts were then passed over a bed 
of celite in order to remove fine impurities before being further purified by passing 
through a C-18 SPE column. Here, 73-DOC was retained on the column whilst 
unwanted, more polar impurities, were washed away with water. 73-DOC, along with 
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other compounds of similar polarity, was then eluted from the column using 90 % 
methanol. This process was repeated, combining eluates and removing any solvents 
under vacuum, producing the semi-crude extract of 73-DOC (Figure 3.2 D). A total of 
150 g of dried sponge tissue was processed in this way, producing 450 mg of a crystalline 





Figure 3.2 Images of procedures used to obtain semi-pure extract of 73-
deoxychondropsin A. Images show the freeze-dried sample of I. ramosa used to 
extract 73-DOC (A), the extraction of the semi-pure compound from shredded 
sponge tissue using methanol (B), the purification of the methanol extract using a 




3.2.2 Isolation of 73-deoxychondropsin A 
 
In order to further purify the semi-crude extract, this was fractionated using 
analytical reversed-phase HPLC on a C18 column using a gradient of acetonitrile in 
water (10-90 % acetonitrile in 30 minutes). Based on the work of Rashid et al. (2001b) 
and advice given by Dr Walt Dunlap, 73-DOC was known to correspond to one of two 
prominent peaks found from the HPLC spectrum detected at 261 nm. Fractions 
corresponding to the two peaks, F1 and F2, were collected and subjected to MS analysis 
to determine which peak corresponded to 73-DOC based on the molecular mass of 
detected compounds (Figure 3.3).    
The molecular formula for 73-DOC was reported as C83H133N3O25 with a 
molecular mass of 1571.92 by Rashid et al. (2001b). The MS data revealed that F2 
corresponded to 73-DOC, assigning a mass of 1594.78 to the fraction, representing a 
sodium adduct [M+Na]+ with a calculated molecular mass of 1594.91 (Figure 3.3 inset). 
F1 was assigned a mass of 1610.78, revealing this fraction corresponded to chondropsin 
A (C83H133N3O26), also detected as a sodium adduct with a calculated molecular mass of 
1610.91  (Figure 3.3 inset) (Cantrell et al., 2000). Peak area analysis of the HPLC 
spectrum showed the semi-crude extract consisted of approximately 18 % 73-DOC at 
this stage.   
 Once the 73-DOC peak had been determined, the HPLC conditions used for 
fractionation of the semi-pure extract of 73-DOC were scaled up for use with a 
preparative HPLC column. Multiple runs using this column and the semi-crude extract 
were performed, collecting the relevant peak each time. All 450 mg of the semi-pure 
extract were processed in this way with each collected 73-DOC fraction dried down 
under vacuum leaving a white powder. A total of 19.5 mg of this material was obtained 
from 150 g of dried sponge tissue, equating to a yield of 0.13 mg g dry wt-1.
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Figure 3.3 HPLC and MS analysis of semi-crude extract reveal peak corresponding to 73-DOC. A sample of the semi-crude extract obtained 
from I. ramosa was run on an analytical HPLC system. The resulting spectrum at 261 nm is shown, with the peaks collected for further MS analysis 
labelled F1 and F2, along with retention times (RT). MS spectra for F1 and F2 are shown in the insets above the HPLC spectrum. F1 shows the 
predominant presence of an ion corresponding to a sodium adduct of chondropsin A, where [M+Na]+ = 1610.91 (Cantrell et al., 2000). The MS 





3.2.3 Confirmation of the 73-deoxychondropsin A extraction 
 
In order to confirm the success of the extraction procedures, the purified 73-DOC 
sample was re-analysed using the same analytical HPLC conditions along with 
additional LC-MS analysis (Figure 3.4). Both the HPLC and LC-MS chromatography 
spectra show the presence of a single peak that was also associated with a smaller, 
unknown shoulder peak. Attempts to further fractionate the sample with HPLC to 
remove the shoulder were performed but were not successful. Quantitative area analysis 
of the 73-DOC peak in Figure 3.4 A showed the sample consisted of 91 % 73-DOC 
following extraction.  
The LC-MS data confirmed the sample to contain 73-DOC, showing prominent 
mass peaks corresponding to [M+H]+ and [M+Na]+ ions with calculated molecular 
masses of 1572.93 and 1595.91 respectively (Figure 3.4 B) (Rashid et al., 2001b). To 
provide an accurate mass estimation of the purified extract, a sample was also subjected 
to HRMS analysis. This data also showed two major peaks corresponding to 73-DOC in 
the form of [M+H]+ and [M+Na]+ ions, with measured masses of 1572.9320 and 
1594.9139 respectively (Figure 3.5). These masses showed deviation from the calculated 
masses of 1572.9305 and 1594.9119, equal to mass errors of 0.95 and 1.25 ppm, 
respectively. Mass errors below 5 ppm are considered sufficient to support molecular 
formula assignment (Organic Letters, Guidelines for Authors, 2015). The HRMS data 





Figure 3.4 HPLC and LC-MS spectra confirms the identity of the isolated extract 
as 73-DOC. A sample of the purified 73-DOC extract was examined using an analytical 
HPLC column, with the spectrum obtained at 261 nm shown along with the retention 
time (RT) of the single peak detected (A). The purified sample was additionally 
analysed using LC-MS, showing the total ion chromatogram spectrum with retention 
time (RT) above the MS spectrum for that peak (B). Major MS peaks for ions 
corresponding to hydrogen and sodium adducts of 73-DOC were found where [M+H]+ 

























Figure 3.5 HRMS analysis of the isolated extract confirms the identity of 73-DOC. The spectrum shows two major peaks 
corresponding to ions, [M+H]+ and [M+Na]+. [M+H]+, calculated for C83H134O25N3 = 1572.9305, measured at 1572.9320. [M+Na]
+, 
calculated for C83H133O25N3Na = 1594.9119, measured at 1594.9139 (Rashid et al., 2001b). 
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A 1H-NMR was also performed on a sample of the purified extract in order to 
confirm the chemical structure of the extracted material and determine any impurities. 
The spectrum obtained from the new extraction was compared with that of an authentic 
sample of 73-DOC prepared by AIMS. The spectrum from the current extraction had an 
enlarged water peak at 4.8 ppm caused by the hygroscopicity of the deuterated methanol 
in which the sample was analysed, but otherwise the profiles are identical (Figure 3.6).  
Major peak values corresponding to chemical shifts from both spectra were 
compared with those reported by Rashid et al. (2001b) and assigned to the chemical 
structure of 73-DOC (Table 3.1). A total of 40 peaks were identified from spectra of the 
AIMS and current extractions. Data for the Rashid extraction were acquired from 73-
DOC in deuterated dimethylformamide, whereas the data for the AIMS and current 
extractions were acquired from 73-DOC in deuterated methanol. Small deviations 
between chemical shift values are attributed to the different solvents used as well as 
inter-laboratory variables such as pH, temperature and concentration (Atta-ur-Rahman, 
2000). Taken together, these data support both the high purity estimation of the current 
extraction, as well as the presence of structural features that confirm the identity of the 
extracted material as 73-DOC. 
 
3.2.4 Biological activity of the 73-deoxychondropsin A extraction 
 
Biological activity of 73-DOC was determined using the MTS assay for cell 
proliferation alongside the authentic sample of 73-DOC prepared by AIMS. The MTS 
assay is used for the quantification of viable cells in proliferation and cytotoxicity 
studies, and is detailed further in Section 2.2.8. The human osteosarcoma cell line, MG-
63, was selected for the assay on the basis that previous work conducted by the NCI had 





Figure 3.6 Comparison of 1H-NMR spectra from the isolated material and an authentic sample confirm the extraction of 73-DOC. NMR 
spectra were obtained from a sample of the current extraction and from an authentic sample of 73-DOC produced by AIMS. Other than an enlarged 
water peak in the current extraction at 4.8 ppm, the two spectra have identical profiles, confirming the identity of 73-DOC in the current extraction. 
Both sets of spectra were obtained from 2.5 mg 73-DOC in deuterated methanol. 
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Table 3.1 1H NMR data for 73-DOC. Chemical shift values taken from NMR 
spectra are shown for the current extraction, the AIMS extraction and the published 
values reported by Rashid et al. (2001b). The corresponding positions on the 73-
DOC chemical structure are also shown above for each identified shift, numbered 
as reported by Rashid et al. (2001b). Small deviations between chemical shift values 
are attributed to the different solvents used as well as pH, temperature and 
concentration variations (Atta-ur-Rahman, 2000). 
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(NCI, 2006, Dunlap et al., 2007), which thus allowed activity of the 73-DOC extraction 
to be compared with data from an almost identical compound.  
The results of the MTS assays showed that both stocks of 73-DOC caused dose-
dependent decreases in MG-63 cell numbers, leading to a 25-45 % decrease at 100 nM 
(Figure 3.7). The results for both stocks showed a similar trend of antiproliferative 
activity, though the second assay conducted with the AIMS extracted material showed 
cell viability was higher than the control at low concentrations, likely as a result of 
pipetting errors during the assay setup leading to low control measurements. The results 
Figure 3.7 Comparison of the biological activities from two stock solutions 
demonstrate the antiproliferative effects of 73-DOC.  
The MTS assay for cell proliferation was used to determine the antiproliferative activity 
of 73-DOC towards the MG-63 human osteosarcoma cell line. Cells were plated out in 
triplicate wells and exposed to 73-DOC for 48 hours before the MTS assay was 
performed. 2 experiments were performed with each of the stock solutions from the 
current extraction and that prepared by AIMS. Data are presented as a percentage of 
control values, error bars are ± SD. 
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show that the newly extracted stock of 73-DOC has antiproliferative activity toward the 




The first objective of this chapter was to extract a stock of 73-DOC for in vitro 
testing. This objective was successfully met with approximately 20 mg of 73-DOC 
isolated from 150 g of I. ramosa tissue. A combination of analytical and preparative 
HPLC was used to identify and isolate solvent-partitioned material corresponding to 73-
DOC, showing a demonstrated increase in purity estimation from 18 % of the semi-
crude extract to 91 % of the final isolated material. As this stock will now be used for in 
vitro experimentation, the work presented in this chapter therefore sets a benchmark of 
purity that future preparations of 73-DOC must meet in order for biological data to be 
comparable with observations made using the current stock.  
To confirm the extraction of 73-DOC, a variety of analytical spectrometry 
procedures were used, including LC-MS, HRMS, and 1H-NMR. Based on molecular 
mass measurements, LC-MS and HRMS both consistently showed major peaks 
corresponding to ions that were consistent with that reported by Rashid et al. (2001b) 
and for 73-DOC, in which a molecular mass of 1571.92 was reported for the compound. 
In both sets of analyses presented here, other ionic species of less relative abundance 
were also observed due to fragmentation of the 73-DOC molecule during the 
electrospray ionisation process. Future work may therefore benefit from using a soft 
source of ionisation to accurately determine molecular mass, such as MALDI (matrix 
assisted laser desorption/ionisation). The HRMS data also accurately confirmed the 
assignment of the molecular formula, C83H133N3O25, identical to that reported by Rashid 
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et al. (2001b) but with greater accuracy as shown by the smaller mass error estimates 
(0.95 and 1.25 ppm versus 1.70 ppm).   
A 1H-NMR spectrum confirmed the structure of the isolated material, producing 
a profile almost identical to that obtained from an authentic sample of 73-DOC produced 
by AIMS, and showing chemical shift peaks that were consistent with the reported 
structure of 73-DOC (Rashid et al., 2001b). However, total assignment of all spectral 
peaks or all proton nuclei in the 73-DOC structure was not accomplished during the 
current work. Previous studies with chondropsin metabolites have shown that, in order 
to account for ambiguities arising from overlapping resonances, extensive interrogation 
of 1H-NMR spectra in a variety of solvents are required for full structural elucidation 
(Cantrell et al., 2000). Such work was beyond the time limitations and aims of this thesis, 
but could be considered for future work alongside acquiring additional 13C-NMR 
spectra, which would also aid in confirming the structure and purity of 73-DOC 
extractions. 
Only two other extractions of 73-DOC from sponge tissue are found in the 
literature. A yield of 0.003 % g wet wt-1 from the sponge Psammoclemma sp. was 
reported by Chevallier et al. (2004), and a yield of 0.018 % g wet wt-1 from I. ramosa 
was calculated from the study by Rashid et al. (2001b). The yield of 73-DOC obtained 
from I. ramosa during the current extraction was equal to 0.013 % g dry wt-1 which, 
when converted to wet weight using data presented by Ricciardi and Bourget (1998), 
showed the current extraction was approximately 0.01 % g wet wt-1. This enabled direct 
comparison with the other extractions of 73-DOC, as well as with other chondropsin 
metabolites (Table 3.2). These data showed that the current extraction yielded over 3 
times the amount obtained by Chevallier et al. (2004) but almost half that obtained by 
Rashid et al. (2001b), though there is some uncertainty in the latter estimate as only the 
weight of the aqueous extract was shown, and not that of the original sponge tissue from 
 122 
 
which the compound was extracted. The estimated tissue concentration from the Rashid 
et al. (2001b) study is likely an overestimate and closer to that of the current work.  
As similar extraction methods were used by both Rashid et al. (2001b) and 
Chevallier et al. (2004), the difference seen in tissue concentrations from I. ramosa and 
Psammoclemma sp. likely reflect environmental variables that are known to influence 
the metabolite concentration in sponge tissues (Ruiz et al., 2013). If chondropsins are to 
be exploited for therapeutic development, the data shown in Table 3.2 imply that, out of 
all the chondropsin metabolites, 73-DOC from I. ramosa can be extracted in the highest 
yields, and would thus be the best option for using natural populations to supply small 
scale in vitro testing and possibly larger scale in vivo and preclinical trials. Yields 
equivalent or lower than those demonstrated in the current work have previously been 
shown to be sufficient for supplying other sponge-derived metabolites for such work 
(Munro et al., 1999, Hadas et al., 2005, Page et al., 2005, Sipkema et al., 2005, Ruiz et 
al., 2013).  
However, extracting the amounts required for full commercial production using 
the method demonstrated in this chapter is likely to be economically unfeasible, as well 
as ethically unsound due to the amounts of sponges that would need to be harvested from 
Table 3.2 Concentrations of chondropsin metabolites extracted from sponge 
tissues. * - Compound concentrations from this reference are likely over estimates as 
the weight of the original sponge tissue was not stated. 
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the natural environment. Despite finding that 73-DOC is present in I. ramosa at 
relatively high concentrations when compared with the other chondropsins, the overall 
small yield of the compound reiterates the supply problems typically associated with 
developing natural products for therapeutics, and reaffirms the need for an alternative 
method of 73-DOC supply if the compound is to meet global market demands. One ideal 
solution to this problem is the heterologous expression of the 73-DOC biosynthetic 
genes in a fermentable host. Work contributing to this solution is further explored in 
Chapter 6.   
The final objective of this chapter was to confirm the biological activity of the 73-
DOC extraction. The new stock of 73-DOC was compared alongside an authentic 
sample prepared by AIMS using a cell proliferation assay similar to those conducted for 
the NCI 60-cell antitumour screen (Boyd and Paull, 1995). Both stocks of 73-DOC were 
shown to have dose-dependent antiproliferative activity against the MG-63 human 
osteosarcoma cell line, comparable to previous work conducted by the NCI with 
chondropsin A, which showed a 50 % decrease in MG-63 cell proliferation at 40 nM 
(NCI, 2006, Dunlap et al., 2007). Chondropsin A, which was the only chondropsin 
metabolite evaluated in the NCI 60-cell screen, was also shown to cause 50 % growth 
inhibition at a mean concentration of 25 nM across a broad panel of cell lines (Cantrell 
et al., 2000). Similar, potent (low nanomolar) antitumour activity has also previously 
been demonstrated in melanoma and leukaemia tumour cell lines for 73-
DOC/chondropsin C (Rashid et al., 2001b) and chondropsin D (Rashid et al., 2001a). 
Additionally, both 73-DOC and chondropsin A were shown to cause dose-dependent 
antitumour activity against a small panel of human tumour cell lines, where 50 % growth 
inhibition was reported at 2 nM and 0.3 nM for chondropsin A and 73-DOC respectively 
(Chevallier et al., 2004). Taken together, it is clear that the chondropsin metabolites are 
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effective in vitro antitumour compounds, and the work presented in this chapter with 73-
DOC and the MG-63 cell line is consistent with that view.  
In conclusion, the objectives of extracting a stock of 73-DOC and confirming 
biological activity were successfully met, as shown by the consistency with published 
chemical and biological data. As biological activity of the 73-DOC extract has been 
demonstrated, work in the next chapter sought to address what effects 73-DOC has on 
the cell types involved in bone remodeling, the osteoclasts and osteoblasts. Interestingly, 
osteosarcoma cells are osteoblastic in origin, so the effect of 73-DOC on the MG-63 
cells suggests that the compound will have activity towards the osteoblast cell type. The 
type of activity, and the effects the compound has on osteoclasts and bone resorption are 
















Chapter 4: The Effects of 73-Deoxychondropsin 





A major aim of this thesis was to evaluate 73-DOC as a bone resorption inhibitor 
with the goal of identifying osteoclasts and/or osteoblasts as potential target cells and 
ultimately providing insights into a novel therapeutic to treat diseases characterised by 
excessive bone resorption. Having shown in the previous chapter that the extracted 73-
DOC had biological activity on MG-63 cells, the aim of this chapter was to now 
characterise specific in vitro effects of the compound on the cell types directly involved 
in bone remodeling, the osteoclasts and osteoblasts. As the inhibition of bone resorption 
can be achieved by targeting osteoclast differentiation as well as specifically inhibiting 
osteoclast function, the work presented in this chapter sought to initially characterise the 
effects of 73-DOC on the proliferation and differentiation of osteoclast precursors, as 
well as the viability of the mature cells. Similarly, the effects of 73-DOC on osteoblast 
precursor differentiation and viability were assessed, with a goal to establish an effective 













73-DOC was extracted as described in Chapter 3 and quantified as detailed in 
Section 2.1.4. As 73-DOC has been proposed as a V-ATPase inhibitor, the non-specific 
V-ATPase inhibitor, bafilomycin, was also used as a positive control in experiments. 
 
4.2.2 Osteoclast cell culture 
 
The effects of 73-DOC on different stages of osteoclast differentiation were 
investigated following the specific protocol summarised in Figure 4.1.  Briefly, 
Figure 4.1 Schematic of in vitro osteoclast differentiation and experiments. Bone 
marrow macrophages (BMM) were directed to become osteoclast precursors through 
the addition of M-CSF to the culture medium on day 1. Precursors were either used in 
proliferation assays or directed to become mature osteoclasts through the addition of 
RANKL, which were then used to investigate the effects of test compounds on osteoclast 
differentiation and mature cell viability.  
Mouse  
BMMs 
Day 1 Day 3 Day 7 Day 5 









 Assay (+/- Test Compounds) 
Mature Osteoclast 
Viability 
+/- Test Compounds 
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osteoclast precursors from murine BMMs, isolated as described in Chapter 2 (Section 
2.2.3.1), were used either in proliferation assays or to generate mature osteoclasts. For 
proliferation experiments, the MTS assay was used as described in Section 2.2.11. 
Precursors were differentiated into mature osteoclasts through the addition of M-CSF 
and RANKL to the culture medium as indicated in Figure 4.1. Test compounds were 
added either with RANKL, to investigate the effects on differentiation, or once mature 
osteoclasts were formed, to determine effects on viability of the mature cell type. TRAP 
staining was used to quantify mature osteoclasts, as described in Section 2.2.4.   
 
4.2.3 Osteoblast cell culture 
 
A schematic summarising osteoblast culturing conditions and the experiments 
performed with 73-DOC in this chapter is shown in Figure 4.2. Briefly, primary murine 
osteoblast precursors were obtained following enzymatic digestions of mice calvaria as 
detailed in Section 2.2.8. These cells were then either used in proliferation assays (see 
Section 2.2.11) or cultured to produce mature osteoblasts through the addition of 
ascorbic acid and βGP to the culture medium. Test compounds were added at early or 
late stages of osteoblast differentiation as indicated in Figure 4.2. ALP activity was 







4.3.1 73-Deoxychondropsin A inhibits the proliferation of osteoclast 
and osteoblast precursors 
 
To establish the effects of 73-DOC on the proliferation of osteoclast and 
osteoblast precursors, the MTS assay was used. Following isolation and an initial period 
in either osteoclastogenic or osteogenic media, the precursors were exposed to varying 
concentrations of 73-DOC or bafilomycin for a period of 48 hours. The MTS assay was 
then performed. 73-DOC was found to cause a dose-dependent inhibition in both 
Figure 4.2 Schematic of in vitro osteoblast differentiation and experiments. 
Primary osteoblast precursors were isolated from the calvaria of neonatal mice and 
were either used in proliferation assays or cultured in the presence of βGP and ascorbic 
acid to stimulate the differentiation of mature osteoblasts, which were then used to 
investigate the effects of test compounds on osteoblast differentiation at early and late 
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osteoclast and osteoblast precursor cell number during the 48 hour exposure period, 
relative to untreated cells (Figure 4.3). A significant decrease in metabolically viable 
cell numbers was seen at 5 nM and 10 nM for osteoclasts and osteoblasts respectively 
(Figure 4.3 A, C). Interestingly, maximal doses of 73-DOC caused a ~70% decrease in 
total osteoclast precursor cell number, but only a 40% decrease in osteoblast number.  
Taken together, these results suggest that osteoclasts appear to be more sensitive to the 
antiproliferative effects of 73-DOC at the precursor stage. Bafilomycin was shown to 
cause similar effects but at higher concentrations (Figure 4.3 B, D). 
 
4.3.2 73-Deoxychondropsin A inhibits the differentiation of 
osteoclasts 
 
 Once a suitable concentration range for 73-DOC was established for the two cell 
types, the effect of 73-DOC on the differentiation of murine osteoclast precursors was 
then investigated. To this end, M-CSF dependent precursor cells were cultured in 96-
well plates on slices of dentin in the presence of the critical osteoclastogenic factors, M-
CSF and RANKL, and mature osteoclasts were quantified after approximately 7 days. 
Culturing in the presence of 73-DOC was found to cause a significant dose-dependent 
decrease in the number of TRAP-positive MNCs formed, with a 40 % decrease at 2.5 
nM and a 60 % decrease at 5 nM (Figure 4.4).  
 
4.3.3 73-Deoxychondropsin A inhibits the viability of osteoclasts 
 
In addition to characterising the effects of 73-DOC on osteoclast precursors, the 
response of mature osteoclasts to 73-DOC was also investigated. Osteoclast precursors 






































































































































Figure 4.3 73-DOC inhibits the proliferation of osteoclast and osteoblast 
precursors. The MTS assay for cell proliferation was performed on 
osteoclast (A, B) and osteoblast (C, D) precursor cells following a 48 hour 
exposure to various concentrations of 73-DOC (A, C) or bafilomycin (B, D). 
Assay measurements were made from triplicate wells and expressed as a 
percent of the control. For 73-DOC, graphs represent the mean ± SEM, n = 3. 
For bafilomycin, results from a single experiment are shown ± SD (n = 2).     




Figure 4.4 73-DOC inhibits the differentiation of murine osteoclasts. 
Osteoclast precursor cells were cultured on dentin slices. When RANKL was 
added to stimulate osteoclast differentiation, 73-DOC was also included in the 
culture medium of test groups and in all subsequent medium changes. Cells were 
fixed after 7 days and stained for TRAP. Representative images of TRAP stained 
cells at various concentrations are shown, scale bar = 200 µm. TRAP-positive 
MNCs (>3 nuclei) were counted from triplicate wells and expressed as a 
percentage of control counts. Bar graph shows mean data ± SEM, n = 3. *** = 
Significant change from control, p<0.001.  
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formed. 73-DOC or bafilomycin were then added at various concentrations for a further 
48 hours and the number of TRAP-positive cells were quantified. 73-DOC caused a 
dose-dependent decrease in the number of mature osteoclasts, becoming significant at 
25 nM (Figure 4.5). Interestingly, this concentration is 10-fold higher than that which 
caused similar significant effects on osteoclast precursors (Figure 4.4). Additionally, the 
cellular morphology of osteoclasts also appeared to be affected by high concentrations 
of 73-DOC, where the more common occurrence of larger, more vacuolated cells was 
observed that also showed a greater intensity of TRAP staining (Figure 4.5 A).  
 
4.3.4 73-Deoxychondropsin A inhibits the differentiation of 
osteoblasts 
 
The effect of 73-DOC on the differentiation of osteoblasts was next investigated. 
Osteoblast precursors were cultured in the presence or absence of 73-DOC or 
bafilomycin, added at two different stages, either early from the outset of culture, or late 
after the cells reached confluence during early bone nodule formation. The activity of 
the osteoblastic differentiation marker, ALP, was then compared between treatment 
groups. Histochemical staining for ALP showed that 73-DOC inhibited osteoblast 
differentiation, especially when added at an early stage (Figure 4.6 A). Quantification 
of the ALP stained area confirmed this observation, showing dose-dependent decreases 
in the area of ALP-positive staining, becoming significant at concentrations of 2.5 nM 
and higher (Figure 4.6 A). Late-stage addition of 73-DOC similarly inhibited ALP 
staining, although slightly higher concentrations were required (Figure 4.6 B). 
Bafilomycin also inhibited osteoblast differentiation, with significant decreases in ALP 
activity observed at 5 and 10 nM for early and late-stage addition, respectively (Figure 
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Figure 4.5 73-DOC inhibits the number of mature murine osteoclasts. Osteoclast 
precursors were cultured on dentin slices. Additional slices were monitored for the 
presence of mature osteoclasts and once observed, concentrations of 73-DOC and 
bafilomycin were added to the culture medium of test wells. Cells were fixed after 48 
hours and stained with TRAP. Representative images are shown (scale bar = 200 µm) 
(A). TRAP-positive MNCs (>3 nuclei) from triplicate wells were counted and 
expressed as a percentage of control counts. Bar graph for 73-DOC shows mean ± 
SEM, n = 3. For bafilomycin, results from a single experiment are shown ± SD (n = 




Figure 4.6 73-DOC inhibits the differentiation of murine osteoblasts. 
Osteoblast precursors were isolated from mouse calvaria and cultured in 
osteogenic media. 73-DOC and bafilomycin were added to the culture 
medium at an early stage on day 2 of culture (A) and at a late stage when 
the cells were confluent (B). Cells were fixed when bone nodules were 
observed in control wells and stained for alkaline phosphatase (ALP) 
activity. Each plate well was imaged and the area of ALP-positive, red 
staining was quantified and expressed as a percentage of control values. 
Representative images of wells following staining are shown. Bar graphs 
show mean values ± SEM, n = 3. Stars represent significant change from 
control,  *- p<0.05, **- p<0.01, ***- p<0.001  
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and bafilomycin, and that early precursors are more sensitive than mature cultures to 




In this chapter, the effects of 73-DOC on the viability and differentiation of 
osteoclasts and osteoblasts were characterised for the first time. This work was important 
in determining a concentration range in which 73-DOC is active towards the two cell 
types, in addition to examining what specific in vitro effects the compound has on the 
precursors and mature cells of osteoclasts and osteoblasts. The results showed that 73-
DOC does have potent, low nanomolar activity towards these cell types. Proliferation of 
both osteoclasts and osteoblasts precursors were dose dependently inhibited by 73-DOC 
and significant inhibition of osteoclast and osteoblast differentiation was found to occur 
at the same concentration (2.5 nM) when 73-DOC was added at comparable stages. 
Additionally, mature osteoclast viability was shown to be inhibited by 73-DOC but at 
concentrations 10-fold higher than those causing effects in the precursor cells. The 
similarity in cellular response of both cell types between 73-DOC and bafilomycin 
suggest that they might share a common inhibitory mechanism, supporting the 
designation of 73-DOC as a V-ATPase inhibitor.  
The inhibition of osteoblast precursor proliferation was not unexpected 
considering the inhibition of MG-63 osteosarcoma cell proliferation by 73-DOC 
(Chapter 3). However, the inhibition of osteoclast precursors by 73-DOC was a novel 
finding, consistent with other reported antiproliferative effects of V-ATPase interference 
in osteoclast precursors (Qin et al., 2011, Yang et al., 2012). Indeed, the proliferation of 
other non-bone cell types have also shown sensitivity to either 73-DOC, other 
chondropsin metabolites, as well as other V-ATPase inhibitors (Manabe et al., 1993, 
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Cantrell et al., 2000, Rashid et al., 2001a, Rashid et al., 2001b, Chevallier et al., 2004, 
Pérez-Sayáns et al., 2009, Rath et al., 2014). The mechanisms underlying the inhibition 
of osteoblast and osteoclast proliferation by 73-DOC are not yet known. However, other 
studies have shown that V-ATPase expression is upregulated during macrophage 
proliferation and that inhibition in other cell types can induce cell-cycle arrest leading 
to apoptosis, or can disturb intracellular trafficking and signalling events (Lee et al., 
1997, McHenry et al., 2010, Rath et al., 2014). What effects 73-DOC has on the cell-
cycle and apoptosis of osteoclasts and osteoblasts are currently unknown. Interestingly, 
it appears that proliferating cells are more susceptible to the effects of 73-DOC as both 
osteoclast and osteoblasts exhibit increased sensitivity when 73-DOC was added at a 
precursor stage in comparison to when added to differentiated cells. This observation is 
consistent with the reported effects of V-ATPase inhibition on the cell-cycle machinery, 
but future experiments characterising cell-cycle kinetics, or apoptotic signalling 
cascades would be worth examining to explain the potential mechanisms of osteoclast 
and osteoblast inhibition by 73-DOC.  
Another possible explanation for decreased proliferation via V-ATPase inhibition 
might be found from a proposed novel function of the V-ATPase in mTOR signalling, 
which is responsible for regulating various cellular functions including proliferation, cell 
survival, amino acid sensing and autophagy (Weichhart, 2012). One theory linking the 
V-ATPase with mTOR signalling concerns cytoplasmic pH, as studies have shown that 
a lowered cytoplasmic pH correlates with inhibition of mTORC1 (mTOR complex 1) 
activity, attributed to impaired V-ATPase function (Balgi et al., 2011, Fonseca et al., 
2012). Another model of mTOR signalling has proposed a more direct involvement of 
the V-ATPase in sensing amino acids, the lysosomal levels of which are known to be a 
crucial signal for mTOR (Jewell et al., 2013). Zoncu et al. (2011) proposed that amino 
acids interact with V-ATPases at the lysosome surface to regulate recruitment of Rag 
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guanosine triphosphates (GTPase), which activate mTORC1 following translocation to 
the lysosome. The V-ATPase was the first downstream target discovered in a putative 
amino acid sensing pathway, though other evidence has suggested the proton-assisted 
amino acid transporter, PAT1, or transcription factor EB (TFEB),  may be the amino 
acid sensor with the V-ATPase acting as a key factor (Ögmundsdóttir et al., 2012, 
Settembre et al., 2012). Many questions regarding this model remain but the 
involvement of the V-ATPase in the mTOR signalling pathway seems clear, and 
components of the mTOR pathway are known to be expressed in osteoclasts (Indo et al., 
2013). Disruption of this pathway by a V-ATPase inhibitor such as 73-DOC could 
therefore lead to inhibited cell growth and survival.  
Other insights into the role of V-ATPase in proliferation and differentiation are 
provided by studies using genetic knockout in vivo, or in vitro knockdown of individual 
V-ATPase subunits. For example, mice with either the heterozygous or homozygous 
R740S mutation in the a3 subunit isoform, as well as a3-knockout mice and a3-truncated 
mice, all had inactive osteoclasts due to a lack of a ruffled border or the uncoupling of 
proton pumping from ATP hydrolysis, but osteoclast numbers were normal or even 
increased (Nakamura et al., 1997, Li et al., 1999, Ochotny et al., 2011, Ochotny et al., 
2013). Using a mouse knockout model of the d2 subunit, Lee et al. (2006) showed that 
osteoclast differentiation was impaired, which was attributed to ineffective fusion of 
precursors, but the proliferation of osteoclast precursors was found to be unaffected by 
d2 knockout. Finally, knockdown of the V-ATPase subunit Ac45 in vitro was shown to 
inhibit osteoclast differentiation via decreased precursor proliferation and fusion, due to 
down regulation of ERK, c-Fos and NFATc1, which suggest that Ac45 acts upstream of 
osteoclastogenic signalling pathways (Yang et al., 2012). Similar effects on NF-κB and 
pERK pathways were also observed using the V-ATPase inhibitors saliphenylhalamide 
and bafilomycin (Qin et al., 2012a), and TRAF6, which mediates RANKL-induced 
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signalling, was shown to directly interact with V-ATPases suggesting a potential link 
with osteoclastogenesis (Ryu et al., 2005).  
Interestingly, the V-ATPase inhibitor enoxacin, which targets the interaction 
between the B2 V-ATPase subunits and actin microfilaments, was shown to directly 
inhibit osteoclastogenesis without inducing apoptosis (Toro et al., 2012b). The authors 
proposed that enoxacin was preventing the specific recruitment of a3-containing V-
ATPase complexes to the ruffled border during differentiation, mediated by the actin-
binding site on the B2 subunit. The plasma membrane sorting of DC-STAMP, a protein 
involved in the fusion of osteoclast precursors, was also perturbed as were the trafficking 
of other proteins, suggesting effects downstream of V-ATPase-actin binding in 
regulating vesicular trafficking and sorting. A similar finding was reported by Voronov 
et al. (2013) where, contrary to other studies examining the a3 subunit mentioned above, 
in vitro differentiation of osteoclasts from mice with the heterozygous R740S mutation 
was impaired, attributed to decreased NFATc1 translocation and elevated lysosomal pH. 
Currently the precise roles of lysosomal pH in osteoclastogenesis are unknown, 
however, there are other reports of inhibited signalling pathways in response to V-
ATPase-mediated pH levels, such as Wnt/β-catenin (Cruciat et al., 2010) and notch (Yan 
et al., 2009). Intracellular pH is known to have a central role in transport along the 
endocytotic pathway as the activity of V-ATPases in different endocytotic 
compartments result in finely regulated pH gradients that are crucial for effective 
trafficking (Xu et al., 2003, Hurtado-Lorenzo et al., 2006, Marshansky and Futai, 2008). 
The effects seen by 73-DOC on osteoclastogenesis, as well as osteoblast differentiation, 
could therefore be attributed to disrupted endocytosis and trafficking of signalling 
molecules.  
The direct effects of 73-DOC on V-ATPase subunits such as a3, d2 or Ac45 are 
currently unknown, but future molecular analyses determining the effects of 73-DOC on 
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the expression of these different subunits would help explain some of the observations 
made in this chapter. Similarly, examining 73-DOC-induced changes in 
osteoclastogenic signalling pathways such as NFATc1, c-Fos, NF-κB, pERK and 
TRAF6 in order to determine whether 73-DOC directly inhibits osteoclastogenesis. 
Regarding osteoblasts, very little is known about the role of V-ATPase in osteoblast 
differentiation, though knockout studies have shown that osteoblast parameters were 
unaffected by dysfunction of the a3 and d2 subunits (Li et al., 1999, Lee et al., 2006, 
Ochotny et al., 2013). In considering the role of V-ATPases in regulating trafficking and 
signalling, it is tempting to speculate that similar mechanisms are also affecting 
signalling cascades in osteoblasts, leading to the observed effects on differentiation. This 
hypothesis could be confirmed in the future by examining the expression of transcription 
factors that drive osteoblast differentiation in response to 73-DOC treatment, such as 
Runx2 or Osx.  
A final explanation for the effects of 73-DOC may relate to autophagy 
(macroautophagy), a protein degradation pathway that functions to maintain cellular 
homeostasis. This process involves the encapsulation of damaged organelles, pathogens 
and protein aggregates by autophagosomes, which then fuse with lysosomes for 
enzymatic degradation of the contents. Crucial to this process is the V-ATPase-mediated 
acidification of lysosomes, as inhibition of V-ATPases by bafilomycin has been shown 
to block maturation of autophagosomes by inhibiting fusion with the lysosome, which 
may also be related to the effects of V-ATPase inhibition on endocytosis (Clague et al., 
1994, Van Deurs et al., 1996, Yamamoto et al., 1998, Klionsky et al., 2008). Bafilomycin 
has since been used as a common tool to study autophagy and the importance of this 




In examining increased apoptosis in osteoclasts from mice with the homozygous 
R740S mutation in a3, Ochotny et al. (2013) found that the relative expression of the 
essential autophagy markers LC3-II and p62 were decreased and increased respectively, 
which led the authors to suggest that inhibition of autophagy as a result of ineffective 
intracellular acidification by V-ATPases caused increased sensitivity to toxic events, 
such as the accumulation of misfolded proteins that would typically be removed by the 
autophagy process. A similar mechanism has been reported in cancer cells, where V-
ATPase inhibitors caused increased autophagy-related apoptosis (Wu et al., 2009b, 
Kallifatidis et al., 2013, von Schwarzenberg et al., 2013). Interestingly, Ochotny et al. 
(2013) also observed morphological defects in osteoclasts from mice with the a3 
mutation, including intense, mis-localised TRAP staining and the occurrence of large 
cytoplasmic vacuoles, consistent with the effects of high 73-DOC concentration on 
mature osteoclasts shown in this chapter. Similar morphological defects were also 
attributed to defective vesicular/endosomal trafficking in osteoclasts from osteopetrotic 
mice lacking either TRAP (Hollberg et al., 2002) or PLEKHM1 (Van Wesenbeeck et 
al., 2007), the latter of which has recently been shown to regulate fusion of 
autophagosomes with lysosomes (McEwan et al.). Inhibited late-stage autophagy often 
leads to the accumulation of autophagosomes due to impaired fusion with lysosomes, so 
it is possible the large vesicles seen in the 73-DOC-treated osteoclasts are indicators of 
inhibited autophagy, but electron microscopy would be required to identify the 
characteristic double membrane of autophagosomes.  
Autophagy has also been directly implicated in osteoclastogenesis as Lin et al. 
(2013) showed that inhibiting autophagy by deletion of Atg7 decreased osteoclast 
differentiation, whereas inducing autophagy by overexpression of Beclin1 stimulated 
the production of mature osteoclasts. Also ERK phosphorylation was shown to be 
regulated by Atg5, Atg7 and LC3 (Martinez-Lopez et al., 2013), and hypoxia-induced 
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enhancement of osteoclast formation and precursor differentiation was found to be 
mediated by the upregulation of autophagy (Wang et al., 2011, Zhao et al., 2012). 
Additionally, pharmacological or genetic inhibition of autophagy has been shown to 
suppress the differentiation of MSCs to osteoblasts, providing a potential mechanism for 
the inhibitory effects of 73-DOC on osteoblasts (Pantovic et al., 2013). Conversely, there 
is evidence suggesting that induction of autophagy via mTOR inhibition may inhibit 
osteoclast formation. Rapamycin and other mTOR inhibitors have been reported to 
inhibit osteoclast formation and activity in vitro and in vivo in rodents and humans 
(Sanchez and He, 2009, Cejka et al., 2010, Smink et al., 2012). The above findings 
demonstrate that a mechanism related to autophagy could explain the observations of 
this chapter. Future experiments examining the expression of autophagy proteins such 
as Atg5, Atg7, LC3 and p62 in both osteoclasts and osteoblasts following 73-DOC 
treatment would help resolve this proposed mechanism of inhibition. 
In conclusion, the studies in this chapter showed clear effects on osteoclast and 
osteoblast precursors. The mechanism of these effects may be related to the roles of V-
ATPases in intracellular pH, endocytotic trafficking, mTOR signalling and autophagy, 
all of which are viable candidates for future experiments examining the effects of 73-
DOC treatment. As the aim of this thesis was to evaluate 73-DOC as a resorption 
inhibitor, still to be determined is what effect the compound has on mature cell function. 








Chapter 5: The Effects of 73-Deoxychondropsin 




The previous chapter sought to investigate specific in vitro effects of 73-DOC on 
osteoclast and osteoblast precursor proliferation, viability and differentiation. This 
chapter will investigate the effects of 73-DOC on mature osteoclasts and osteoblasts, 
and whether there is differential responsiveness between these two cell types. The 
specific objectives were to investigate the effects of 73-DOC on the function of 
osteoclasts and osteoblasts through quantitative resorption and mineralised bone nodule 
formation assays, respectively, and to examine the effect of the compound on osteoclast 
cellular acidification, which is the putative primary function of V-ATPases in 
osteoclasts.  
 
5.2 Materials and methods 
 
5.2.1 Cell culture 
 
Murine osteoclasts and osteoblasts were derived from primary cultures of BMMs 
and calvarial digests, respectively. Additionally, human osteoclasts were used in this 








For resorption assays, osteoclasts were cultured on tissue culture plastic before 
mature cells were detached and re-plated onto dentin in the presence of test compounds. 
Quantification of resorption pit surface area and depth was performed using reflected 
light microscopy as described in Section 2.2.7. Actin rings were fluorescently labelled 
using TRITC-phalloidin in mature human osteoclasts in order to quantify mature cell 
number, and the activation state of osteoclasts. For the analysis of cellular acidification, 
osteoclasts were fluorescently labelled with acridine orange and imaged using confocal 
microscopy as described in Section. 2.2.6  
5.2.3 Osteoblasts 
 
For quantification of mineralised bone nodule formation, experiments setup as 





5.3.1 73-Deoxychondropsin A inhibits murine and human osteoclastic 
resorption 
 
The effects of 73-DOC on the resorptive function of murine osteoclasts were first 
examined by quantifying resorption from cells cultured on dentin following exposure to 
the compound throughout RANKL-induced differentiation (Figure 4.4). The data show 
that 73-DOC caused a significant dose-dependent decrease in the surface area of 
resorption, with a 65 % and 90 % reduction at concentrations of 2.5 nM and 5 nM 





























































Figure 5.1 73-DOC inhibits the function of osteoclasts formed following 
continuous exposure during differentiation. Osteoclast precursor cells were 
cultured on dentin slices. When RANKL was added to stimulate osteoclast 
differentiation, 73-DOC was also included in the culture medium of test groups and 
in all subsequent medium changes. Cells were fixed after 7 days, stained for TRAP 
and counted (Figure 4.4). Cells were then removed from the dentin substrate and 
resorption surface area was quantified (red bars), shown alongside cell count data 
(blue bars) (A). Resorption activity per cell was estimated using matched cell count 
data (B). Bar graph shows mean data ± SEM, n = 3. *** = Significant change of all 
data from control, p<0.001. 
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mature TRAP-positive osteoclasts, a significant decrease in the amount of resorption per 
cell was seen at identical concentrations, suggesting that the decrease in resorption 
cannot be attributed to a decrease in cell number alone (Figure 5.1 B).    
In order to further examine the specific resorptive function of murine osteoclasts, 
mature cells were re-seeded onto dentin before being exposed to varying concentrations 
of 73-DOC for a period of 48 hours. The data show that 73-DOC caused a significant 
dose-dependent decrease in the surface area of resorption, showing a 20 % decrease at 
concentrations as low as 0.5 nM 73-DOC, and a complete abolition of resorption at 25 
nM (Figure 5.2 A-C, D). Normalisation of the resorption area to the number of mature 
TRAP-positive osteoclasts showed a similar significant dose-dependent decrease in the 
resorptive activity per cell (Figure 5.2 E). Measurement of resorption pit depth also 
revealed that 73-DOC caused a dose-dependent decrease in the depth of resorption pits, 
showing a significant 10 % decrease at 0.5 nM (Figure 5.2 F). Bafilomycin also caused 
a dose-dependent decrease in resorption as well as resorption per cell (Figure 5.2 D, E).  
The effects of 73-DOC were next investigated on the function of human 
osteoclasts derived from purified PBMCs, cultured with M-CSF and RANKL. Similar 
to the procedure utilised with murine osteoclasts, mature human osteoclasts were 
generated on tissue culture plastic and then re-seeded onto dentin discs before exposure 
to 73-DOC for a period of 72 hours. TRAP staining of human osteoclasts was found to 
be highly variable and so actin ring staining was used to quantify osteoclasts before 
resorption surface area was assessed using reflected light microscopy (Figure 5.3 A-C). 
The results showed that, similarly to murine osteoclasts, 73-DOC caused a dose-
dependent decrease in the number of human osteoclasts, leading to a significant 70 % 
decrease at 100 nM (Figure 5.3 D). 73-DOC also caused a significant dose-dependent 
decrease in the total surface area of resorption, showing a 30 % decrease at 1 nM and 
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Figure 5.2 73-DOC inhibits the function of mature murine osteoclasts. 
Mature osteoclasts were re-seeded onto triplicate dentin slices and exposed to 73-
DOC and bafilomycin for 48 hours. TRAP-positive MNCs were counted and 
removed before the dentin slices were stained with toluidine blue and resorption 
area was quantified using reflected light microscopy. Representative images of 
darkly stained resorbed areas are shown (scale bars = 400 µm) (A-C). Resorption 
surface area over the whole dentin slice was estimated (red bars), shown 
alongside cell count data (blue bars) (D), and then normalised to area per cell (E). 
Resorption pit depths were also estimated (F). Bar graphs for 73-DOC represent 
mean data (n = 3) ± SEM. Black or colour-coded stars represent a significant 
change from control values, *- p<0.05, **- p<0.01, ***- p< 0.001. Bafilomycin 







Figure 5.3 73-DOC inhibits the function of human osteoclasts. Human 
osteoclasts cultured from PBMCs were re-seeded onto dentin slices and 
exposed to 73-DOC for 72 hours. Typical TRAP (A) and matched fluorescent 
actin stained osteoclasts are shown (B). A reflected light microscopy image 
of TRAP-stained osteoclasts within out-of-focus resorption pits is also shown 
(C) (all scale bars = 50µm). Actin ring-positive cells were quantified and then 
removed. Dentin slices were then stained with toluidine blue and the whole-
slice surface area of resorption was estimated (red bars), shown alongside cell 
count data (blue bars) (D), and then normalised to resorption per cell (E). 
Resorption pit depth was also estimated (F). Bar graphs show the mean values 
of triplicate data from 1 representative experiment (n = 2) ± S.D. Black or 
colour-coded stars represent a significant change from control values, *- 
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also showed a dose-dependent decrease, and resorption pit depth was decreased at all 
concentrations tested (Figure 5.3 D, E).  
The inhibitory effect of 73-DOC on human osteoclasts was also confirmed by 
quantifying the number of osteoclasts that bear a characteristic crescent-shaped actin 
ring, as this is a hallmark of actively resorbing osteoclasts (Lakkakorpi et al., 1989, 
Lakkakorpi and Väänänen, 1996). Exposure of human osteoclasts to 73-DOC caused a 
dose-dependent decrease in the proportion of actively-resorbing osteoclasts, with a 
significant 65 % decrease at 10 nM, and the complete absence of active osteoclasts at 30 
nM 73-DOC (Figure 5.4). Interestingly, significant reductions in resorbing osteoclasts 
were seen at concentrations that had no significant effect on the total number of actin 
ring-positive cells. Taken together, these results indicate that 73-DOC can inhibit the 
function of both mature murine and human osteoclasts.   
 
5.3.2 73-Deoxychondropsin A inhibits osteoclast acidification 
 
The decrease in the number of actively resorbing osteoclasts suggested that 73-DOC 
inhibits osteoclast function. This was further investigated by examining cellular 
acidification, which is essential for osteoclast function (Baron et al., 1985). To this end, 
acridine orange staining was used which fluoresces orange when protonated in regions 
of cellular acidification, and green in less acidic conditions when viewed using 
fluorescence microscopy. Confocal microscopy analysis following acridine orange 
staining of mature, actively-resorbing murine osteoclasts showed the expected orange 
fluorescence staining (Figure 5.5 A, B). Closer examination showed that the 
fluorescence was localised in putative intracellular vesicles, and significantly, to the 
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Total Osteoclasts Proportion of Resorbing Osteoclasts
Figure 5.4 73-DOC inhibits the number of actively resorbing 
osteoclasts. Actin rings from human osteoclasts exposed to 73-DOC for 
72 hours were fluorescently stained. Representative images are shown 
with white arrows indicating osteoclasts with the characteristic actin ring 
morphology of actively resorbing osteoclasts, and white stars indicating 
non-resorbing osteoclasts (scale bar = 50 µm). The number of actively 
resorbing osteoclasts were counted and expressed as a proportion of the 
total number of actin ring-positive osteoclasts (red bars). Total cell count 
data is also shown (blue bars). Bar graph shows the mean values of 
triplicate data from 1 representative experiment (n = 2) ± S.D. Colour-
coded stars represent a significant change from control values, *- 






Figure 5.5 73-DOC inhibits cellular acidification in osteoclasts. Murine 
osteoclasts were cultured on dentin slices. 24 hours prior to imaging, 73-DOC 
(5 nM) and bafilomycin (1 nM) were added to test wells. Live untreated, (A-
D), 73-DOC-treated (E-H), and bafilomycin-treated (I-L) cells were then 
imaged using confocal microscopy as described in Chapter 2. Images of z-
stacks projections (A, E, I) and cross sections of individual cells (B-D, F-H, J-
L) are shown. Scale bars: A, E, I = 50 µm; B-D, F-H, J-L = 10 µm. 
1 nM Bafilomycin: 
Control: 
5 nM 73-DOC: 









ruffled border on the resorbing surface of the osteoclasts (Figure 5.5 C, D). Treatment 
with 73-DOC or bafilomycin for 24 hours showed a marked reduction in overall orange 
fluorescence (Figure 5.5 E-F, I-J) and significantly, there was reduced fluorescence 
localised at the resorbing surface of the osteoclasts (Figure 5.5 G-H, K-L). These results 
suggest that 73-DOC prevented acidification of the resorption lacunae, which would 
correlate with the inhibition of resorption activity.  
 
5.3.3 73-Deoxychondropsin A inhibits murine osteoblast 
differentiation and matrix deposition 
 
Finally, to further characterise the effects of 73-DOC on the differentiation of 
osteoblasts, bone nodule assays were performed using primary mouse osteoblasts. 
Varying concentrations of 73-DOC and bafilomycin were added to osteoblast 
differentiation cultures at two different stages (Figure 4.2), at early stages to investigate 
the effects on osteoblast precursors, and at later stages after nodule formation had 
started, to investigate the effects on nodule formation, matrix deposition and 
mineralisation.  
Addition of 73-DOC to early stage cultures resulted in a dose-dependent 
decrease in bone nodule formation, with a ~60 % decrease in mineralised nodules at 2.5 
nM and a complete inhibition at 5 nM 73-DOC (Figure 5.6 A). This correlated with the 
effects seen with ALP staining though the effect on mineralisation was marginally more 
sensitive (Figure 4.6 A). Addition of 73-DOC to late stage cultures after nodules had 
already started forming showed a 70 % decrease in mineralised bone nodule area at 5 
nM with complete inhibition at 10 nM (Figure 5.6 B). Again, a similar effect was seen 
with ALP activity but the effect on mineralisation was more marked (Figure 4.6 B).  
Bafilomycin also caused a dose-dependent decrease in mineralised bone nodule 
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Figure 5.6 73-DOC inhibits the formation of mineralised bone nodules. Osteoblast 
precursors, isolated from mice calvaria, were cultured in osteogenic media. 73-DOC 
and bafilomycin were added to the culture medium of test groups at an early stage on 
day 2 of culture (A) and at a late stage when cells were confluent (B). Cells were fixed 
when mineralised bone nodules were evident in control wells and, following ALP 
staining (Chapter 4, Figure 4.6), mineralised bone nodules were visualised using von 
Kossa staining and imaged. Representative images of stained cells are shown (scale 
bar = 500 µm). The area of von Kossa staining was quantified from each well and 
expressed as a percentage of control values. Bar graphs the mean values of mineralised 
bone nodule area ± SEM, n = 3. Stars represent significant change from control values, 




formation at both time points but with increased sensitivity at an early stage (Figure 5.6 
A, B). Interestingly, many unmineralised nodules were observed at concentrations where 
von Kossa staining was negative, implying that the process of mineralisation was 
inhibited whereas matrix deposition and nodule formation was still occurring. These 
results suggest that 73-DOC causes an overall inhibition of mineralisation of bone 
nodules and that osteoblast precursors are more sensitive to the effects than mature, 




In this chapter, the effects of 73-DOC on osteoclasts and osteoblasts were 
demonstrated using functional assays. The inhibition of osteoclast function by 73-DOC 
was demonstrated in both mouse and human derived cells, showing significant inhibition 
of resorption at 0.5 and 1.0 nM respectively. This result is consistent with previous 
studies which showed that targeting the V-ATPase pharmacologically with inhibitors 
(Sundquist et al., 1990, Visentin et al., 2000, Niikura et al., 2004, Karsdal et al., 2005, 
Niikura et al., 2005, Niikura et al., 2007, Sorensen et al., 2007, Kartner et al., 2010, Qin 
et al., 2012a, Toro et al., 2012a, Crasto et al., 2013) or through knockdown/interference 
of the whole V-ATPase or its subunits (Laitala-Leinonen and Vaananen, 1999, Li et al., 
1999, Hu et al., 2005b, Lee et al., 2006, Feng et al., 2009b, Yang et al., 2012, Ochotny 
et al., 2013), can lead to inhibition of osteoclast mediated bone resorption. Interestingly, 
the inhibition of osteoclast function was attained at concentrations that had no effects on 
the proliferation, differentiation and viability of osteoclasts, where such effects were 
seen at concentrations of 2.5 nM and above. To date, the most potent chemical inhibitor 
of in vitro osteoclast resorption has been bafilomycin, with half maximal inhibition 
reported at 0.625nM to 5nM (Karsdal et al., 2005, Qin et al., 2012a). In the current work, 
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although 73-DOC was found to be as potent as bafilomycin, mature osteoclasts appeared 
to be more tolerant of higher concentrations of 73-DOC than bafilomycin. As 
bafilomycin is generally considered unsuitable for therapeutic use due to off-target 
effects, this suggests that 73-DOC may represent an equally effective, but more 
therapeutically suitable V-ATPase inhibitor (Keeling et al., 1998). 
The use of acridine orange staining showed that osteoclasts treated with 73-DOC 
were consistently found to have less overall cellular acidification, and in particular, less 
acidification localised at the ruffled border, than untreated cells. This result strongly 
implies that V-ATPase inhibition is indeed occurring and would provide one explanation 
for the inhibition of resorption by 73-DOC. That 73-DOC itself can inhibit V-ATPase 
activity was shown previously by Bowman et al. (2003) using a biochemical assay and 
isolations of membrane-bound V-ATPases from fungal and bovine sources. However, 
the results of this chapter demonstrated for the first time that 73-DOC inhibits 
human/murine V-ATPase-mediated osteoclast resorption. Furthermore, 73-DOC was 
found to elicit half maximal inhibition of osteoclast resorptive activity (~5 nM in mice) 
at concentrations 20- and 600-fold less than those causing similar inhibition of fungal 
(100 nM) and mammalian (3 µM) V-ATPase activity, respectively. These exciting 
findings demonstrate that 73-DOC has highly potent, novel activity in osteoclasts that 
provide further support for its potential application as a therapeutic. The inhibitory 
effects of 73-DOC on isolated human membrane V-ATPase activity have not yet been 
determined, but future experiments with differential V-ATPase-containing membrane 
fractions or microsomes, sourced from osteoclasts and other human cell types, would be 
of value in confirming specificity for the osteoclast V-ATPase. In this regard, the 
methods of either Bowman et al. (2003), or those involving spectroscopic in vitro 
measurements of acridine orange fluorescent quenching in response to ATP and test 
compounds (Wu et al., 2009a), could be applied. 
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The absence of acidic acridine orange staining at the ruffled border in 73-DOC-
treated osteoclasts could suggest that the targeted localisation of V-ATPase-containing 
vesicles to the ruffled border is disrupted by 73-DOC. This would represent one exciting 
possible role of 73-DOC action, and is reminiscent of the proposed mechanism 
responsible for impaired bone resorption in osteoclasts depleted of the Ac45 subunit, 
which showed disrupted localisation of fluorescently labelled V-ATPases in resorbing 
osteoclasts (Qin et al., 2011, Yang et al., 2012). However, the lack of acridine orange 
staining may also be explained by the lack of a ruffled bored. Indeed, osteoclasts treated 
with bafilomycin or from mice/humans lacking the a3 V-ATPase subunit are not 
functional due to the absence of cell polarisation and ruffled border formation (Seifert 
and Marks, 1985, Nakamura et al., 1997, Bruder et al., 2003, Sahara et al., 2003, 
Ochotny et al., 2013). This cannot be ruled out at the present time, therefore electron 
microscopic analysis of 73-DOC-treated cells is one possible direction for future work.  
Whilst it is clear that inhibition of specific V-ATPase subunits contribute to the 
loss of V-ATPase activity in osteoclasts, the putative binding site for 73-DOC remains 
to be resolved. In this regard, it is interesting to note that bafilomycin and concanamycin 
A have both been shown by two independent studies to bind to the c subunit of the V0 
V-ATPase domain (Bowman and Bowman, 2002, Huss et al., 2002) and that Bowman 
et al. (2003) also found that a mutated bafilomycin-resistant yeast strain exhibited 
decreased sensitivity to the effects of 73-DOC in comparison with wild-type yeast. 
Whether 73-DOC also binds directly to the c subunit, or to any other V-ATPase subunit 
is a very interesting question and remains a goal for future work (see Chapter 7) 
alongside characterising V-ATPase subunit transcription and expression in 73-DOC-
treated osteoclasts.  
Another possibility is that osteoclastic resorption in response to 73-DOC was 
inhibited due to the roles of V-ATPases in other cellular processes such as endosomal 
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trafficking. The role of the V-ATPase in maintaining intracellular pH for proper 
functioning of vesicular trafficking has been established previously, and it is known than 
trafficking of late endosomes/lysosomes is critical for the formation of the ruffled border 
and for bone resorption (Coxon and Taylor, 2008). Treatment of osteoclasts with 
bafilomycin has been shown by to interrupt endocytosis, vesicular trafficking as well as 
formation of a ruffled border (Sahara et al., 2003, Xu et al., 2003). Interestingly, 
osteoclasts treated with brefeldin A, a potent inhibitor of intracellular vesicular transport, 
also lacked ruffled borders and showed accumulation of extremely large vesicles 
consistent with the unusual osteoclast morphology observed following 73-DOC 
treatment (Sahara and Sasaki, 2001). Therefore, it is tempting to speculate that 73-DOC 
could be also be acting in a similar way, reducing resorptive activity through specific 
disrupted targeting of the ruffled border V-ATPase complex, or through dysfunctional 
endocytosis in general. This could be confirmed in the future by examining fluorescently 
labelled V-ATPase trafficking in response to 73-DOC treatment.  
Disrupted endosomal pH is one indirect explanation to account for V-ATPase-
mediated effects on intracellular trafficking but the crucial trafficking of late 
endosomes/lysosomes to the ruffled border is thought to also directly involve the V-
ATPase and the microfilament cytoskeleton of the cell. F-actin binding domains have 
been found in the V-ATPase subunits B (Holliday et al., 2000) and C (Vitavska et al., 
2003), with other studies demonstrating that the V-ATPase-actin interaction is essential 
for osteoclast activation (Lee et al., 1999), actin ring formation (Feng et al., 2009b) and 
proper ruffled border formation (Zuo et al., 2006). This led to the understanding that this 
interaction could mediate the tethering of V-ATPases to cortical actin following 
endosomal trafficking and prior to insertion at the ruffled border (Coxon and Taylor, 
2008). This interaction also appears specific for a3-containing V-ATPases, as the V-
ATPase fails to associate with the cytoskeleton in osteoclasts derived from oc/oc mice 
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(Nakamura et al., 1997) and actin-V-ATPase binding activity was specifically observed 
with the a3 and not the a1 subunit (Toro et al., 2012b). 
Actin staining of 73-DOC-treated osteoclasts indeed showed that the proportion 
of actively resorbing osteoclasts was significantly reduced at levels greater than cortical 
actin ring formation, suggesting effects on the rearrangement of the cytoskeleton during 
osteoclast activation. This result could be explained by interference of the V-ATPase-
actin interaction or by disrupted vesicular trafficking of the V-ATPase complex. 
Enoxacin, an inhibitor of the actin-V-ATPase interaction, was shown to inhibit 
osteoclast resorption and osteoclastogenesis similar to 73-DOC (Ostrov et al., 2009). 
However, the authors reported that actin ring formation was disrupted at concentrations 
that inhibited resorption, contradicting that found with 73-DOC. A similar situation was 
reported for a3 siRNA interference (Hu et al., 2005b), though this was contradicted by 
Feng et al. (2009b) who showed that C2 silencing disrupted actin ring formation but not 
a3. Knockdown of the Ac45 V-ATPase subunit did not affect cortical actin ring 
formation (Yang et al., 2012).  
Many processes involved with osteoclast polarisation and vesicular trafficking are 
regulated by small GTPases. In osteoclasts, the lysosomal GTPase Rab7 is particularly 
important in ruffled border formation and the targeted trafficking of V-ATPases, as 
shown by antisense knockdown studies (Zhao et al., 2001, Itzstein et al., 2011). An 
interesting result from the study by Yang et al. (2012) was that the Ac45 subunit co-
localised with Rab7 in resorbing osteoclasts and directly interacted with Rab7. This 
demonstrates an additional possible mechanism of V-ATPase inhibition leading to 
consequences for vesicular trafficking and ruffled border formation. The similarities 
between the effects of the 73-DOC and the Ac45 knockdown would suggest that 
dysfunctional trafficking of the V-ATPase complex could be responsible for the 
observed decreases in resorption and osteoclast activation. The effects of 73-DOC on 
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the Ac45 subunit or the Rab7 pathway also represent directions for future experiments 
alongside further examination of the osteoclast cytoskeleton and V-ATPase localisation 
in response to 73-DOC treatment. 
A final mechanistic explanation for reduced osteoclast function following V-
ATPase inhibition concerns autophagy. The bone remodelling disorder Paget’s disease, 
characterised by excessive osteoclast numbers and activity, has been shown to be 
associated with mutations affecting the essential autophagy protein, SQSTM1, and 
indeed, autophagic protein degradation was found to be inhibited in osteoclasts with the 
SQSTM1 (also known as p62) mutations (Helfrich and Hocking, 2008, Hocking et al., 
2012). Further evidence of autophagy participating in osteoclast function comes from 
genetic knock-out studies of the key autophagosome proteins Atg5, Atg7, Atg4B and 
LC3. These were all shown using electron and immunofluorescence microscopy to be 
required for ruffled border formation and the function of osteoclasts in vitro and in vivo 
(DeSelm et al., 2011). Additionally, Rab7 localisation at the ruffled border was shown 
to be Atg5-dependent and lysosomal targeting to actin rings was disrupted by all the 
knockouts. These intriguing discoveries imply an important role for autophagy in 
lysosomal targeting and osteoclast function and may explain the observed effects of 73-
DOC on osteoclast activity. Future experiments could confirm this hypothesis by 
examining Atg5, Atg7, Atg4B and LC3 expression and localisation in 73-DOC-treated 
osteoclasts. 
A combination of the above mechanisms may also be occurring in osteoclasts, 
which may explain the 5-fold difference in magnitude between the concentration of 73-
DOC needed to significantly affect osteoclast resorption versus differentiation. This 
observation may reflect the different levels of V-ATPase required by the relevant 
processes, as more complexes are required for resorption than for other 
endosomal/lysosomal-based intracellular functions, as shown by a3 expression and 
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localisation relative to other a isoforms present in osteoclasts (Toyomura et al., 2000, 
Toyomura et al., 2003). This implies that resorption will be more sensitive to V-ATPase 
inhibition than other cellular processes. However, a compensatory mechanism may also 
be taking place with non-ruffled border V-ATPases leading to a higher tolerance of 73-
DOC. Nyman and Vaananen (2010) demonstrated such a situation, showing that the V-
ATPase subunit a1 could compensate for a3 inhibition in lysosomal V-ATPases, but not 
in the ruffled border V-ATPase. If 73-DOC is targeting a subunit that is present in both 
lysosomal and ruffled border V-ATPases, but that can be compensated for in the 
lysosome, this would explain the differential sensitivity between differentiation and 
resorption.   
73-DOC was also shown to inhibit the formation of mineralised bone nodules by 
osteoblasts with osteoblast precursors being more sensitive than fully mature 
osteoblasts. However, when added after nodules started forming, 73-DOC appeared to 
have a greater inhibitory effect on mineralisation (~70 % decrease) than it did on 
differentiation (~30 % decrease). This was also evident by the persistence of 
unmineralised bone nodules at high concentrations of 73-DOC. This would suggest that 
73-DOC regulates the processes of differentiation/matrix deposition and mineralisation 
via different mechanisms. Inhibition of mineralised nodule formation was also seen with 
bafilomycin but, as with osteoclasts, 73-DOC was found to be more potent. The role of 
V-ATPases in osteoblasts are scarcely studied and poorly understood. However, the 
effect of bafilomycin is consistent with that shown by Sorensen et al. (2007), where a 
60 % decrease in bone nodule formation was seen at 10 nM bafilomycin. Interestingly, 
another V-ATPase inhibitor utilised in that study, diphyllin, was shown not to impair 
nodule formation despite inhibiting osteoclast resorption at comparable concentrations. 
Ostrov et al. (2009) also reported normal bone mineralisation despite impaired osteoclast 
function with enoxacin, suggesting that the V-ATPase-actin interaction or the B2 subunit 
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is not critical in osteoblasts. In d2 knockout mice, bone formation was actually found to 
be stimulated rather than inhibited but as d2 is not expressed in osteoblasts, the effect 
was indirect (Lee et al., 2006). These results suggest that some V-ATPase subunit 
isoforms are not critical in osteoblasts but that some inhibitors, such as bafilomycin and 
73-DOC, do have targets expressed in this cell type.  
It is currently unknown what role the V-ATPase has in the bone mineralisation 
process of osteoblasts, however, it is possible that V-ATPase inhibition is modulating 
the secretory pathway of osteoblasts due to the effects on endosomal/vesicular 
trafficking. V-ATPases have indeed been shown to have a role in the 
mineralisation/demineralisation of epithelial cuticles in terrestrial isopods (woodlouse) 
during moulting, showing a contribution to the process of CaCO3 deposition (Ziegler et 
al., 2004). The secretory processes of other cell types have been shown to be inhibited 
by V-ATPase targeting (Sun-Wada et al., 2006), so it is possible that the processes of 
matrix deposition and matrix vesicle exocytosis for bone formation may be similarly 
affected. Interestingly, autophagy appears to be an important process for other secretory 
cell-types including osteoblasts, where knockdown of autophagy genes has been shown 
to inhibit osteoblast mineralisation capacity in vitro and in vivo, and furthermore, 
autophagosomes have been implicated as vehicles for the secretion of apatite crystals 
(Nollet et al., 2014). Autophagy thus provides a mechanism that could explain the 
functional effects in both osteoclasts and osteoblasts following treatment with 73-DOC, 
suggesting an examination of autophagy proteins in both cell-types would be an 
important direction for future experiments. Characterisation of the subunit composition 
of osteoblast V-ATPases, with comparison to the osteoclast V-ATPase, would also be 
worthwhile to explain the mechanisms of 73-DOC inhibition.  
In conclusion, the work presented clearly indicated that 73-DOC has potent 
inhibitory effects on osteoclast activity, whilst also exhibiting some inhibitory activity 
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on osteoblast function. Further characterisation of the mechanisms underlying these 
responses are necessary, with potential candidates including specific V-ATPase subunit 
expression, endosomal/vesicular trafficking and autophagy. Ultimately, characterisation 
of in vivo effects will also be crucial in clarifying any remaining questions regarding the 
efficacy of 73-DOC as a potential therapeutic (see Chapter 7). However, considering the 
supply problems of other commercially viable natural products, prior to investigating 
long-term mechanistic and in vivo studies, as critical way forward is to establish 
methodology that would allow for a sustainable and renewable supply of 73-DOC that 
would eliminate the need to harvest sponge stocks from the natural environment. Work 















Chapter 6: Partial Cloning and Sequencing of 





The final aim of this thesis was to isolate the gene products responsible for 73-
DOC biosynthesis. Previous chapters have shown that 73-DOC has biological activity 
that requires future investigation, but many natural products are prevented from 
advancing as therapeutics due to issues of providing sufficient material to sustain a 
global market. This prompted an investigation into a potential solution for the 
sustainable supply of 73-DOC through cloning of the biosynthetic genes.  
The chemical structures of 73-DOC and the other chondropsin metabolites 
indicate they are from polyketide family (Cantrell et al., 2000, Rashid et al., 2001a, 
Rashid et al., 2001b). As many marine sponges including I. ramosa are host to large 
communities of symbiotic microorganisms and given that the PKS enzymes responsible 
for polyketide biosynthesis are mainly produced by bacteria, fungi and plants, it is highly 
likely that 73-DOC is produced by a member of the I. ramosa microbial consortia 
(Taylor et al., 2007a, Webster et al., 2010). A compound with a microbial, polyketide 
origin has distinct benefits for overcoming the supply problem as the biosynthetic genes 
typically exist as gene clusters that facilitate the isolation of complete biosynthetic 
pathways using large-insert clone libraries, which might then also be directly shuttled 
into heterologous hosts. The first step in this ultimate goal was to clone and sequence 
the genes likely involved in the biosynthesis of 73-DOC.  
Following the co-linearity principles of non-iterative type I PKS biosynthesis, 
where the number of modules dictate the chain length of the final product and the 
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structures of intermediates directly correspond to the PKS module domain architecture, 
such polyketide structures can be predicted from PKS domain architecture and vice versa 
(Staunton and Weissman, 2001, Weissman and Leadlay, 2005, Fischbach and Walsh, 
2006). As the chemical structure for 73-DOC is already known (Rashid et al., 2001b), a 
putative model for the domain order of the PKS biosynthetic enzymes was predicted 
(Figure 6.1 A). A complete predictive model of 73-DOC biosynthesis was provided by 
Dr Paul Long (KCL) and Professor Barry Wilkinson (Department of Molecular 
Microbiology, John Innes Centre), showing a modular type I hybrid PKS/NRPS system 
consisting of a loading module and 26 extension modules, 3 of which were predicted as 
NRPS modules (modules 4, 10 and 26) that implied the incorporation of leucine, 
threonine and 3-hydroxyaspartic acid amino acids (Figure 6.1 B).  
The likely domain architecture of each module, including enzymatic domains 
involved in acyl chain reduction and the type of extension units incorporated by each 
module, have also been predicted. Based on the presence of α-methyl branches in parts 
of the structure, the incorporation of methylmalonyl-CoA units (modules 1, 2, 6, 7, 9, 
11, 13-16) was predicted, whilst malonyl-CoA extension units were putatively 
incorporated by modules corresponding to non-methyl branched parts of the structure 
(modules 3, 5, 8, 12 and 17-25). Chain release and the formation of the macrocycle is 
predicted to occur via a dedicated TE domain, similar to deoxerythronolide B synthase 
(DEBS), the PKS responsible for the biosynthesis of 6-deoxyerythronolide B (Staunton 
and Weissman, 2001). The starter unit used to initiate polyketide chain assembly by the 
putative loading module is unusual due to the presence of a geminal-dimethyl group, 
where two methyl groups are attached to one carbon atom (yellow moiety in Figure 6.1 
A). One explanation for this is that the starter acid is methylmalonyl-CoA, or its ester, 
with a subsequent α-methylation step suggesting the presence of a methyltransferase 
domain in the loading module. A similar mechanism was also predicted in module 2. 
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Figure 6.1 A putative model for 73-DOC biosynthesis. PKS and NRPS domain 
organisation of the first 5 modules from the predicted 73-DOC pathway is shown 
(A). The products produced by each module are colour-coded to their location in the 
73-DOC structure shown below. The colour-coded structures for the three amino 
acids putatively incorporated into 73-DOC are also shown. The complete predicted 
model of 73-DOC biosynthesis for all 26 modules is also shown (B). The predicted 
extension unit selected by the acyl transferase (AT) domains of PKS modules are 
shown below each module, where mal is malonyl-CoA and methyl-mal is 
methylmalonyl-CoA. The substrate specificity of the adenylation (A) domains for 





Another possibility is that the unusual starter unit is a result of post-assembly 
carboxylation, as chondropsin C, which likely has similar biosynthesis, lacks the same 
starter group (Rashid et al., 2001b). Further post-assembly modifications could also be 
required for the biological activity of 73-DOC, performed by dedicated enzymes 
encoded in the gene cluster that may result in oxygenative tailoring, or group transfer 
reactions such as glycosylation and acylation (Fischbach and Walsh, 2006).  
In order to isolate the genes involved in 73-DOC biosynthesis, suitable screening 
targets were required. Previous successful metagenomic strategies for cloning PKS 
genes from sponge holobiomes have typically relied upon targeting the KS domain from 
metagenomic DNA libraries (Piel et al., 2004, Schirmer et al., 2005, Fieseler et al., 2007, 
Fisch et al., 2009). These domains contain highly conserved structural motifs across 
multiple microbial phyla, which allows the use of degenerate primers, designed from 
consensus sequences, to amplify KS domains without prior knowledge of the producing 
organism (Piel, 2002, Moffitt and Neilan, 2003). Once sequenced, the degree of 
conservation amongst KS domains also allows for the phylogenetic classification of 
novel KS sequences into PKS groups by aligning and clustering the sequences with 
reference KS domains (Moffitt and Neilan, 2003). Target KS sequences can then be 
selected and used as screening targets.  
The predicted involvement of NRPS-like domains in the biosynthesis of 73-DOC 
provides additional screening targets for 73-DOC biosynthetic components. Any clone 
from an I. ramosa metagenomic DNA library that was found to contain coding 
sequences for both PKS and NRPS domains would likely be a highly attractive candidate 
for containing part of the 73-DOC biosynthetic gene cluster. As with KS domain, the 
adenylation domain of NRPSs is known to be highly conserved at the amino acid level, 
enabling amplification using degenerate primers (Marahiel et al., 1997). The function of 
the adenylation domain in NRPS modules is to select and transfer the relevant amino 
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acid due to be incorporated into the molecule structure. Following the 3D structural 
resolution of the phenylalanine-activating adenylation domain of gramicidin synthetase, 
the amino acid residues responsible for substrate coordination in adenylation domains 
were identified  and found to be highly conserved, forming 10 core binding pocket 
motifs based on alignments with other adenylation domains (Conti et al., 1997, 
Stachelhaus et al., 1999, Schwarzer et al., 2003). Software, such as that of Baranasic et 
al. (2014), was subsequently developed that can detect adenylation domain binding 
pockets from amino acid sequences and provide in silico prediction of substrate 
specificity. Such a tool could therefore be applied to facilitate the screening of 
adenylation domains by examining and comparing the substrate specificity with the 
predicted activities of the 73-DOC gene cluster.  
The aim of this chapter was therefore to clone and sequence PKS genes from the 
metagenome of I. ramosa that encode proteins with domain architecture analogous to 
the predicted model of 73-DOC biosynthesis. To this end, the objectives were: Isolation 
of metagenomic DNA from I. ramosa; construction of a large-insert fosmid library; 
screening clones for nucleotide sequences indicative of type I hybrid PKS/NRPS 
biosynthesis using colony blot hybridisation; sequencing and annotating PKS/NRPS 
genes from candidate clones and metagenomic sponge DNA; and comparing PKS/NRPS 
translated peptides for homology to the predicted architectural domain model of 73-








6.2 Materials and methods 
 
For specific details and parameters not mentioned below, see Section 2.3. 
 
6.2.1 Fosmid library construction and screening 
 
Metagenomic I. ramosa DNA was extracted and used to construct a fosmid clone 
library. Degenerate KS primers were used to amplify type I KS domains from 
metagenomic sponge DNA and a nucleotide sequence showing homology to a type I 
PKS/NRPS was used as template in generating a DIG-labelled probe. Transformed E. 
coli DNA was then screened using colony blot hybridisation and the DIG-labelled probe. 
A total of 1200 colonies were screened in this way, a number calculated to ensure 99 % 
probability of capturing a DNA sequence from a 10 Mb genome in a fosmid library 
containing 40 kbp inserts (Sambrook, 2001). Positive clones were then additionally 
screened for adenylation domains using degenerate primers. This work was assisted by 
Miss Urvi Shah, Miss Jaya Sanger and Miss Ptidya Boonvasit (all KCL undergraduate 
project students) 
 
6.2.2 DNA sequencing 
 
A chain termination method of sequencing was used for PCR products and 
primer-walking of fosmids. Next generation sequencing of fosmid DNA and microbial-
enriched metagenomic DNA was performed using Illumina technologies. Metagenomic 
sequencing reads were assembled by Mr Ranko Garcesa (KCL) using the Velvet 
software (Zerbino and Birney, 2008).  
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6.2.3 Sequence annotation 
 
Nucleotide and translated amino acid sequences were annotated using BLAST or 
Pfam searches using default parameters (Camacho et al., 2009, Finn et al., 2014). 
Multiple KS amino acid sequences were aligned using the MEGA software (Tamura et 
al., 2013). Alignments were used to construct phylogenetic trees using the Neighbour-
Joining method (Saitou and Nei, 1987). Reference KS sequences from characterised 
PKS/FAS systems were also used in alignments, downloaded from the NCBI GenBank 
database (Benson et al., 2013). A web-based program designed by Baranasic et al. 
(2014) was used for in silico prediction of adenylation domain substrate specificity from 
the amino acid sequences. Contigs assembled from either fosmid or metagenomic 
sequence reads were automatically annotated for secondary metabolite biosynthetic 
genes using antiSMASH (Blin et al., 2013), with PKS domain organisation manually 




6.3.1 Fosmid library construction 
 
Metagenomic DNA was obtained from I. ramosa tissue using chemical lysis and 
ethanol precipitation. Gel electrophoresis was used to confirm the DNA was of high 
molecular weight and not excessively degraded, as evidenced by a lack of smearing in 
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the gel lane (Figure 6.2).  A metagenomic fosmid library was generated from blunt-
ended DNA fragments that were purified following gel electrophoresis, corresponding 
to a size of 30-40 kbp (Figure 6.2). The titer of the phage-packaged fosmids was 
determined, showing the library consisted of 2x106 colony forming units, equal to 60-
80 Gb of metagenomic DNA sequence.  
 






 1       2       3         
Figure 6.2 Agarose gel electrophoresis of metagenomic 
DNA used in fosmid library construction. A 0.8 % (w/v) 
agarose gel image. Lane 1: Total metagenomic DNA 
extracted from I. ramosa. Lane 2: Size-selected I. ramosa 
metagenomic DNA used in construction of the fosmid 




To screen the fosmid library using colony blot hybridisation, a suitable 
oligonucleotide probe for the KS domains of type I PKSs was first required. A PCR 
using metagenomic I. ramosa DNA as a template and the degenerate KS primer set 
KSDPQQF/KSHGTGR (Piel, 2002) was performed, producing a band of the expected 
size (700 bp) (Figure 6.3). The 700 bp KS PCR products were purified following gel 
electrophoresis and cloned into E. coli. Correctly sized inserts were then sequenced from 
clones using the M13 forward sequencing primer. A total of 14 sequences were 
annotated as partial KS domains through comparison with the NCBI non-redundant 
nucleotide database using default parameters (BLASTn). The sequences showed high 
levels of identity (75-92 % across a coverage of 93-98 %) with partial KS sequences 
found from bacterial sponge symbionts (see Appendix, Table 1). Nucleotide KS 
sequences that shared less than 97 % similarity to each other were regarded as unique, 
resulting in 9 sequences which were each translated into the correct amino acid 
sequence.  
To determine the phylogenetic classification of the uncharacterised KS domains 
from the current study, the amino acid sequences representing partial KS domains were 
aligned with truncated KS domains from modular type I PKS/FAS systems typically 
found from sponge metagenomes. The reference KS sequences were downloaded in 
FASTA format from the GenBank database. These included the cis-AT and trans-AT 
PKSs, as well as the hybrid PKS/NRPSs, which are all known to be involved in the 
biosynthesis of bioactive polyketides. Additionally, KS domains from the sponge-
specific group of PKSs called sup (sponge symbiont ubiquitous PKS) were also 





A multiple alignment of the sequences was then performed (shown in Appendix, 
Figure 1), before a Neighbour-Joining phylogenetic tree was constructed, which group 
Figure 6.3 PCR amplification of KS domains from metagenomic sponge DNA 
using degenerate primers. A schematic of conserved KS structural motifs is shown 
along with the binding sites of the KSDPQQF/KSHGTGR primer pair and the 
procedure followed for sequencing the PCR products (A). Agarose gel 
electrophoresis image of KS PCR products (B). PCR products were run on a 1.6 % 
(w/v) agarose gel. The positive control was genomic S. rimosus DNA. The negative 
control was genomic E. coli DNA, strain K12 JM109.       
 173 
 
sequences together by pairwise evolutionary distances, computed based on the number 
of amino acid changes at a particular site following alignment of the sequences (Saitou 
and Nei, 1987). This analysis showed that many (89 %) of the KS sequences amplified 
from I. ramosa clustered with the sup type of KS sequences, supported by high bootstrap 
values, which show the robustness of the inferred tree following iterative resampling or 
removal of alignment characters (Figure 6.4) (Felsenstein, 1985). However, a single 
sequence designated KS1 clustered with the hybrid PKS/NRPS reference sequences. As 
the 73-DOC gene cluster was predicted to encode a hybrid PKS/NRPS, the KS1 
nucleotide sequence was chosen as a template for the oligonucleotide probe used to 
screen the metagenomic fosmid library. 
 
6.3.3 Library screening 
 
Fosmid clones were induced to high copy number in E. coli cells grown on agar 
plates before the colonies were blotted onto nylon membranes and screened using 
hybridisation with the KS1 probe. A total of 1200 colonies were screened, with positive 
colonies sub-cultured overnight before fosmid DNA was extracted. This screening 
procedure identified 118 KS positive colonies. To further reduce the number of 
candidate clones, a secondary screening procedure was performed targeting the 
adenylation domain of NRPS enzymes, as the structure of 73-DOC was predicted to 





Figure 6.4 Phylogenetic analysis of KS amino acid sequences from I. ramosa 
shows KS1 to be a suitable fosmid library probe. Partial KS amino acid sequences 
amplified from I. ramosa were aligned with reference KS sequences before the 
Neighbour-Joining method was used to construct the tree shown (Saitou and Nei, 
1987). The labels of reference KS sequences are shown with the GenBank accession 
numbers and the source organism. The PKS/FAS type enzymes from which they 
originated are labelled as groups on the far right. KS sequences amplified from I. 
ramosa are given the prefix KS- and the sequence chosen as a library screening probe 
is highlighted with a red circle. The percentage of replicate trees in which the 
associated sequences clustered together in the bootstrap test (1000 replicates) are 
shown next to the branches (Felsenstein, 1985). Only values over 50 % are shown. 
The evolutionary distances were computed using the Poisson correction method 
(Zuckerkandl and Pauling, 1965) and are in the units of the number of amino acid 
substitutions per site, also shown by the scale bar.  
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            Fosmid DNA from the 118 KS-positive fosmids was then used as a template in 
a PCR using degenerate adenylation domains primers. A total of 6 fosmids (Fos114, 
Fos353, Fos441, Fos970 and Fos1118, Fos1207) were found to consistently produce a 
band of the expected size (~850 bp) (Figure 6.5). The 850 bp-sized PCR products from 
these 6 fosmids were sub-cloned into E. coli and sequenced. The nucleotide sequences 
were then translated into all 6 reading frames and analysed using the LSI tool for in 
silico prediction of adenylation domain substrate specificity (Baranasic et al., 2014). The 
HMM alignments (shown in Appendix, Figure 2) confirmed the presence of adenylation 
domain binding pockets in the PCR products amplified from the 6 fosmid templates. 
One fosmid, Fos1118, encoded two adenylation domain sequences whilst single 
domains were encoded by the 5 remaining fosmids. The results from the LSI predictor 
indicated that none of the substrate specificity predictions for the fosmid PCR product 
sequences matched the amino acids predicted in the 73-DOC structure (Table 6.1). As 
two putative adenylation domains were encoded by PCR products from the Fos1118 
template, a decision was made to further investigate this fosmid further by partially 
sequencing the inserted sequence. 
 
6.3.4 Sequencing of fosmids 
 
Partial sequencing of the inserted sequence from Fos1118 was achieved using 
ten rounds of primer-walking, yielding approximately 9.5 kbp of fosmid insert DNA 
sequence. Annotation of this sequence was carried out using antiSMASH and revealed 






Figure 6.5 PCR amplification of adenylation domains from fosmid DNA 
using degenerate primers. A schematic of conserved adenylation domain 
structural motifs is shown along with the binding sites of the NP1/NP2 primer 
pair and the procedure followed for sequencing the PCR products (A). Agarose 
gel electrophoresis image of PCR products from the 6 fosmids identified 
following a PCR screen for adenylation domains (B). PCR products were run 
on a 1.6 % (w/v) agarose gel. The positive control was genomic Nostoc sp. 





In order to further annotate the proteins encoded by the Fos1118, the sequence 
was then searched against the Pfam database of protein families. The results confirmed 
that no PKS/NRPS domains could be detected from the Fos1118 insert sequence (Table 
6.2). 
Table 6.1 Output data from LSI tool shows adenylation 
domain substrate specificity. Adenylation domain amino acid 
sequences were analysed using the LSI tool (Baranasic et al., 
2014). Binding pockets were detected through comparison with an 
adenylation domain HMM profile (Appendix I, Figure 2), showing 
the alignment score and E value for each. The top 3 LSI-based 
amino acid substrate predictions for each binding pocket are also 




   
 Due to time constraints, a decision was made to fully sequence all of the 
remaining candidate fosmids at once using NGS, alongside a sample of metagenomic 
DNA from I. ramosa (see Section 6.3.5).  Sequencing libraries were made for each of 
the 6 candidate fosmids plus the metagenomic sponge DNA. However, due to technical 
limitations, only 6 samples in total could be sequenced simultaneously and so one fosmid 
(Fos1207) was dropped to be included on a future sequencing run. The sequencing run 
was performed, resulting in a total of 14.4 million, 300 bp-length reads. Following 
assembly of the sequencing reads, each of the fosmid samples were annotated using 
antiSMASH, which showed that none of the fosmid insert sequences were likely to have 
encoded homologs to PKS/NRPS domains. Further annotation using the Pfam database 
showed that various protein families were identified from the fosmid inserts. Whilst 
there were no predicted proteins common to all 5 of the fosmid sequences, 3 out of 5 
were found to contain aminotransferase domains (Table 6.3).   
In order to explain the results of the adenylation domain PCR screen, pairwise 
DNA alignments of the whole fosmid insert sequence and the PCR products amplified 
Table 6.2 Table of Pfam matches found from the Fos1118 sequence. The DNA 
sequence obtained from primer walking Fos1118 was searched against the Pfam database. 
All matches are shown with the associated E-value. Alignments of these matches are 
shown in Appendix, Figure 3. 
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from those fosmids were performed (see Appendix, Figure 5). These showed that none 
of the adenylation sequences aligned perfectly with their respective full sequence. 
Furthermore, the regions of the fosmid inserts that did align with the adenylation 
sequences, when searched against the Pfam database, showed no similarity in terms of 
the protein families found between each of the 5 fosmids. Similarly, pairwise alignments 
were constructed between the KS1 sequence that was used as a template for screening 
the fosmid library, and the sequenced fosmid inserts. The KS1 sequence was also found 
Table 6.3 Table of top matches found following searches of the fosmid insert 
sequences against the Pfam database. Fosmid insert DNA sequences were translated 
into all 6 reading frames and searched against the Pfam database. The top 3 matches 
from each fosmid sequence are shown with the associated E-value. Alignments of these 
matches are shown in Appendix I, Figure 4. 
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to imperfectly align with the fosmid insert sequences. The aligned region of the fosmid 
insert with the KS1 sequence, when searched against the Pfam database, also showed no 
similarity in terms of the protein families found between each of the 5 sequence fosmids. 
 
6.3.5 Metagenomic whole genome shotgun sequencing (mWGS) of 
Sponge DNA 
 
After quality filtering, the metagenomic sponge DNA sample was sequenced with 
~10 million, 300 bp-length reads, corresponding to 4.1 Gb of sequence. The optimum 
assembly resulted in 78 % of the sequencing reads assembling into contigs, which 
corresponded to a total of 152,650 sequences of varying size and a total of 174 Mb of 
assembled sequence. Following automatic annotation using antiSMASH, a total of 300 
biosynthetic genes were annotated, 18 of which were annotated as type I PKS. No 
contigs were found to contain NRPS domains. The annotation of PKS domains was 
manually confirmed using ClustScan (see Appendix, Figure 7), which showed that each 
of the 18 sequences encoded 1 out of 2 types of consistent domain order (Table 6.4). 
Additionally, ClustScan predicted that the only active reductive domains in 14 of these 
sequences was the DH, whilst the remaining 3 had active DH, ER and KR domains and 
1 partial sequence had no active reductive domains (Appendix, Figure 7). The AT 
substrate specificities were predicted as malonyl-CoA for 13 of the sequences, whilst 
the remaining sequences, and those with a second AT domain were non-predictable 
(Appendix, Figure 7).  
 An alignment of KS domains from each of the 18 sequences was constructed to 
include other reference KS domains (Appendix, Figure 8), in order to allow phylogenetic 
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classification of the mWGS PKS sequences. The reference KS sequences included were 
the same as those shown in Figure 6.4, with additional sequences representing another 
novel, sponge-specific type I PKS named swf (sponge symbiont widespread FAS), 
discovered from the sponge Planktoris simplex (Della Sala et al., 2013). The swf 
sequences were included as 5 of the mWGS PKS sequences (23, 840, 1020, 21467, 
Table 6.4 Summary of type I PKS domain annotation following screening of 
mWGS contigs with antiSMASH. Sequences detected as type I PKS were 
automatically annotated as shown. Annotation was manually confirmed using 
ClustScan (Appendix I, Figure 7). * indicates a partially recovered sequence. 
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26257) showed common annotation of PKS domain architecture. A Neighbour-Joining 
phylogenetic tree constructed from the KS alignment showed that 13 (72 %) of the KS 
sequences clustered with sup sequences, whilst the remaining 5 sequences clustered with 
swf sequences (Figure 6.6).  
To confirm the phylogenetic analysis, BLASTp searches of entire mWGS PKS 
sequences detected by antiSMASH were conducted. This showed that 13 of the mWGS 
PKS sequences had homology (55-80 % identity over at least 97 % sequence coverage) 
of SupA from either T. swinhoei or A. aerophoba (see Appendix, Figure 9). The 
remaining 5 PKS sequences showed homology (66-80 % identity over at least 96 % 
coverage) with SwfA from P. simplex (see Appendix, Figure 9). Additionally, 9 of the 
13 sup sequences, and 3 of the 5 swf sequences, had regions flanking the PKS which 
showed homology with components in either the sup (Fieseler et al., 2007) or swf (Della 
Sala et al., 2013) operons, including SupB-E and SwfB-C (see Appendix, Figure 9). 
Furthermore, the C-terminal AT domains of PKS genes showing homology to SupA 
were found to include a characteristic serine to glycine substitution at a residue 
considered crucial for activity (Fieseler et al., 2007) (see Appendix, Figure 10), and the 
KS domains of PKS genes which showed homology to SwfA were found to include the 
characteristic QCALVEL motif (see Appendix , Figure 11), which is unique to SwfA-
AT domains (Della Sala et al., 2013). Taken together, these findings support and confirm 
the phylogenetic KS-classification of the mWGS PKS genes as members of either the 
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Figure 6.6 Phylogenetic analysis of KS amino acid sequences from type I PKS 
clusters encoded by mWGS contigs. Whole KS amino acid sequences from 
mWGS contigs were aligned with characterised KS sequences from various PKS 
and FAS enzymes. The Neighbour-Joining method (Saitou and Nei, 1987) was used 
to construct the tree shown. The labels of known KS sequences retrieved from the 
GenBank database are shown with accession numbers, and the PKS types from 
which they originated are labelled as groups on the far right. KS sequences 
discovered from I. ramosa are highlighted with a red circle. The percentage of 
replicate trees in which the associated sequences clustered together in the bootstrap 
test (1000 replicates) are shown next to the branches (Felsenstein 1985). The 
evolutionary distances were computed using the Poisson correction method 
(Zuckerlandl and Pauling, 1965) and are in the units of the number of amino acid 





The aim of this chapter was clone and sequence PKS/NRPS genes from the 
metagenome of I. ramosa that could be compared with the predicted model of 73-DOC 
biosynthesis (Figure 6.1 B). To this end, two different strategies were employed in order 
to clone PKS/NRPS sequences. The first involved a KS-guided, hybridisation-based 
screen of a metagenomic fosmid library constructed from I. ramosa DNA, followed by 
screening for adenylation domains. The second strategy involved using bioinformatic 
tools to annotate genomic sequences for PKS/NRPS genes, obtained from mWGS of 
metagenomic I. ramosa DNA.  
The first strategy employed was unsuccessful in isolating PKS/NRPS genes as 
none of the fully sequenced fosmids were found to contain a KS domain, nor any other 
common protein showing homology to KS domains. This result implied that the 
hybridisation screening conditions may not have been fully effective and resulted in the 
detection of sequences unrelated to KS domains and the identification of false-positive 
fosmids. The KS1 sequence used as a probe in hybridisation screening was certainly a 
suitable choice as, out of all the KS sequences obtained from I. ramosa, this particular 
sequence was the only one found to show phylogenetic similarities with KS domains 
typical of hybrid PKS/NRPS systems (Figure 6.4). Positive and negative controls were 
also used during the colony screening, the positive represented by E. coli DNA 
containing the KS1 plasmid, the negative by host E. coli DNA, and each membrane 
screened with the KS1 probe showed positive detection of positive control cell DNA. 
However, this experiment could perhaps have included additional controls, such as 
clones containing entire, characterised PKS clusters, which would have confirmed the 
conditions were suitable for the detection of KS-containing PKS clusters.  
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The method used to screen the fosmid library could, perhaps, also be improved. 
With metagenomic studies, due to the uncertainty in total genome size, the decision of 
how many clones to screen is difficult to predict. During the current work, a total of 
1200 colonies were screened, a number calculated based on achieving suitable coverage 
of a typical cyanobacterial genome size of 10 Mb, as cyanobacteria were previously 
shown to be abundant in I. ramosa (Dunlap et al., 2007). However, since NGS 
technologies have been utilised for sponge microbial diversity studies, estimates for 
symbiont diversity have been extended into the hundreds (Schmitt et al., 2012) and even 
thousands (Lee et al., 2011). One study involving deep pyrosequencing of 16S rRNA 
sequences amongst 3 Australian sponge species found a total of over 5,000 OTUs 
(operational taxonomic units) (Webster et al., 2010). I. ramosa was included in this study 
and was reported to be host to 1199 OTUs.  
Whilst it is possible that these numbers are inflated due to the low similarity 
threshold (97 % or 99 % usually used instead of 95 %) or from potential sequencing and 
PCR artefacts (Quince et al., 2009, Kunin et al., 2010), these findings fit with the 
generally accepted underestimation of microbial diversity in marine environments and 
invertebrate hosts (Sogin et al., 2006, Sunagawa et al., 2010, Behrendt et al., 2012, White 
et al., 2012). Considering the seemingly high level of bacterial diversity in I. ramosa, 
the number of clones screened in the current work was likely an underestimate of the 
total number that required screening. The combined genomes associated with I. ramosa 
would likely require screening many thousands of clones. Such a task would benefit 
from either using a robotic system with colonies in microplates, as used by Schirmer et 
al. (2005) for the sponge Discodermia dissoluta and by Parsley et al. (2011) for a soil 
metagenome, or by using a PCR based approach with pools of clone DNA such as that 
advocated by Gurgui and Piel (2010).  
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During the second round of screening, adenylation domains were amplified and 
sequenced from fosmids using degenerate PCR primers. Once sequenced however, 
neither adenylation domain genes, nor the complete sub-cloned PCR sequence were 
found from the fosmid insert sequence. The amplified sequences from fosmid templates 
were found to encode conserved motifs and residues consistent with adenylation 
domains, as shown by significant HMM alignments using the LSI software developed 
by Baranasic et al. (2014). However, the absence of the complete PCR sequences from 
the fosmid template DNA implies PCR errors occurred, such as primer-template 
mismatching or low fidelity extension. Such errors could be occurring due to the use of 
highly degenerate primers (total degeneracy of 224). The primer pair used for PCR 
screening of the KS-positive fosmids was chosen based on the previous success by 
Zhang et al. (2009) with sponge metagenomic DNA templates. Furthermore, the primers 
were initially tested by sequencing PCR products from I. ramosa metagenomic DNA 
which, when analysed using HMM alignments, showed homology to adenylation 
domains, indicating that the primers were suitable for screening purposes. An alternative 
approach to the adenylation domain screen could have involved designing novel PCR 
primers based on consensus sequences from characterised adenylation domains with 
substrate specificities for either leucine, threonine or 3-hydroxyaspartic acid. If 
successful, this would have enabled specific detection of adenylation domains that have 
activity consistent with the predictions of 73-DOC biosynthesis.    
The second strategy used to capture PKS/NRPS sequences was successful, and 
resulted in the isolation of 18 PKS genes from the metagenome of I. ramosa, which were 
all characterised as belonging to the sup or swf groups. Only one other similar study has 
attempted to capture PKS/NRPS domains from sponges using mWGS, where deep 
sequencing was used to characterise the diversity of PKSs and NRPSs from 5 different 
sponge metagenomes (Woodhouse et al., 2013). For 4 out of the 5 sponges sampled 
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during this study, only 5 or less PKS sequences were found, which is over three-fold 
less than the number recovered during the current work. Of the 18 type I PKS genes 
sequenced from I. ramosa, 5 were annotated as showing homology to swf gene clusters. 
Swf gene clusters are the second example (after sup) of PKS/FAS genes found only from 
sponge symbionts and were first described by Della Sala et al. (2013) following a 
metagenomic investigation into the PKS genes of the sponge P. simplex. The results 
presented here therefore extend the occurrence of the swf genes to the sponge I. ramosa. 
The authors characterised the swf operon as composed of swfA, a gene encoding for a 
single PKS module with unique features such as a characteristic QCALVEL motif only 
found in AT domains from SwfA, also found in all 5 swf homologues from I. ramosa. 
Downstream of swfA is swfB, which encodes a predicted fusion of a thioester reductase 
domain with a sulfotransferase domain, and swfC, which may or may not be present, but 
shows homology to enzymes that act as methyltransferases. The association of swfB and 
swfC with swfA suggests a product that could be expected to be a methylated alkyl 
sulphate, but no such metabolites are found in sponges and so the actual biosynthetic 
function of the swf cluster remains to be established (Della Sala et al., 2013).  
The KS sequences cloned from I. ramosa during the current study using either 
PCR or mWGS were found to be dominated (72-89 %) by sup sequences, which is 
consistent with the original discovery of sup genes by Fieseler et al. (2007), as well as 
other studies that have also reported the widespread occurrence and dominance of this 
group amongst sponge KS sequences (Piel et al., 2004, Schirmer et al., 2005, Kim and 
Fuerst, 2006, Fieseler et al., 2007, Hochmuth and Piel, 2009b, Hochmuth et al., 2010, 
Woodhouse et al., 2013, Della Sala et al., 2014, Wilson et al., 2014). The sup operon 
contains the supA gene, which encodes a single PKS module composed of an unusual 
domain architecture that terminates with KS and AT domains. The C-terminal AT 
domain of SupA was also reported to lack a conserved serine residue considered crucial 
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for activity, having a glycine instead (Fieseler et al., 2007). All 13 of the mWGS PKS 
sequences that were annotated as sup systems were shown to have PKS genes 
homologous to supA and most had the C-terminal AT domains bearing the reported 
amino acid substitution, indicating this domain may be non-functional. Additional non-
functional ER and KR domains in the supA homologues were also predicted by 
ClustScan.  
The predicted domain architecture of SupA is almost identical to type I 
mammalian FAS systems, but includes an active methyltransferase domain which is 
non-functional in the mammalian FAS (Fieseler et al., 2007, Maier et al., 2008), and C-
terminal KS/AT domains instead of a TE domain (Figure 6.7). Amongst the few cases 
of type I FAS in bacteria are the enzymes from pathogenic mycobacteria, which are 
involved in the biosynthesis of methyl-branched fatty acids for cell walls (Minnikin et 
al., 2002). The architectural similarities of SupA to the mammalian FAS and the 
presence of an active methyltransferase domain implied that the products of this protein 
are also methyl-branched fatty acids, which are present in numerous sponges containing 
Figure 6.7 Schematic of the sup operon. The 5 genes (SupA-E) constituting the sup 
operon are shown (Fieseler et al., 2007). The domain organisation of the SupA PKS is 
also shown for comparison with the mammalian FAS and a hypothetical multimodular 
PKS. Adapted from Hochmuth et al. (2010) 
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symbiotic microorganisms (Gillan et al., 1988, Thiel et al., 1999, Robainac et al., 2002, 
Thiel et al., 2002, Hochmuth et al., 2010). As methylated fatty acids are common in 
fossil sediments and fuels, an interesting hypothesis has suggested that microbial 
producers of methyl-branched fatty acids were once widespread but are now rare, with 
sponges representing one of the last extant habitats for such microorganisms (Thiel et 
al., 1999, Fieseler et al., 2007).  
Clearly the majority of PKS sequences found from I. ramosa share high levels of 
similarity with the sup systems but it is also possible that these genes may be involved 
in the biosynthesis of 73-DOC. Considering the role of sup in the biosynthesis of 
methylated fatty acids, it is interesting to note that the chemical structure of 73-DOC 
was reported as containing numerous methyl branches, particularly on the polyketide 
backbone at locations corresponding to the predicted starter and first 2 extender units 
(Figure 6.1 A) (Rashid et al., 2001b). Whilst the model for 73-DOC biosynthesis shown 
in Figure 6.1 does not have domain architecture consistent with SupA, this was a purely 
hypothetical model based on the paradigm of type I PKS structure and organisation that 
emerged following intense investigation of DEBS and many other cis-AT PKSs (Katz, 
2009). However, when non-canonical PKS organisation is taken into account, along with 
the predicted inactivity of the ER, KR and C-terminal AT domains of SupA, a potential 
role of a SupA homologue in 73-DOC biosynthesis can be considered.  
Type I PKS modules are a convenient way to organise enzymatic domains but 
have no reality in terms of protein structure and ultimately the executed biochemical 
sequence of a PKS determines the product structure. Accordingly, there are instances of 
split modules where module domains are found on different polypetides. For example, 
in the disorazole PKS system, the 4th module is split between the DH domain of DsxA 
and the KR domain of DsxB (Carvalho et al., 2005), and there are other similar examples 
in the PKS systems for myxalamid (Silakowski et al., 2001), bacillaene (Butcher et al., 
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2007) and etnangien (Menche et al., 2008). If a similar situation is applied with modules 
2 and 3 from the putative 73-DOC model, the resulting active domain architecture is 
similar to that of SupA (Figure 6.8). The remaining differences are biosynthetic order, 
the lack of a second active AT domain and contrasting AT specificities, all of which can 
be accounted for (see below).  
In regards to AT domain specificity, the first AT region in SupA was shown to 
catalyse malonyl-CoA extender units (Hochmuth et al., 2010), which was consistently 
predicted for all SupA homologues from I. ramosa (Appendix I, Figure 7). In the original 
architectural domain model of 73-DOC, module 2 was predicted to incorporate 
methylmalonyl-CoA due to the presence of a geminal dimethyl group in the 73-DOC 
structure. However, characterised PKS gene clusters for bryostatin (Sudek et al., 2007) 
and onnamide (Piel et al., 2004), which produce similar dimethyl groups, imply 
methyltransferase enzymes catalysing malonyl-CoA substrates. This has also been 
empirically demonstrated by Miller et al. (2002) using radiolabelled isotope feeding 
studies and the yersinabactin synthase, where the AT domain involved in the 
biosynthesis of a gem dimethyl group exhibited a 500-fold preference for malonyl-CoA 
Figure 6.8 Comparison of SupA active domain architecture with a hypothetical 
rearrangement of the 73-DOC domain model of biosynthesis 
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over methylmalonyl-CoA. A similar mechanism could also occur with 73-DOC 
biosynthesis, allowing the predicted AT specificity of modules 2/3 to be consistent with 
SupA. 
In regards to the contrasting biosynthetic order of the rearranged module 2/3 and 
that of SupA, recent crystal structures for both the PikAIII type I PKS (Dutta et al., 2014) 
and mammalian type I FAS (Maier et al., 2008) systems show a homodimeric quaternary 
structure, where monomers are arranged head-to-head (Figure 6.9 A). Whilst 
furthermore, during fatty acid synthesis (Joshi et al., 1997, Witkowski et al., 2004) and 
polyketide synthesis (Kao et al., 1996, Staunton et al., 1996, Gokhale et al., 1998), the 
domains of either monomer have been demonstrated as functional. Currently, it is 
unknown whether SupA has structure similar to the type I FAS or PKS but with either 
situation, the likely homodimeric, head-to head arrangement of the enzyme subunits 
would allow the domain organisation of SupA to be reconciled with the biosynthetic 
order of the rearranged module 2/3, as both AT monomers could be used during chain 
extension. If SupA has mammalian FAS structure, this situation could involve the 
iterative use of the same ACP domain, via a process that has been shown to include 
rotation of the lower portion of the FAS structure relative to the upper portion, providing 
access for a flexible, mobile ACP to all domains (Figure 6.9 B) (Maier et al., 2008). If 
SupA has PKS structural similarities, the arrangement of the domain active sites around  
a single, arch-shaped reaction chamber would also permit the biosynthetic order of the 
rearranged module 2/3 due to the use of either monomer, the close proximity of the 
opposing subunits around a single reaction chamber and a highly mobile ACP domain 
(Figure 6.9 A) (Dutta et al., 2014).  
Non-canonical iterative polyketide biosynthesis may also help resolve SupA 





Figure 6.9 Schematics of proposed SupA structure and mechanism. The potential 
3D structures of SupA are shown, following structural models of the mammalian FAS 
and the PikAIII PKS module from Maier et al. (2008) and Dutta et al. (2014) 
respectively (A). Red stars indicate reaction chambers. Positions of domains with a 
black border are purely hypothetical and not based on crystal structure knowledge. 
Assuming a mammalian FAS structure, a proposed biosynthetic route for the 
rearranged module 2/3 from the 73-DOC gene cluster is shown (B). This route shows 
the iterative use of the ACP domain, which is provided access to both AT monomers 
following rotation of the upper portion of the FAS (above black dotted line) relative 





well known from fungal systems but has also been reported in bacteria (Moss et al., 
2004, Cox and Simpson, 2009). Described as stuttering and involving the repeated use 
of a single module or domain, this phenomenon is usually implicated when the number 
of modules present in a PKS is fewer than the number of condensation cycles needed 
for the corresponding polyketide. For example, stigmatellin is assembled from 10 
condensations by a PKS with 9 modules, leading to the prediction that either one of two 
identical modules in the stigmatellin PKS are used twice (Gaitatzis et al., 2002). The 
most unusual example of stuttering is found from the biosynthesis of lankacidin, where 
5 out of 8 rounds of condensation are carried out iteratively by a single module, but 
involving a different set of reductive domains in each cycle (Tatsuno et al., 2007). This 
implied that, for this PKS, the reductive domain use by a particular module can be 
optional during repeated cycles (Hertweck, 2009). The biochemical basis of stuttering 
is not completely understood but considering the similarity of SupA to the iteratively 
acting type I FAS, and the lack of a terminal TE domain, it is tempting to speculate that 
SupA may also function iteratively. If, like the lankacidin PKS, the reductive domains 
are optionally used during each extension, this would also support a role of SupA domain 
architecture in the predicted 73-DOC biosynthetic sequence of the loading module up to 
module 3, where additional KR activities were predicted. However, a more rigorous 
examination of reductive domain functionality in SupA would be required to establish 
whether this is possible.  
In summary, whilst the exact function of the sup or swf operon has yet to be 
demonstrated, it is possible that the potential chemistry produced by SupA could be 
reconciled with the activities of modules 2 and 3 from the hypothetical 73-DOC 
biosynthetic model. Methyltransferase activity from SupA could presumably also be 
responsible for additional branching patterns seen in the unusual loading unit and the 
extension unit attributed to module 1. This suggests a possible role of SupA in supplying 
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methylated fatty acid extension units or perhaps a precursor for 73-DOC biosynthesis. 
Hybrid FAS-PKS systems have previously been described, such as in aflatoxin 
biosynthesis in Aspergillus spp., where an unusual hexanoyl starter unit is formed by a 
dedicated FAS and then extended by a PKS (Watanabe et al., 1996, Hitchman et al., 
2001). Here, the C6 fatty acid is selected and transferred to the PKS ACP via a specialised 
starter-unit AT domain (Crawford et al., 2006, Foulke-Abel and Townsend, 2012). 
Similarly in mycobacteria, several complex cell-wall lipids are produced by the 
combined actions of FASs and PKSs (Kolattukudy et al., 1997, Sirakova et al., 2001). 
Long-chain fatty acids in these systems are transferred to PKSs for further extension by 
fatty acyl-AMP ligases, which activate fatty acids as adenylates then transfer them to 
carrier proteins that show homology with the thiolation domain of NRPSs (Trivedi et 
al., 2004, Gokhale et al., 2007). These studies show a precedent for chain-transfer 
mechanisms between FAS and PKS biosynthetic systems which could also be occurring 
between SupA and the main 73-DOC-producing synthase. This would implicate an 
intriguing role of SupA in providing for primary and secondary metabolism, which could 
lead to future research directions exploring sponge holobiome physiology.  
To confirm the ideas presented above, future work could focus on the heterologous 
expression and protein purification of SupA which, in tandem with site-directed 
mutagenesis, could ultimately allow determination of products and functional reductive 
domain activities, as well as the opportunity to obtain a crystal structure which could 
lead to establishing SupA protein structure. Additionally, once expression and protein 
purification of SupA is achieved, intersubunit domain interactions could be examined to 
test the proposed biosynthetic mechanisms of SupA. These could mirror the cross-
linking and mutated subunit complementation experiments that were applied for the 
study of type I FAS/PKS subunit organisation (Kao et al., 1996, Joshi et al., 1997, 
Gokhale et al., 1998, Weissman and Müller, 2008). The origin of the sup genes has not 
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been conclusively demonstrated but the Poribacteria, a sponge-specific bacterial 
phylum, have been implicated (Fieseler et al., 2004, Siegl et al., 2011, Della Sala et al., 
2014). Taxonomic classification of the sup sequences was beyond the aims of this thesis, 
but future work involving further phylogenetic examination of these sequences and 
surrounding genes could be one additional direction for future work that may support or 
contradict the hypothetical involvement of the Poribacteria.  
Clearly there are parts of the 73-DOC gene cluster that were not isolated during 
the current work. This was especially noticeable as no NRPS genes were annotated 
following mWGS, despite the predicted role in 73-DOC biosynthesis and the frequent 
occurrence of these genes in other sponge holobiomes (Schirmer et al., 2005, Siegl and 
Hentschel, 2009, Zhang et al., 2009, Pimentel-Elardo et al., 2012). The PKS genes 
responsible for bioactive metabolites from sponge metagenomes are known to be rare 
(Fieseler et al., 2007, Hochmuth and Piel, 2009b). Between 2001 and 2010, 30 bioactive 
polyketides have been discovered from sponges (Mehbub et al., 2014) but during this 
time, only 3 sponge-derived PKSs responsible for bioactive polyketides (pysmmberin, 
onnamide and theopederin) have had their gene clusters successfully mapped (Piel et al., 
2004, Fisch et al., 2009),  and all from one research group working with compounds that 
share structural and biosynthetic similarities. Capturing the biosynthetic genes for 
compounds known to be present in sponges is thus not a straightforward task, even when 
that compound is known to be present in large amounts (Della Sala et al., 2014).  
In conclusion, this chapter detailed the first ever investigation of biosynthetic 
genes from I. ramosa. PKS genes were successfully cloned, sequenced and annotated 
using a metagenomic sequencing approach, with many showing homology to the sup 
group of single module PKSs. A potential role for SupA homologues in the biosynthesis 
of 73-DOC was proposed but cloning and sequencing additional 73-DOC biosynthetic 
genes remains a goal for future work. Intriguingly, all the PKS clusters mapped from 
 196 
 
sponges to date belong to the non-canonical trans-AT group and there are certain 
indicators that are highly suggestive of such a system being responsible for the 
biosynthesis of 73-DOC. First, all known enzymes generating complex polyketides from 
non-actinomycete symbionts belong to the trans-AT group (Hochmuth and Piel, 2009b, 
Piel, 2010), indicating the relevance of such systems in the secondary metabolism of 
sponge symbionts. Second, a β-branch was also predicted for the 73-DOC chemical 
structure (C-37) and most trans-AT PKSs contain unusual domains or external 
components, such as the β-branching cassette; a groups of genes encoding enzymes that 
convert β-keto groups to carbon branches (Piel, 2010). Finally, the I. ramosa-sourced 
compound irciniastain A (Pettit et al., 2004), was found to be identical to pysmberin 
(Jiang et al., 2005), the complete biosynthetic pathway of which utilises a trans-AT PKS 
(Fisch et al., 2009). This indicates that trans-AT PKS systems are present in I. ramosa 
and could also be involved in the biosynthesis of 73-DOC. Consideration of a trans-AT 
PKS is particularly interesting as it would enable the application of strategies that could 
greatly facilitate the future characterisation of 73-DOC biosynthesis. This and other 
strategies for proposed further research into 73-DOC biosynthesis are discussed in the 
following final chapter. 
 








Chapter 7: General Discussion                          
and Future Work 
 
The work presented in this thesis detailed studies conducted with 73-DOC, a 
sponge-derived marine natural product. Following demonstrated antiproliferative 
activity in cancer cells (Rashid et al., 2001b), as well as suggested V-ATPase inhibitory 
activity (Bowman et al., 2003), work with 73-DOC ceased due to an exhausted supply 
of the compound in collections (Bowman and Bowman, 2005). Since the V-ATPase is 
critical for bone resorption, this thesis sought to determine whether a putative V-ATPase 
inhibitor could inhibit the function of osteoclasts, ultimately leading to further research 
into developing this compound as a novel therapeutic to treat diseases characterised by 
excessive bone resorption. Considering the importance of natural product leads in 
developing valuable pharmaceuticals, and the supply problems that often impede such 
development, research into a method of supplying these novel compounds is certainly 
needed alongside investigating the biological activity of the compound itself. This led 
to the multidisciplinary work presented in this thesis: One aim dedicated to evaluating 
the in vitro activity of 73-DOC, the other aim directed at cloning the biosynthetic 
pathway to eventually provide a sustainable supply of the compound. 
 Prior to the commencement of in vitro testing, a stock of 73-DOC was first 
extracted from sponge tissues, achieved using procedures detailed in Chapter 3. A yield 
of 73-DOC (19.5 mg) equating to 0.013 % g dry wt-1 and with an estimated 91 % purity 
was successfully obtained, consistent with, or superior to other published reports of 73-
DOC extractions (Rashid et al., 2001b, Chevallier et al., 2004). The purified 73-DOC 
was tested on osteosarcoma cells and antiproliferative effects confirmed its activity. The 
extraction and purification procedure therefore yielded sufficient material for small scale 
in vitro testing, and possibly even for larger scale in vivo work. However, any 
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commercial production using this approach would be economically unfeasible and 
ethically controversial due to the amounts of sponges that would need to be harvested 
from the natural environment. This therefore highlights the need for an alternative 
method of 73-DOC production, the principle behind the work presented in Chapter 6. 
Another option for generating a sustainable supply of 73-DOC lies in chemically 
synthesising the compound. Whole or semi-chemical synthesis was previously 
considered to be economically nonviable in producing sufficient quantities of bioactive 
natural products due to the complex structures of the compounds (Munro et al., 1999, 
Sipkema et al., 2005). However, as improvements in synthetic chemistry have been 
constantly evolving, this approach is much more feasible than it has been in the past 
(Kuttruff et al., 2014, Woerly et al., 2014). Indeed, there have been successes with 
marine natural products such as the sponge metabolites discodermolide (Florence et al., 
2008) and eribulin (Yu et al., 2013), as well as the ascidian metabolite trabectabin 
(Cuevas and Francesch, 2009). The synthesis of natural products is usually not attempted 
until after there is preclinical or clinical evidence to support its exploitation, but 
considering the promising potential of 73-DOC shown in Chapters 4 and 5, such work 
may now be worth expediting (Carballo et al., 2010). This work could also involve 
research into testing synthetic structural analogues in structure-activity relationships 
studies that may lead to a simpler compound that retains the biological activity of 73-
DOC (Smith et al., 2011). Synthetic derivatives of 73-DOC could also be further 
investigated in photoaffinity or fluorescent labelling studies (Gonçalves, 2008, 
Bockelmann et al., 2010, Carballo et al., 2010, Osteresch et al., 2012). Photoaffinity 
labelling of synthetic derivatives of V-ATPase inhibitors has previously been used to 
determine V-ATPase binding sites, so similar experiments using 73-DOC could 
ultimately facilitate in vitro and in vivo identification of targets and mechanisms 
(discussed in Chapters 4 and 5). There are still uncertainties regarding the 
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stereochemistry and absolute configuration of 73-DOC that require resolution. 
Obtaining absolute 3D structure is not only a necessity for pharmaceutical development 
but would also enable structure-activity relationships to be probed using virtual 
screening and docking models before synthesis is attempted, which could also help 
predict targets and binding sites on V-ATPase subunits (Ma et al., 2011). Application of 
single crystal x-ray crystallography is typically used to determine the relative 
stereochemistry of natural products and attempts to generate crystals of 73-DOC have 
already commenced (Albright and White, 2013).  
 The work in this thesis described a novel biological application for 73-DOC 
through inhibition of the osteoclast V-ATPase, representing a potential opportunity for 
developing a new therapeutic to treat osteolytic diseases. Comparisons with other 
compounds that target V-ATPases, including bafilomycin, or novel compounds such as 
enoxacin, diphyllin and luteolin, show that whilst 73-DOC shares some overlapping 
properties, it also appears to have unique effects on bone cells and, other than 
bafilomycin, has superior potency (Karsdal et al., 2005, Sorensen et al., 2007, Toro et 
al., 2012a, Toro et al., 2012b, Crasto et al., 2013). As both osteoclasts and osteoblasts 
are involved in bone remodeling and are tightly coupled as a result of catabolic and 
anabolic signals that occur between the two cell types, characterisation of the effects of 
a potential resorption inhibitor on both cell types was required for demonstrating 
therapeutic potential. Work presented in Chapter 4 showed that 73-DOC exhibited 
similar inhibitory effects towards precursor proliferation, differentiation and viability of 
both cell types, but dose-response proliferation analyses revealed a greater sensitivity of 
osteoclast lineage cells to 73-DOC compared to osteoblasts. Furthermore, the viability 
of mature osteoclasts was found to be 10-fold less sensitive to the effects of 73-DOC 
than precursor cells, demonstrating specificity and tolerance by some cell-types and 
contrasting with the results of bafilomycin treatment.  
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In Chapter 5, 73-DOC was found to inhibit both osteoclastic bone resorption and 
osteoblastic bone formation. However, it was also shown that the compound could 
significantly reduce bone resorption at concentrations 5-10 fold lower than those causing 
functional impairment of osteoblasts, as well as the inhibitory effects seen in Chapter 4. 
Taken together, these exciting in vitro observations show differential activity between 
osteoclasts and osteoblasts and imply that 73-DOC may represent an ideal novel bone 
resorption inhibitor that can functionally attenuate the resorptive activity of osteoclasts 
whilst having no impact on the generation and viability of new osteoclasts/osteoblasts, 
as well as the bone forming capabilities of osteoblasts. In an in vivo situation, this should 
theoretically translate into the uncoupling of bone resorption, leading to a net gain in 
bone tissue as normal numbers of functionally attenuated osteoclasts can be maintained, 
providing anabolic signals to osteoblasts. This is the ideal therapeutic outcome for 
osteolytic diseases such as osteoporosis. However, in order to fully satisfy these criteria, 
it remains to be seen what effects 73-DOC has on the putative anabolic factors produced 
by osteoclasts, such as glucocorticoids (Kim et al., 2006), ephrin-B2 (Zhao et al., 2006) 
and sphingosine 1-phosphate (Pederson et al., 2008). For example, it may be possible 
that conditioned media from 73-DOC-treated osteoclasts retains the capability of 
stimulating bone formation by osteoblasts, as was previously demonstrated in a similar 
experiment by Karsdal et al. (2008) using conditioned media from resorbing and non-
resorbing osteoclasts. Further future work will be necessary to firmly establish whether 
73-DOC can regulate potential cross-talk between osteoblasts and osteoclasts. 
The exact mechanism by which 73-DOC inhibits resorption in osteoclasts is still 
to be determined. Decreased overall and localised acidification in osteoclasts treated 
with 73-DOC does imply V-ATPase inhibition, as the V-ATPase is primarily 
responsible for intracellular pH regulation. However, the reduction in localised 
acidification at the osteoclast ruffled border could be attributed to either direct inhibition 
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of the ruffled border-bound V-ATPases, or it may be an indirect effect, caused by 
ineffective trafficking of the V-ATPase complex to the ruffled border during activation 
of resorption, or indeed, the absence of the ruffled border itself. In comparing the in vitro 
effects of 73-DOC with V-ATPase subunit isoform knockdowns/knockouts, it was of 
great interest that similarities were seen with the knockdown of Ac45, which include 
normal actin ring formation and decreased osteoclast precursor proliferation, 
differentiation and resorption (Qin et al., 2011, Yang et al., 2012). The effects of Ac45 
knockdown were attributed to ineffective vesicular trafficking, potentially mediated by 
a V-ATPase interaction with Rab7 GTPases. It is therefore tempting to speculate that 
the Ac45 V-ATPase subunit could be the target of 73-DOC, though further work will be 
necessary to verify this.   
Other possible explanations for the observed effects of 73-DOC include mTOR 
signalling, a key pathway involved in the proliferation and growth of cells, or the 
endocytotic pathway, which is crucial for intracellular signalling and trafficking events. 
There was also the suggestion that the inhibition of autophagy may be occurring, as the 
autophagy proteins Atg5, Atg7, Atg4B and LC3 have been shown to be essential for 
ruffled border formation as well as effective osteoclast resorption in vitro and in vivo 
(DeSelm et al., 2011). More work remains in conclusively determining the exact roles 
of V-ATPases in both mTOR signalling and autophagy, but the potential involvement 
of 73-DOC in these cellular processes is particularly intriguing. Considering the roles of 
lysosomal pH in both the mTOR and autophagy pathways, as well as endosomal 
trafficking, future work examining the specific magnitude of lysosomal acidification in 
response to 73-DOC using modern pH-sensitive probes would aid clarification of the 
effects of 73-DOC on these processes (Vegesna et al., 2014, Aldrich et al., 2015, Shen 
et al., 2015). Determining the response of autophagy, mTOR and osteoclast/osteoblast 
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differentiation markers to 73-DOC would also be very informative and would help 
resolve outstanding questions related to mechanism of action.  
Work presented in this thesis also showed clear effects on osteoblasts. The 
viability of proliferating precursors was inhibited by 73-DOC, confirming initial work 
with osteosarcoma cells, but differentiation and mineralisation were also impaired, 
demonstrating another novel aspect of 73-DOC. Previous studies using V-ATPase 
inhibitors and knockouts have suggested that some subunit isoforms are unimportant in 
osteoblasts (a3, d2, B2) and whilst bafilomycin has been reported to inhibit osteoblastic 
bone mineralisation, consistent with the work presented in this thesis, other inhibitors 
such as diphyllin and enoxacin do not cause inhibitory effects in osteoblasts (Lee et al., 
2006, Sorensen et al., 2007, Ostrov et al., 2009, Ochotny et al., 2011). This suggests that 
73-DOC and bafilomycin have a common V-ATPase target in both osteoclasts and 
osteoblasts but additional work is needed to clarify the subunit composition and function 
of osteoblast V-ATPases. Interestingly, vesicular trafficking is known to be important 
for the mineralisation process of osteoblasts and autophagy has recently been identified 
as contributing to both mineralisation (Nollet et al., 2014) and osteoblast differentiation 
(Pantovic et al., 2013). These processes may indicate a common 73-DOC-induced 
mechanism of action between osteoclast and osteoblast V-ATPases, explaining the 
observed effects on both cell types. However, further work is required to address this 
proposal and to also elucidate the complex interactions between V-ATPases, autophagy 
and mTOR signalling.  
 Ultimately the next step in the goal of developing 73-DOC as an osteoclast 
resorption inhibitor therapeutic should be to commence in vivo testing. The use of an 
osteoporotic animal model such as ovariectomised rodents (Kalu, 1991), would 
conclusively demonstrate the efficacy of using 73-DOC as an osteoporosis therapeutic 
through quantification of bone density using x-ray computed tomography, before and 
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after administration of 73-DOC. This experiment would provide unambiguous answers 
regarding the potential off-target effects of the compound, as well as characterising 
direct effects on osteoclasts and osteoblasts in vivo. Preliminary work in this direction 
has already started, where a small pilot toxicity study was conducted involving 
intravenous injection of mice with 73-DOC to achieve an estimated blood concentration 
of 2.5 µM. The treated mice, alongside untreated controls, were monitored and then 
sacrificed after 24 hours and 7 days, with multiple organ and bone marrow samples taken 
in order to ascertain any biological effects from 73-DOC. Interestingly, despite a 
comparatively high dose compared with that eliciting in vitro effects with osteoclasts 
and osteoblasts, the administration of 73-DOC caused no mortalities at either time point 
and, additionally, there were no observable gross morphological defects in any of the 
organs sampled, including kidney, spleen, liver, heart, lungs and brain. These initial 
observations therefore suggest 73-DOC is safe to use in vivo and that the compound does 
not cause any noticeable toxicity that would be expected if the compound was a universal 
V-ATPase inhibitor, as has been observed for bafilomycin (Keeling et al. 1998). These 
promising initial observations justify further extensive in vivo experimentation that 
could include a full pharmacokinetic assessment of the compound, as well as an 
investigation using the animal model of osteoporosis.  
 Having established a biological effect of 73-DOC, the final aim of this thesis 
concerned the cloning and sequencing of biosynthetic genes from in I. ramosa. As the 
biogenic origin of 73-DOC is likely microbial, and specifically via a PKS, work 
conducted in Chapter 6 was undertaken as a first step towards a goal of providing a 
sustainable supply of 73-DOC through expression of the biosynthetic genes in a 
fermentable host. The mWGS strategy led to the isolation of 18 unique PKS gene 
sequences, which showed homology to 1 of 2 groups of sponge-specific PKS, named 
sup and swf. Whilst the function of the swf group are still under investigation, putatively 
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involved in alkyl sulphate biosynthesis (Della Sala et al., 2013), the sup group of PKSs 
have been suggested to have roles in the biosynthesis of methyl-branched fatty acids. In 
Chapter 6, the speculative involvement of SupA in supplying methyl-branched 
precursors for 73-DOC biosynthesis was suggested. Examining the structure and 
biosynthetic mechanisms of SupA is one potential direction for future research.  
 Another direction concerns cloning additional genes involved in 73-DOC 
biosynthesis that were not isolated during the course of the current study. One approach 
to this goal could adopt similar methods utilised in this thesis but with important 
modifications. The use of degenerate KS primers has been successful in isolating several 
PKS gene clusters from sponge metagenomes, but crucially, these are used to sequence 
large numbers of KS domains from a holobiome, from which sequences of interest can 
then be selected based on phylogenetic clustering (Piel et al., 2004, Schirmer et al., 2005, 
Fisch et al., 2009). The KS domains involved in the biosynthesis of bioactive sponge 
metabolites are typically rare in sponge metagenomes, representing ~2 % of KS 
amplicons containing hundreds of sequences (Fieseler et al., 2007, Hochmuth and Piel, 
2009b), but the study by Woodhouse et al. (2013) demonstrated that amplicon-based 
NGS strategies are particularly successful in detecting rare, novel KS sequences that are 
undetected when deep sequencing techniques are not applied (Della Sala et al., 2014). If 
KS sequences indicative of a trans-AT mode of biosynthesis are sequenced, these could 
be directly related to the chemical structure of 73-DOC as Nguyen et al. (2008) 
demonstrated that the phylogeny of KS domains from trans-AT PKSs directly correlates 
with the structural moieties incorporated during biosynthesis. There are also other 
biosynthetic components implied by the 73-DOC chemical structure that could be worth 
targeting, such as the methyltransferase domains responsible for geminal dimethyl 
groups in other sponge-derived PKS clusters such as onnamide or psymberrin (Piel et 
al., 2004, Fisch et al., 2009), or the β-branching cassette. Degenerate primers for the 
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latter were recently used by Grindberg et al. (2011) to clone the PKS/NRPS apratoxin 
biosynthetic pathway from a cyanobacterial metagenomic library. Once suitable targets 
are sequenced and identified, the loci of these targets of interest can then be isolated by 
screening a fosmid library with specific primers and the application of a 3D colony 
screening/PCR method using pools of clone DNA (Hrvatin and Piel, 2007, Gurgui and 
Piel, 2010). This strategy would lead to the isolation of clones with rare biosynthetic 
genes likely involved in complex polyketide/non-ribosomal peptide biosynthesis and 
would thus dramatically increase the chances of capturing the 73-DOC biosynthetic gene 
cluster. 
 An alternative approach could involve examination of Entotheonella spp. from 
I. ramosa. Two members of this bacterial phylotype were recently found to be 
responsible for the biosynthesis of almost all of the many bioactive polyketides and non-
ribosomal peptides found in the sponge, T. swinhoei (Wilson et al., 2014). These species 
were suggested as belonging to a distinct, biosynthetically-rich novel candidate phylum 
called the Tectomicrobia that are also widespread in sponges (Wilson et al., 2014). The 
relevance of these bacteria as sources of bioactive polyketides/non-ribosomal peptides 
in sponges was recently supported by Ueoka et al. (2015), where the misakinolide gene 
cluster was isolated following screening of a fosmid library and was shown to originate 
from Entotheonella spp., demonstrated using fluorescent sorting of Entotheonella cells 
and whole genome amplification. On the basis of such rich secondary metabolism in a 
sponge symbiont, investigation of similar species in I. ramosa would be of great interest 
in isolating the biosynthetic genes responsible for 73-DOC. Intriguingly, this idea is 
given additional weight as sequences flanking a supA homologue showed homology to 
genes from Entotheonella spp. If confirmed present in I. ramosa, isolation of 
Entotheonella cells using fluorescent cell-sorting, or the enrichment techniques detailed 
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in Wilson et al. (2014), could then be followed by whole genome amplification and 
sequencing, or fosmid library screening. 
 In conclusion, the inhibition of osteoclast-mediated resorption by 73-DOC was 
demonstrated for the first time, thereby establishing a novel application for this 
compound and confirming the hypothesis of this thesis. Differential functional activity 
between osteoclasts and osteoblasts was also shown, suggesting that 73-DOC could 
represent a novel candidate for therapeutic use in osteolytic diseases to inhibit bone 
resorption whilst maintaining bone formation. Future in vivo work using an osteoporotic 
animal model is planned, which will enable further verification of the therapeutic 
potential of 73-DOC. Concurrent work further examining the role of SupA in 73-DOC 
biosynthesis was recommended, in addition to deep sequencing of I. ramosa KS 
domains for specific-PCR screening targets. This work should inevitably lead to cloning 
of the 73-DOC biosynthetic genes, perhaps eventually leading to an inexhaustible supply 
























Table 9 KS sequences amplified from the metagenome of I. ramosa share identity with KS domain sequences from 
uncultured sponge symbionts. PCR-amplified partial KS domain sequences from I. ramosa were subjected to BLASTn searches 
against the NCBI non-redundant nucleotide database (Camacho et al., 2009). The top match description for each sequence is shown 
along with % coverage, % identity and the accession number for that match. The E-value for that match is also shown, where a 




Figure 1 Multiple alignment of uncharacterised KS amino acid sequences from I. ramosa. The 9 unique, partial KS sequences found from I. 
ramosa were aligned with characterised KS domains from various type I PKS and FAS enzymes. The characterised KS sequences were retrieved 
from the GenBank database with the accession numbers shown in brackets. See Figure 6.4 and text in section 6.3.2 for details of the known KS 
sequences. Uncharacterised KS sequences found from I. ramosa are given the prefix KS-. The sequences were aligned using the MEGA software 


























Fos114 :  Score: 94.5  E-value: 3x10
-31
 Fos353 :  Score: 96.1  E-value: 9.4x10
-32
 
Fos441 :  Score: 92.9  E-value: 1.0x10
-21
 Fos970 :  Score: 94.0  E-value: 4.3x10
-31
 
Figure 2 HMM alignments of adenylation sequences subcloned from fosmids. Following a PCR screen, 6 fosmids (Fos114, Fos353, Fos441, 
Fos970, Fos1118 and Fos1207) were shown to be produce a PCR band of the correct size using degenerate primers for adenylation domains. The 
PCR products from each of the 6 fosmids were subcloned into E. coli and sequenced. Amino acid sequences were then analysed using the LSI software 
(Baranasic et al., 2014) for in silico prediction of adenylation domain substrate specificity. The alignment of sequences (Seq) from each of the 6 
fosmids against an HMM profile specific for the adenylation domain binding pocket is shown. Fos1118 was found to encode two unique sequences 
whilst a single sequence was found from the remaining fosmids.  Scores and E-values for each alignment are also given where an E-value below 1x10-
10 is considered reliable (Baranasic et al., 2014). Residues highlighted in red correspond to the amino acids used to determine substrate specificity by 


















Fos1118 (1/2):  Score: 66.8  E-value: 1.0x10
-22
 Fos1118 (2/2):  Score: 94.5  E-value: 3x10
-31
 








Figure 3 Alignments of proteins identified following a HMM search of the 
sequence obtained from Fos1118. The DNA sequence found following primer 
walking of Fos1118 was translated into all 6 reading frames and searched against the 
Pfam protein families database (Finn et al., 2011). Alignments for each protein match 
found are shown along with scores and E-values for that alignment. See key at top of 















Figure 4 Alignments of proteins identified following a HMM search of the 
candidate fosmid insert sequences. The DNA sequences of all 5 of the candidate 
fosmids were translated into all 6 reading frames and searched against the Pfam 
protein database (Finn et al., 2011). The output alignments from Pfam for the top 3 
matches based on score are shown along with scores and E-values for that alignment. 













































































Figure 5 Pairwise DNA alignments of putative adenylation domain 
sequences and fosmid insert sequences. The sequences were aligned using the 
EMBOSS Needle tool for pairwise alignements (Rice et al., 2000). Nucleotides 
with matching identities have matching colours. The aligned sequence from the 
fosmid insert was characterised by searching the DNA sequence against the Pfam 































































Figure 6 Pairwise DNA alignments of KS1 sequence and fosmid insert 
sequences. The sequences were aligned using the EMBOSS Needle tool for 
pairwise alignements (Rice et al., 2000). Nucleotides with matching identities 
have matching colours. The aligned sequence from the fosmid insert was 
characterised by searching against the Pfam protein database (Finn et al., 






















































































Figure 7 Domain annotation of type I PKS sequences identified by antiSMASH. A 
total of 18 type I PKS sequences were identified following screening of mWGS contigs 
using antiSMASH. To confirm the automatic domain annotation of antiSMASH, each 
sequence was also manually annotated using ClustScan (Starcevic et al., 2008) with the 
output shown for each sequence. This included a schematic showing the colour-coded 
locations of each domain encoded by that sequence, a table showing the scores and E-
values from HMM profile alignments, and a prediction of AT domain specificity and 








































































































































Figure 8 Multiple alignment of KS amino acid sequences from type I PKS clusters encoded by mWGS contigs. 
Whole KS sequences from mWGS contigs were aligned with characterised KS sequences from various type I PKS and 
FAS groups. The characterised KS sequences were retrieved from the GenBank database with the accession numbers 
shown. See Figure 6.6 and text in section 6.3.5 for details of the characterised KS sequences. The sequences were 















































Figure 9 BLASTp results of PKS proteins identified from mWGS contigs. Following screening of assembled mWGS contigs using antiSMASH, 
18 sequences were identified as encoding a type I PKS. Open reading frames (ORF) for each of contigs were annotated using the Gimmer3 (Delcher 
et al., 2007) software within antiSMASH, and then subjected to BLASTp searches against all non-redundant protein databases. For each sequence, 
the closest homologue to the encoded PKS sequence is shown in the tables, along with the GenBank accession number in brackets. Identified 
homologues for genes reported from the sup (Fieseler et al., 2007) and swf (Della Sala et al., 2013) operons are also shown. Above each table is a 
































































Figure 10 Multiple amino acid alignment of C-terminal AT domains from PKS genes showing homology to SupA. Out of the 18 type I PKS 
sequences detected by antiSMASH, 13 were shown to be homologues of SupA, of which, 9 were found to have a C-terminal AT domain. These 9 
whole AT domains were aligned with the SupA C-terminal AT domain from T. swinhoei (accession number: ABE03935) with the red arrow 
showing the presence of a glycine residue instead of a conserved serine residue considered crucial for activity (ref). An AT domain from the eryA 
gene of the erythromycin gene cluster (accession number: Q03131) was also included for comparison. The sequences were aligned using the 

















Figure 11 Multiple amino acid alignment of AT domains from PKS genes showing homology to SwfA. Out of the 18 type I PKS 
sequences detected by antiSMASH, 5 were shown to be homologues of SwfA, of which. Whole AT domains from the 5 sequences were 
aligned with the SwfA AT domain from P. simplex (accession number: AGH13590). The red line indicates the location of the QCALVEL 
motif shown to be unique to SwfA AT domains, though with some variation in the first and last amino acid (ref). An AT domain from the 
eryA gene of the erythromycin gene cluster (accession number: Q03131) was also included for comparison. The sequences were aligned 
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